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SUMMARY
1. The biology and chem istry of the endogenous opioid peptide precursors and 
the d is tribu tion , release and metabolism of the products o f proenkephalin are 
summarised, together w ith  a review of the in v itro  and in vivo cardiovascular 
e ffects  o f endogenous opioid peptides.
2. The four m ajor products o f proenkephalin, [ M e t] enkephalin,
[Leu ] enkephalin, [M e t] enkephalyl-arg^-phe^ and [Met] enkephalyl-arg^- 
7 8gly -leu , were studied fo r the ir d irec t e ffects  on isolated ra t a tria  and 
perfused mesentery in v itro  and fo r the ir ind irect e ffe c ts  on responses of the 
tissues to exogenous noradrenaline. The e ffec ts  o f the proenkephalin products 
upon a tr ia l responses to noradrenergic and cholinergic nerve s tim u la tion  were 
also investigated. [M e t] Enkephalin, [ Leu] enkephalin, [ M e t] enkephalyl- 
arg^-phe^ and [ M et ] enkephalyl-arg^-g ly^- leu® (10 ^ - 10 ^M) had no d irec t 
e ffec ts  upon isolated a tria  or the perfused mesentery and did not produce any 
modulatory e ffe c ts  upon responses to exogenous noradrenaline or on a tr ia l 
responses to noradrenergic and cholinergic nerve stim u la tion .
3. The cardiovascular responses to proenkephalin products were investigated in 
the urethane-anaesthetised ra t. Blood pressure and in tegra ted heart ra te  
were measured using a pressure transducer connected to a caro tid  a rte ry  
cannula. Intravenous adm in istra tion o f proenkephalin products (30-300pg/kg) 
produced a dose-related decrease in mean a rte ria l pressure and heart ra te . 
This was o f a s im ila r magnitude fo r the four opioid peptides. The response 
was abolished by naloxone (1 mg/kg) demonstrating th a t i t  was op io id-receptor 
mediated, and was qua lita tive ly  s im ila r to tha t produced by the p-opio id 
receptor selective agonist DAGO. The involvem ent o f p -receptors in the
( i i i )
response is fu rth e r supported by the lack o f e ffe c t of the 6 -recepto r 
selective agonist DPDPE and k-recepto r selective agonist U-50, 488H. This 
m ilita te s  against an involvement o f 6 - and k-receptors in the cardiovascular 
response to proenkephalin products.
An "a typ ica l response" to  [M e t] enkephalyl-arg^-phe '7 was exhibited in 25% 
of preparations studied. This consisted o f an in it ia l bradycardia and decrease 
in mean a rte ria l pressure fo llowed by a tachycardia and increase in mean 
a rte ria l pressure. The tachycardia and pressor response were m im icked by the 
dipeptide arg-phe and antagonised by propranolol and phentolamine 
respective ly. Both components of the response were abolished by 
hexamethonium which suggests tha t the response may have been due to the 
s tim u la tion  o f sym pathetic ganglia. The "a typ ica l response" was produced in 
l i t t e r  mates and may re fle c t genetically contro lled d iffe re n tia l capabilities 
to enzym atica lly  degrade the heptapeptide and generate the 
pharm acologically active dipeptide.
The cardiovascular responses to proenkephalin products were potentia ted 
fo llow ing p re -trea tm en t w ith  captopril, the angiotensin converting enzyme 
in h ib ito r, or bestatin, the aminopeptidase inh ib ito r, although to a lesser 
extent. The e ffe c ts  o f captopril on the duration o f the responses, especially 
to  the heptapeptide and octapeptide, were most marked ind icating th a t the 
a c tiv ity  o f a captopril-sensitive enzyme may be responsible fo r the re la tive ly  
short duration o f the observed responses.
Pharm acological manipulations, such as the use o f atropine and the 
quaternary opioid antagonist N -m ethy l levallorphan, and surgical procedures,
inc lud ing  b ila te ra l vagotom y and p ith ing , were em ployed to exam ine the 
mechanisms invo lved  in the  card iovascu la r response to  proenkephalin 
products. Through these techniques i t  was dem onstrated th a t the response 
was vaga lly  dependent, m ed ia ted  by periphera l opioid recepto rs  and 
dependent on the ce n tra l nervous sytem function ing . The card iovascu la r 
response to  proenkephalin  p roducts the re fo re  arises fro m  the s tim u la tio n  o f 
periphe ra l opioid recep to rs . This is then tra nsm itte d  to  the ce n tra l nervous 
system  by the vagus nerve and resu lts  in the p roduction  o f a c e n tra lly  
m ediated decrease in mean a r te r ia l pressure and an a trop ine -sens itive  
bradycard ia .
Non-op io id  e ffe c ts  o f N -m e th y l leva llo rphan ( in it ia l n ic o tin ic  agonist a c t iv ity  
fo llow ed by ganglion b locking  e ffe c ts ) were observed at doses only tw o -fo ld  
higher than those required  to  block ca rd iovascu la r responses to  
M et enkephalin. The narrow s e le c tiv ity  o f th is  compound makes i t  
inappropria te  fo r  opioid antagonist studies where n ic o tin ic  recepto rs may be 
involved.
M anipu la tions o f the hypo tha la m u s-p itu ita ry -ad re n a l axis, through 
adrena lectom y and suppression o f p itu ita ry  fu n c tio n  by dexamethasone 
a dm in is tra tio n , had s ig n ific a n t e ffe c ts  upon the ca rd iovascu la r responses to  
proenkephalin  p roducts. This ind ica tes th a t the a c t iv ity  o f the hypotha lam us- 
p itu ita ry -a d re n a l axis and /or changes in the leve ls o f c irc u la tin g  opioids has a 
considerable in fluence  on the m agnitude o f the evoked response.
The re sp ira to ry  e ffe c ts  o f proenkephalin  p roducts  and ca rd iovascu la r 
responses in a r t i f ic ia l ly  ve n tila te d  ra ts were studied. The resu lts  con firm ed  
tha t the ca rd iovascu la r responses to proenkephalin  products in the u re thane- 
anaesthetised ra t were not secondary to re sp ira to ry  e ffe c ts .
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1. INTRODUCTION
1.1 THE DISCOVERY OF THE ENDOGENOUS OPIOID SYSTEM
The pow erfu l pharmacological e ffec ts  of the natura lly occurring plant 
e x tra c t opium have been known fo r  m illen ia. The drug is present in the m ilky 
exudate obtained by incising the unripe seedpod of the poppy Papaver som niferum . 
Opium has been used as a drug a t least since classical Greek tim es, not only to 
deaden pain, but also because i t  gives rise to euphoria. The word opium comes from  
the Greek opion meaning poppy ju ice. Such were the remarkable analgesic 
properties o f the drug th a t in 1680 the English physician Thomas Sydenham wrote 
"Among the remedies which i t  has pleased A lm igh ty  God to give man to  re lieve his 
sufferings, none is so universal and so e fficacious as opium".
In 1803, a young German pharm acist, F riedrich  SertUrner, isolated an opium 
alkaloid tha t he named morphine, a fte r  Morpheus the Greek God o f dreams. By the 
middle of the 19th century, the use o f pure morphine ra ther than crude opium 
preparations was widespread. The to x ic ity  and addictiveness o f morphine were 
recognised only a fte r the drug had become an established feature  o f c lin ica l 
medicine. This awareness, together w ith  the lack of analgesic actions in other 
known classes o f drugs, s tim u la ted  an intensive research e ffo r t  in to  developing 
synthetic opioids w ith  the bene fic ia l properties of morphine but w ithou t the 
undesirable side e ffects . The discovery in 1975 of natural m orphine-like substances 
in the brain has since opened up avenues in understanding the pharm acological 
e ffects  o f opioids, the mechanisms underlying the ir m ediation and a fu lle r  
understanding o f addiction.
The main impetus behind the search fo r the endogenous opioids was the 
discovery o f the opioid receptor in the early 1970's (Simon e t al., 1973; P e rt and 
Snyder, 1973; Terenius and Waldstrom, 1975a). The existence o f stereospecific 
binding sites fo r narcotic drugs raised questions concerning the b io log ica l 
significance o f such sites. The possib ility  o f an as yet unknown endogenous ligand 
fo r such receptors became a re a lity  when several research groups demonstrated,
through the use o f isolated tissue bioassays, tha t p itu ita ry  and brain extracts  
contained compounds w ith  op io id-like  a c tiv ity  (Terenius and Waldstrom, 1975; 
Pasternak et a l., 1975; Cox et al., 1975).
Follow ing the demonstration tha t the opioid antagonist naloxone reversed the 
op io id -like  a c tiv ity , pu rifica tion  o f the active fac to r commenced (Hughes, 1975). 
F urther characterisation by Hughes e t al. (1975) resulted in the id e n tifica tio n  of 
two closely re la ted opioid pentapeptides, named methionine enkephalin and leucine 
enkephalin. These two peptides were synthesised and the synthetic m a te ria l was 
shown to have potent pharmacological a c tiv ity  on the mouse vas deferens and 
guinea-pig ileum  (W aterfie ld  et a l., 1977). The isolation o f these two 
pentapeptides, which d iffe r  only in th e ir carboxy-te rm inal amino acid, in itia te d  a 
surge o f in te rest in opioid peptide research which has continued in momentum and 
resulted in the id en tifica tio n  o f numerous endogenous opioid peptides.
Most o f the endogenous opioid peptides have been shown to  be derived from  
three genetica lly d is tinc t precursor molecules, whose amino acid sequences have 
been revealed through the use o f cloning and recombinant DNA techniques. The 
determ ination of the structure  and processing of these precursors, named pre- 
proopiom elanocortin, pre-proenkephalin and pre-prodynorphin, has resulted in the 
elucidation o f three fam ilies o f opioid peptides which are listed in Table 1 and 
described in de ta il in Section 1.2. O ther endogenous opioid peptides, not associated 
w ith  the three precursors, are described in a review  by K itchen (1984).
On a light-hearted note, the charac te ris tic  analgesic and euphoric properties 
o f the endogenous opioid peptides have inspired the fo llow ing com position:-
"O f endorphins, there are numerous classes,
Some may be as potent as grass is,
But when you're in pain,
Just depend on the brain,
For enkephalin's the opiate o f the masses." A llen  Bauman
Table 1: The Major Opioid Peptide Products of the Three Precursor Peptides
Peptide Reference
Pre-proopiom elanocortin Products
8-Endorphin Nakanishi et al., 1979
y-Endorphin M
a-Endorphin t l
Pre-proenkephalin Products
[M e t] Enkephalin Hughes et al., 1975
[Leu] Enkephalin Hughes et al., 1975
[M et] Enkephalyl-arg^-phe^ Stern e t al., 1979
[M et] Enkephalyl-arg^-gly^-leu^ K ilp a tr ic k  et al., 1981
Peptide F Jones e t al., 1980
Peptide I Jones e t al., 1980
Peptide B Stern e t al., 1981
Peptide E K ilp a tr ic k  et al., 1981
BAM-12P Mizuno e t al., 1980a
BAM-20P Mizuno at al., 1980
BAM-22P Mizuno at al., 1980
Metorphamide Weber e t al., 1983
Am idorphin Seizinger et al., 1985
Pre-prodynorphin Products
a-Neoendorphin Kangawa et al., 1981
8 -Neoendorphin Minamino et al., 1980
Dynorphin 1-8 Minamino et al., 1980
Dynorphin A Goldstein et al., 1979
Dynorphin B Fischli e t al., 1982
Dynorphin 32 F ischli e t al., 1982
Leumorphin Suda et al., 1983
1.2 THE OPIOID PEPTIDE PRECURSORS
The biosynthesis of opioid peptides illu s tra tes  what appears to be a common 
trend in neurobiology. L ike many other b io log ica lly  active peptides, the opioid 
peptides are not synthesised ind iv idually. Instead, a single gene codes fo r a large 
inactive  polypeptide tha t contains w ith in  its  s tructu re  the sequences o f several 
small active  opioid peptides tha t are subsequently sp lit from  the precursor 
polypeptide by processing enzymes.
The fin a l peptides produced by and stored w ith in  a given cell depend not only 
on the genetic code fo r the precursor, but also on the ac tiv ities  of enzymes 
responsible fo r processing the precursor molecule. C u tting  specific peptides out of 
the precursor polypeptide and a ltering these products by acetyla tion, sulphonation, 
am idation, phosphorylation, m ethylation, g lycosylation or fu rthe r cleavage are 
m odifica tions c r it ic a l in activa ting  or in ac tiva ting  the processing products (Lynch 
and Snyder, 1986). These changes resu lt in peptides o f d iffe ring  potencies, 
pharmacological p ro files  and receptor se lec tiv itie s . Post-translational events 
determ ine the exact mix o f peptides in a given nerve and seem to vary from  one 
tissue to  the next, in spite of the existence o f a common gene fo r the precursor 
(Hollt, 1986).
The fo llow ing sections describe the s tructure , processing and d is tribu tion  o f 
pre-proopiom elanocortin, pre-proenkephalin and pre-prodynorphin. I t  is worthy o f 
note tha t the d iffe rence between pre-propeptides and propeptides lies in the signal 
sequence at the amino term inus of the peptide molecule. When describing 
enkephalin precursors the term  propeptide, instead of pre-propeptide, is o ften 
inappropria te ly used.
1.2.1 Pre-proopiomelanocortin
Soon a fte r  the discovery of the two enkephalin pentapeptides, [M e t] - and 
[Leu ]-enkepha lin , the [M e t] enkephalin sequence was found to be present in an
11,000-dalton peptide, 3 -lipo trop in , 3 -LPH, (L i and Chung, 1976a) and in a 3,000- 
dalton fragm ent of 3LPH, named 3-endorphin (L i and Chung, 1976)! These larger 
peptides were present in appreciable amounts in the mammalian p itu ita ry  gland 
(Chretien e t al., 1976; G uillem in et al., 1977) along w ith  smaller enkephalin- 
containing peptides, apparently derived from  3-endorphin. A s t i l l  larger 
enkephalin-containing peptide o f about 31,000 daltons was subsequently isolated 
from  the p itu ita ry  gland and shown to  contain the sequence of adrenocorticotropic 
hormone (ACTH) as w e ll as 3-LPH (Kim ura et al., 1979)
The copy DNA, or cDNA, fo r th is common precursor was isolated, cloned and 
its sequence established (Nakanishi e t al., 1979), see Figure 1. The precursor 
molecule consists o f 265 amino acids and contains seven d is tinc t b io log ica lly  active 
peptides:- 3-endorphin, 3-LPH, ACTH, a-m eianocyte-stim ula ting hormone (a- 
MSH), 3-MSH, y-MSH and co rtico trop in -like  in term ediate lobe peptide (CLIP). The 
name pre-proopiom elanocortin was given to indicate its  precursor relationship to  
the three d iffe re n t types o f peptide. The precursor molecule contains a signal 
sequence consisting of about 20 amino acid residues and is cleaved fo llow ing 
transport across the endoplasmic re ticu lum , resulting in the release o f the 
propeptide sequence. Proopiom elanocortin (POMC) d iffe rs  from  the other opioid 
precursors in th a t i t  contains both opioid and non-opioid b io log ica lly  active  
peptides. The ind iv idua l peptides w ith in  POMC are bounded on both sides by pairs 
of basic amino acids, combinations o f lysine and/or arginine, whose occurrence 
marks p ro teo ly tic  enzyme cleavage sites (Steiner et al., 1980).
In the brain, POMC is d istributed in discrete neuronal ce ll populations (Bloom 
et al., 1978). The m ajor site o f POMC production is in the anterio r and 
in term ediate lobes o f the p itu ita ry  gland (Zakarian and Smyth, 1982). Studies o f the 
biosynthesis o f POMC in rats have revealed tha t the processing in the in te rm ed ia te  
lobe is d iffe re n t from  tha t in the an terio r lobe (C ive lli, e t al., 1984).
In general, POMC undergoes more cleavages and its  products more post- 
trans la tiona l m odifica tions in the in term ediate p itu ita ry  than in the an terio r 
p itu ita ry . In the in term edia te  p itu ita ry , 6 -endorphin is post-trans la tiona lly  
modified by a -N -ace ty la tion  which leads to  the complete loss o f a c t iv ity  a t opioid 
receptors. In addition, 6 -endorphin is shortened at its  carboxyl term inus, or C- 
term inus, by 4 or 5 amino acids. N -a -A c e ty l-6-endorphin^ ^7 and N -a c e ty l-6 - 
endorphin^ 25 are therefore  m ajor end products in the processing o f POMC in the 
in term ediate p itu ita ry  o f ra ts (Zakarian and Smyth, 1982). There is l i t t le  or no 6 - 
LPH in the in term edia te  p itu ita ry , whereas 6-LPH is a major processing product of 
POMC in the an terio r p itu ita ry . Its  concentration is about tw o -fo ld  higher than 
tha t of 6-endorphin2 which is not post-transla tiona lly  m odified. D iffe re n tia l 
processing in the an te rio r and in term ediate p itu ita ry  lobe also occurs fo r the ACTH 
domain o f POMC (H o llt, 1986).
Processing of POMC in the brain appears to be s im ila r to th a t occurring in 
the in term ediate p itu ita ry . In general, im m unoreactive m a te ria l o f a s im ila r 
molecular size to tha t o f 6 -endorphin and a-MSH are the predom inant POMC 
products in the brain o f rats and humans (Gramsch et al., 1980). However, N - 
acety la tion o f 6 -endorphin seems much less pronounced in the brain than in the 
in term ediate p itu ita ry  (Dennis et al., 1983). Cleavage of 6 -endorphin at the C- 
term inus also appears to  occur in the brain. This is indicated by the detection of 
acetylated and non-acetylated forms of 6-endorphin2 25 anc* 6 -endorphin2 27 
(Zakarian and Smyth, 1982).
Shorter cleavage products o f 6-endorphin such as a-endorphin, also known as 
6-endorphin2_25* and y-endorphin, also known as 6 -endorphin2 ^7* have been 
isolated from  the p itu ita ry . There is, however, evidence to suggest th a t they are 
not true processing products o f POMC (Verhoef et al., 1982).
In it ia lly , the presence o f the [ M et] enkephalin sequence in POMC suggested 
tha t the pentapeptide was derived from  POMC via processing o f 8 -LPH and 6 - 
endorphin. However, several studies suggested that i t  was doubtfu l tha t 13- 
endorphin served as a precursor o f enkephalin in the brain. F irs t, the brain 
d is tribu tion  and levels o f 8-endorphin and [M e t] enkephalin d iffe r  s ign ifican tly  
(Bloom et al., 1978). Secondly, although the 6 -endorphin sequence is preceded by a 
lys-arg sequence, a recognised processing signal, the [M e t] enkephalin sequence is 
not fo llowed by a. recognised signal fo r p ro teo ly tic  processing. The indications are 
tha t the 6-endorphin sequence is cleaved in ta c t from  POMC and does not serve as 
a precursor o f [M e t] enkephalin. Furtherm ore, a separate precursor coding fo r the 
[M e t] enkephalin sequence has been cloned (Section 1.2.2).
1.2.2 Pre-proenkephalin
As the characterisation o f POMC had not resolved the nature o f the 
precursor to [M e t ] -  and [Leu ]-enkepha lin , the p itu ita ry  gland and brain were 
examined fo r other opioid precursors (Lewis e t a l., 1978). The precursor o f the two 
pentapeptides was shown to  be present, although in such low concentrations tha t 
iso lation and pu rifica tion  would have taken a substantial e ffo r t  and been extrem ely 
d if f ic u lt .  A t  the same tim e, bovine adrenal medulla was found to contain high 
concentrations o f opioid peptides (Schultzberg et al., 1978). Among the peptides 
isolated from  this source were [M e t ] -  and [Leu ]-enkepha lin , extended 
[M e t] enkephalin sequences and peptide E, as well as several longer opioid- 
containing fragments. One of the extended [M et] enkephalin sequences, which 
contained the C-term inus dipeptide sequence arg-phe, was considered to  be the 
te rm inating  carboxyl peptide sequence in the parent peptide since this d ipeptide is 
not a recognised cleavage processing signal (Stern et al., 1981).
C oncom itan t w ith  the work on peptide iso lation and pu rifica tion , recom binant 
DNA techniques were being applied to characterise the enkephalin precursor. The 
complete s truc tu re  o f the enkephalin precursor, pre-proenkephalin, was announced 
simultaneously by two independent research groups (Gubler e t al., 1982; Noda e t 
al., 1982). Shortly a fte r the cloning o f bovine adrenal pre-proenkephalin, human 
adrenal pre-proenkephalin was cloned and a high degree o f homology between the 
two molecules was shown to exist (Comb et al., 1982). The structures o f pre- 
proenkephalin and its  m ajor processing products are shown in Figure 1.
Pre-proenkephalin consists o f 263 amino acids and, like  pre-proopio­
m elanocortin, possesses a signal sequence at its  amino term inus (Noda et al., 1982; 
Gubler e t a l., 1982). The precursor molecule has a widespread d istribu tion, which is 
fu lly  described in Section 1.3.1. This includes the centra l nervous system, endocrine
it
system and gastro in testina l tra c t (H okfe lt e t a l., 1977; Watson e t al., 1984). In the 
brain, proenkephalin-derived peptides are w idely spread at every level o f the 
neuraxis from  cells in the cortex to cells in the spinal cord. F ibre projections 
include both local and long tra c t systems and are associated w ith  many functions 
including pain, respiration, endocrine actions, m otor actions and general lim b ic  
a c tiv ity . The m a jo rity  o f proenkephalin is found in the adrenal medulla, where i t  is 
present in re la tive ly  higher concentrations (Gubler e t al., 1982; Noda et al., 1982).
The amino term inus, or N-term inus, th ird  of the precursor is sometimes
called synenkephalin and contains no opioid peptide sequences. The C -term inus tw o
thirds o f proenkephalin contains four copies of [M e t] enkephalin, two extended
[M et] enkephalin squences, [M e t] enkephalyl-arg^-phe^, a heptapeptide and
6 7 8[M et] enkephalyl-arg -g ly  -leu , an octapeptide, and one copy o f 
[Leu ] enkephalin. The structures o f these peptides are shown in F igure 2. Each 
peptide sequence is flanked by dibasic amino acid processing signals. In addition, a 
wide va rie ty  o f la rger enkephalin-containing peptides have been isolated from
bovine adrenal medulla (Lewis and Stern, 1983; Udenfriend and K ilp a tr ick , 1984) 
suggesting th a t processing occurs a t several selected cleavage sites (see Figure 3).
The m a jo rity  o f processing seems to occur at the C -term inus part of the 
molecule, since many more isolated enkephalin-containing peptides possess the N - 
term inus o f proenkephalin. In contrast, only two peptides have been isolated tha t 
contain the in ta c t C -term inus, one o f which has been named peptide B (Stern et al.,
1981). In addition, several enkephalin-containing peptides have been isolated tha t 
are derived from  the m id-portions of the precursor, peptide I being one of them 
(Stern et al., 1981).
There is a series o f peptides tha t contain the [M e t] enkephalin sequence at 
the ir N -term inus and exh ib it opioid a c tiv ity . One such example is peptide F, a 
peptide containing two [M e t] enkephalin sequences, one a t its  N -term inus and one 
at its C -term inus (Jones e t al., 1980). A C -term inus am idated peptide consisting o f 
the f irs t  26 amino acids o f peptide F has recently been isolated and named 
amidorphin (Seizinger et a l„  1983). Peptide E possesses the sequence o f 
[M e t] enkephalin at its  N -term inus and tha t o f [Leu] enkephalin a t its  C -term inus 
(K ilpa trick  at a l., 1981a). Several C -term inus shortened peptides from  peptide E, 
namely BAM-22P (Mizuno et a l., 1980), BAM-20P (Evans e t al., 1983), BAM-12P 
(Mizuno a t al., 1980a) and a C -term inus amidated octapeptide corresponding to the 
f irs t  8 amino acids o f peptide E, have also been isolated. This last peptide has been 
named metorphamide or adrenorphin (Matsuo et al., 1983).
Most o f these peptides appear to be processed by cleavage at pairs of basic 
amino acids, exceptions to th is are BAM-22P and BAM-12P. I t  has therefore  been 
claimed tha t these peptides are products o f non-specific proteolysis (Udenfriend 
and K ilp a tr ick , 1984). The generation of metorphamide (Matsuo et al., 1983) 
involves p ro teo ly tic  cleavage at a single arginine amino acid, a cleavage site tha t 
exists in several peptide precursors (Mains e t al., 1983). Furtherm ore, the C-
term inus glycine residue is converted in to  an amino group by a specific am idating 
enzyme (Bradbury et a l., 1982). S im ila r mechanisms exist fo r the conversion o f 
peptide F in to  amidorphin (Seizinger e t al., 1983).
There is strong evidence tha t brain proenkephalin is s im ila r to tha t found in 
the adrenal medulla. L is ton £ t  al. (1983) isolated a peptide from  bovine caudate 
nucleus w ith  an identica l sequence to tha t o f synenkephalin found in adrenal 
medullary proenkephalin. Using antibodies against opioid peptides from  the adrenal 
medulla, im m unoreactive peptides corresponding to [ M et] enkephalyl-arg^-phe^, 
[M e t] enkephalyl-arg^-gly^-leu® (Giraud e t al., 1984), BAM-12P (Baird et al., 
1982), BAM-22P, peptide F (H alit, e t al., 1982), amidorphin (Seizinger et a l., 1985), 
metorphamide (Matsuo e t a l., 1983) and BAM-20P (Evans e t al., 1985) have been 
found in bovine brain.
There is evidence to suggest tha t the processing o f proenkephalin in the 
adrenal medulla is d iffe re n t from  tha t in the brain. In the form er, the in it ia l 
cleavage occurs near the C -term inus since most isolated enkephalin-containing 
peptides possess an in ta c t N -term inus. However in the supraoptic nuclei, in it ia l 
processing steps appear to  involve the removal o f the N -term inus fragm ent (L iston 
et al., 1984). The larger enkephalin-containing peptides are predominant in the 
supraoptic nucleus whereas the neurophypophysis almost exclusively contains free 
enkephalins. This indicates an almost complete processing o f proenkephalin along 
the hypothalamus-neurohypophyseal pathway (L iston et al., 1984).
In general, the processing o f proenkephalin appears to  be more com plete in 
the brain than in the adrenal medulla. Consequently, bovine adrenal glands contain 
more large enkephalin-containing peptides than fin a l processing products 
(Udenfriend and K ilp a tr ic k , 1984), although th is may be due to  a higher turnover o f 
the low molecular weight products o f proenkephalin. However in the brain, the 
above evidence suggests tha t neuronal proenkephalin is processed rapid ly and th a t 
the processing in term ediates do not accumulate to any s ign ifican t extent.
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1.2.3 Pre-prodynorphin
D eterm ina tion  o f the structures o f pre-proopiomelanocortin and pre- 
proenkephalin did not account fo r  o ther [Leu] enkephalin-containing peptides, such 
as a-neoendorphin, 3-neoendorphin and dynorphin, tha t were known to  be present in 
porcine p itu ita ry  glands and other tissues (Kangawa et al., 1981; Goldstein and 
Ghazarossian, 1980), Further research also led to  the discovery o f other [Leu] - 
enkephalin-containing peptides from  porcine p itu ita ry . This included a 
tridecapeptide, called rim orphin or dynorphin 8 (K ilpa trick  et al., 1982), and a 32- 
amino acid peptide, containing dynorphin at the amino term inus and the 
tridecapeptide a t the C -term inus (F isch li e t al., 1982).
The common genetic origin of these [Leu] enkephalin-containing peptides 
was convincingly demonstrated by Kakidani et al. (1982) through cloning 
techniques. Sequencing of the cloned cDNA from  porcine hypothalamus 
demonstrated the existence o f a precursor tha t contained the com plete sequence of 
dynorphin and a-neoendorphin, but did not contain a [M et] enkephalin sequence 
(see Figure 1). The precursor, pre-prodynorphin, consists o f 236 amino acids which 
include the puta tive  signal sequence o f approxim ately 20 amino acids.
Pre-prodynorphin has been found in the gastro in testinal tra c t, the posterio r 
p itu ita ry  and the brain (Khachaturian et al., 1982). In the brain, i t  has been found in 
several hypothalam ic ce ll groups including the vasopressin-producing cells o f the 
m agnocellular neurosecretory nuclei. Pre-prodynorphin has also been found in many 
w idely scattered ce ll populations in the brain stem.
Prodynorphin has been shown to  contain three [Leu] enkephalin sequences, 
each flanked by pairs o f basic amino acids. I f  lys-arg pairs were the only processing 
signals, prodynorphin would be cleaved in to three larger opioid peptides, 8- 
neoendorphin (Minamino et a l., 1981), dynorphin A (Goldstein et a l., 1981) and a 
peptide called leumorphin (Nakao et a l., 1983). However, other peptides are derived
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from  prodynorphin, ind ica ting tha t enzymes w ith  more complex specifications are 
involved in processing the precursor. The pro-lys bond at the C-term inus o f 8- 
neoendorphin is o ften  resistant to proteolysis and the larger decapeptide, a - 
neoendorphin, is a m ajor processing product (Kangawa et al., 1981). Cleavage may 
also occur where single arginine residues exist. Thus, the fo rm ation  o f dynorphin B 
or rim orphin (F ischli et al., 1982) results from  cleavage between th re o n in e ^  and 
arg in ine"^ o f leumorphin. By a s im ila r cleavage, dynorphin A (1-8) is form ed from  
dynorphin A (M inamino £ t  a l„  1980). This type o f cleavage appears to occur 
frequently and the sm aller peptides are more abundant than the la rger ones in 
many areas o f the brain (Seizinger et al., 1984). In addition, several la rger peptides 
have been id en tified  as pu ta tive  processing products. This includes dynorphin 32, 
which contains dynorphin A at the N-term inus and dynorphin B at the C-term inus 
(Fischli et al., 1982), and dynorphin 24, which contains dynorphin A w ith  a C- 
term inus extension o f lys-arg and the sequence o f [L e u ] enkephalin (F ischli et al.,
1982).
Several products o f prodynorphin have been found in the posterior p itu ita ry , 
including dynorphin 32, dynorphin A, dynorphin A (1-8), a-neoendorphin, 8- 
neoendorphin and dynorphin 8 (Seizinger et al., 1981). There is also some evidence 
tha t [Leu ] enkephalin is a processing product o f prodynorphin in the ra t posterior 
p itu ita ry . Osmotic s tim u li such as salt-loading im m ediate ly decrease dynorphin A 
and [ Leu] enkephalin levels in the posterior p itu ita ry , but have no e ffe c t on 
[M e t]  enkephalin levels (Zam ir et al., 1983). There is also evidence fo r d iffe re n tia l 
processing o f prodynorphin in the anterio r lobe of the p itu ita ry . A peptide 
exhibiting opioid a c tiv ity , consisting o f the C -term inus portion o f prodynorphin and 
the N-term inus sequence o f dynorphin, is a puta tive  end product, w ith  no evidence 
of fu rthe r processing to the sm aller peptide fragments (Seizinger e t a l., 1981). a - 
Neoendorphin and 8-neoendorphin are also processing products, together w ith
large, N -te rm in a l extended, non-opioid form s of a - and 8-neoendorphin (Seizinger 
et al., 1984).
There is evidence fo r d iffe re n tia l processing o f prodynorphin in various brain 
areas. Whereas dynorphin A and dynorphin A (1-8) occur in about equal amounts in 
the posterior p itu ita ry , dynorphin A (1-8) is the predominant peptide in the brain 
(Seizinger et al., 1984). S im ila rly , the m olar ra tio  o f a-neoendorphin to  8- 
neoendorphin d iffe rs  in various brain regions (Weber e t al., 1982).
1.2.4 Summary
The three opioid peptide precursors have been characterised and shown to 
give rise to  a t least tw enty d iffe re n t opioid peptides. The p ro teo ly tic  processing o f 
each o f the three precursors seems to be d iffe re n tia lly  regulated in d iffe re n t 
tissues and brain regions. The various products from  a given precursor show vast 
differences in receptor se lec tiv ity  and opioid potency (see Section 1.4), suggesting 
tha t post-transla tiona l processing may be a prim ary fac to r in regulating opioid 
a c tiv ity  in d iffe re n t tissues and brain regions. Much in fo rm ation  regarding th is 
issue has accumulated over the last few  years and i t  is like ly  tha t the endogenous 
opioid system w ill serve as a model which w ill help to  determ ine how p ro te o ly tic  
processing regulates peptide neurotransm itters.
THE THREE OPIOID PEPTIDE PRECURSORS
1. Pre-proopiomelanocortin (265amino acids)
rMSH
T ip s s T
_ lm x u ~ u V il
A c m
3MSH 3-ENDORPHIN
r ' M SSSSSHCQQH
pcMSH c u p
3-LPH
2. Pre-proenkephalin (263aminoacids)
MEAGL LE
NHr—  E3~R1 KM M  M IT  ~ E ^ -cooh
ME ME ME ME MEAP
3. Pre-prodynorphin (256 amino acids)
n rk in „ nouikI DYNORPHIN B
3-NEO-ENDORPHIN ^
1-8 i-13 14-29
'---- *------' i 1-17 ,oc-NEO-ENDORPHIN '-------*------ ’
DYNORPHIN A
Figure 1: Schematic representation o f the opioid peptide precursors showing the
major processing products. The solid area at the amino term inus 
represents the signal sequence (not drawn to scale). MSH represents 
m elanocyte-stim ula ting hormone, ACTH represents adrenocortico trop ic 
hormone and CLIP represents co rtico tro p in -like  in term edia te  lobe 
peptide, ME, LE, MEAP, MEAGL .represent [M e t] enkephalin
[L ^ jj] e^kepl^alin, [M e t] enkephalyl-arg -phe and [M e t] enkephalyl- 
arg -g ly  -leu . The processing o f pre-proenkephalin is shown in more 
de ta il in F igure 3.
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FINAL PROCESSING PRODUCTS OF PRE-PROENKEPHALIN • 
Tyr-Gly-Gly -  Phe-Met 
[Met-] enkephalin 
Tyr-Gly-G ly -  Phe -  Leu 
[Leu] enkephalin 
Tyr-Gly-Gly-Phe -Met-Arg-Phe 
[Met] enkephalyl-Arq-Phe7 
Tyr-Gly-Gly-Phe-Met-Arg -Gly-Leu 
[Met] enkephalyl-Arq-Gly-Leu8
Figure 2: The amino acid sequences o f the fina l processing products of
proenkephalin. Abbreviations are as fo llow s:- Tyr = tyrosine, Gly = 
glycine, Phe = phenylalanine, Met = methionine, Leu = leucine and Arg = 
arginine. The tyrosine residue represents the amino term inus of the 
peptide.
PROCESSING OF PRE-PROENKEPHALIN.
KK KR KK KR KRi ET M  \ i KR.
Putative
signal
sequence
Preproenkephalin
1. PROCESSING AT SELECTED DIBASIC AMINO ACIDS
KR m
Peptide F Peptide Peptide B
R KRLJ
Peptide E
2- CLEAVAGE AT A SINGLE ARGININE RESIDUE
f
3- AMIDATION
KK
Amidorphin
4- COMPLETE PROCESSING AT DIBASIC AMINO ACIDS
RR NHoHI
Metorphamide
3xME MEAGL ME LE MEAP
Figure 3: M ajor processing pathways fo r pre-proenkephalin. K and R represent
the basic amino acids lysine and arginine. ME, LE, MEAP and MEAGL 
represent [M e t] enkephalin, [* -eP] enkephalin, [M e t]  enkephalyl- 
arg -phe and [M e t] enkephalyl-arg -g ly -leu respective ly.
1.3 PROENKEPHALIN PRODUCTS
I t  is now clear tha t there are at least three d iffe re n t fam ilies o f opioid 
peptides. The work described in th is thesis is concerned p rim arily  w ith  the fin a l 
processing products o f proenkephalin. In order to understand the re la tive  roles o f 
these peptides in physiological mechanisms i t  is necessary to be aware of th e ir 
d is tribu tion , release and metabolism; topics which are covered in the fo llow ing  
sections.
1.3.1 Distribution
1.3.1.1 Enkephalinerqic Nerves
The ce llu la r biology o f the enkephalin-containing nerve is assumed to be the 
same as fo r  any peptidergic nerve (H bkfe lt e t al., 1980; Eipper et al., 1986). The 
pre-proenkephalin precursor is formed by ribosomal translation o f the messenger 
RNA encoding its  amino acid sequence. The pre-proenkephalin molecule then 
passes through the endoplasmic re ticu lum  to  the Golgi apparatus, where its  signal 
sequence is cleaved upon entry. This yields proenkephalin molecules which are 
subsequently packaged in vesicular com partm ents and transported down the nerve 
axon to the nerve term ina l (Sejnowski, 1982). A t what stage the processing steps 
and post-transla tiona l m odifications take place are as yet unknown. F rac tiona tion  
studies ind ica te tha t the proenkephalin products are stored in synaptic vesicles 
(Simantov et a l., 1976), although whether i t  is in large granular-type (-s^  70-100 nm) 
or small c lear-type  (^3 0 -5 0  nm) vesicles is uncertain. There is evidence to  suggest
ii
tha t co-existence w ith  other neuro transm itte rs may occur (H okfe lt e t al, 1980). 
Work in th is area is gaining momentum and there is increasing evidence fo r 
in teractions o f m u ltip le  neurotransm itters on e ffe c to r organs (H bkfe lt e t a l., 
1980a; Section 1.6).
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A t the nerve term inals, proenkephalin products are released in a calcium - 
dependent process (Hughes, 1983) and have access to the corresponding receptor or 
receptors. They are then presumably degraded and the resulting peptide fragments 
released. This is substantiated by the reported rapid h a lf- life  of the enkephalins 
(Clement-Jones et a l., 1980), the widespread d is tribu tion  o f enkephalin-degrading 
enzymes (see Section 1.3.3) and the lack of evidence supporting a re-uptake 
mechanism (Eipper et al., 1986).
The presence o f proenkephalin and proenkephalin-derived peptides has been 
demonstrated in sym pathetic, parasympathetic and peptidergic neurones. Hughes et 
al. (1977) demonstrated enkephalin-like a c tiv ity  in the vagus nerve o f rats and 
rabbits. This was also shown in the human vagus nerve (Lundberg et al., 1979). 
Further studies o f the location o f proenkephalin products in the vagus nerve, have 
shown tha t they are confined to preganglionic neurons orig inating from  the centra l 
nervous system (A tweh and Kuhar, 1983; Lundberg e t a l., 1978). Enkephalin- 
im m unoreactiv ity  is also present in preganglionic pelvic parasym pathetic nerves 
term inating in local ganglia o f the urogenital t ra c t (Lundberg e t al., 1980). 
Enkephalins have also been shown to occur w ith in  several autonomic ganglia 
(Schultzberg et a l., 1979). In the guinea-pig and ra t, the superior cerv ica l, superior 
and in fe rio r mesenteric, and coeliac ganglia a ll contain enkephalin-like 
im m unoreactiv ity  (Tang et al., 1982).
In sym pathetic nerves, the presence o f enkephalins has been detected in 
preganglionic sym pathetic axons extending in to  cerv ica l sym pathetic trunk nerves 
and splanchnic nerves te rm inating  in sym pathetic ganglia (Lundberg e t al., 1980). A 
recent study has examined the d is tribu tion  o f proenkephalin products in the s te lla te  
ganglion and the postganglionic sym pathetic fibres o f the vas deferens and has 
demonstrated the co-storage o f enkephalins and noradrenaline in sym pathetic nerve 
term inals (Bastiaensen and de P o tte r, 1987). A simultaneous investigation o f the
biosynthesis o f proenkephalin products in the sym pathetic nerve showed tha t the 
postganglionic nerves o f the vas deferens contained only small m olecular weight 
enkephalin-containing peptides, therefore suggesting tha t complete processing o f 
the proenkephalin products had occurred. In the s te lla te  ganglion, only high 
m olecular weight enkephalin-containing peptides were found, suggesting tha t 
m inim al processing had occurred a t th is site (Bastiaensen and de P o tte r, 1987; 
Fried et al., 1986). This suggests th a t proenkephalin molecules are synthesized in 
the ce ll body and then transported down the nerve te rm ina l. During th e ir m igration 
along the axon, they are processed in to  the sm aller enkephalin-containing peptides. 
By the tim e the vesicles arrive  in nerve term ina l, proenkephalin processing is near 
completion.
1.3.1.2 Proenkephalin Products in Cardiac Tissue
There are numerous reports of the presence o f proenkephalin and 
proenkephalin-derived peptides in the heart o f a va rie ty  of species (Reinecke and 
Forssman, 1984; Lang et al., 1983a; Weihe et al., 1983; Xiang e t al., 1984; Maeda et 
al., 1986; Howells e t a l., 1986). Proenkephalin peptides are mostly found in 
neuronal structures including sym pathetic innervating nerves (Lang et al., 1983a), 
cardiac ganglia (Weihe et a l., 1983; Reinecke and Forssman, 1984; Xiang ^ t  al.,
1984) and nerve networks throughout the heart (Maeda et al., 1986).
Using antibodies specific  fo r [M e t] - and [Leu]-enkephalin , high levels o f 
enkephalin-im m unoreactiv ity ind icate complete processing o f proenkephalin in the 
heart. However, recent evidence suggests tha t processing is fa r from  com plete in 
some areas o f the heart (Howells et al., 1986). This is substantiated by the presence 
o f high levels o f high m olecular weight peptides but v ir tu a lly  no low  m olecular 
weight peptides, a s im ila r s itua tion  to tha t which occurs in the adrenal medulla. 
This may be due to d ifferences in peptide turnover or a mechanism may exist tha t 
rapid ly increases the transla tion o f proenkephalin in cardiac tissue.
1.3.1.3 Proenkephalin Products in Other Peripheral Tissues
The fo llow ing section describes the wide d istribu tion o f proenkephalin 
products throughout the periphery and is summarised in Table 2.
Enkephalin-containing neurons are found extensively in the pancreas and 
throughout the gastro in testina l t ra c t in loca l in tram ura l neurons innervating 
ganglion cells and smooth muscle (Schultzberg et al., 1980; Lundberg et al., 1980; 
Tang et a l., 1982). C e ll bodies possessing enkephalin-im m unoreactiv ity are 
abundant in the m yenteric plexus, however very few have been demonstrated in the 
submucous plexus. The ra tio  o f proenkephalin products in the muscular layer o f the 
human stomach has been shown.to be the same as tha t resulting from  com plete 
processing of the precursor (Sakamoto et al., 1983). Proenkephalin products have 
also been located in specific  ce ll types in the anterio r p itu ita ry  (Gramsch et al., 
1979) and are found w ith in  nerve term inals involved in the release o f 
neurohypophyseal hormones (Zam ir e t al., 1983).
Elsewhere in the periphery, proenkephalin products have been shown to  be 
present in the lung and heart o f various species (see Section 1.3.1.2). R e la tive ly  
high concentrations o f the heptapeptide [M e t] enkephalyl-arg^-phe^ are found in 
cells o f the walls of the bronchi, w ith  l i t t le  or no [M et] enkephalin present (Tang 
et a l., 1982; Tang et ai., 1983a). The physiological significance o f th is is uncertain, 
but i t  has been in ferred tha t [M et] enkephalyl-arg^-phe^ may possess a ro le  in lung 
function or, more unlike ly, may serve as a precursor fo r [M e t] enkephalin. F u rthe r 
studies have demonstrated the presence o f re la tive ly  high concentrations o f 
[M e t] enkephalyl-arg^-phe^ im m unoreactiv ity  in the heart and various parts o f the 
in testine, but very l i t t le  in the pancreas and liv e r (Tang et al, 1983a).
The presence o f proenkephalin products in the adrenal glands o f several 
species has been well documented (Schultzberg et al., 1978; Lew is e t al., 1979; 
Viveros et al., 1980; Lindberg et al., 1983; Boarder et al., 1982). These peptides are
Table 2: Peripheral Distribution of Proenkephalin Products in the Rat
S tructu re Density Reference
Parasym pathetic nerve
Vagus * * Hughes et al., 1973; 
Lundberg £ t  al., 1978
Preganglionic nerves * Lundberg et al., 1980
Sym pathetic nerve
Preganglionic nerves * Lundberg et al., 1980
Autonom ic ganglia * Schultzberg e t al., 1979; 
Tang et al., 1982
H eart
A tr ia * Hughes et al., 1975
Sym pathetic innervation * Lang et al., 1983a
Cardiac ganglia * Xiang et al., 1984
In tracard iac nerves * Maeda, e t al., 1986; 
Howells e t al., 1986
Lung * * Hughes e t al., 1975; 
Tang et al., 1983a
Adrenal gland
Medulla * * * Schultzberg e t al., 1978; 
Boarder et al., 1982
Cortex * Viveros e t al., 1980
G astro in testina l t ra c t
M yenteric  plexus * * Hughes et al., 1975; 
Lundberg et al., 1980
Ileum * Hughes et al., 1975
Duodenum * Tang et al., 1982
Pancreas * Schultzberg et al., 1980; 
Lundberg et al., 1980
P itu ita ry * Gramsch et al., 1979; 
Zam ir et al., 1985
Vas deferens * Bastiaensen and de P o tte r, 1987
Key: * * *  high
* *  medium 
*  low
pre fe ren tia lly  located in the adrenal medulla, but are also found in the cortex in 
much sm aller quantities. In the medulla they are present in chrom affin  cells w ith  
catecholamines and chromogranins (Schultzberg e t al., 1978). O rig ina lly  
enkephalin-im m unoreactiv ity was demonstrated in both adrenaline and 
noradrenaline synthesising m edullary cells. However, more recent reports suggest 
the exclusive association of enkephalin-im m unoreactiv ity w ith  adrenaline 
synthesising cells (Lang et al., 1983b). This may be m is in terpre ta tion due to the 
higher adrenaline compared to noradrenaline content in the adrenal medulla 
(StjSrne, 1972) and is an unresolved issue.
Hook and L is ton  (1987) have shown th a t w ith in  the chrom affin  granule, the 
larger enkephalin-containing peptides are associated w ith  the granule membrane 
w h ils t the small enkephalin peptides are d istribu ted in the soluble granule 
com partm ent. This d iffe re n tia l d is tribu tion  may represent a general mechanism fo r 
organising the p ro teo ly tic  cleavage of proenkephalin and fo r ensuring tha t the 
larger peptides are not released into the extrace llu la r environment upon 
exocytosis. A s im ila r organisation fo r the processing of proopiom elanocortin has 
been demonstrated (Loh and Tam, 1985).
The proenkephalin content o f adrenal medulla d iffe rs  from  tha t o f the brain 
in tha t there are large amounts o f high m olecular weight enkephalin-containing 
peptides and re la tive ly  low amounts o f free enkephalins (Udenfriend and K ilp a tr ic k ,
1984). However, as previously described, in the brain free enkephalins are the 
predominant processing products of proenkephalin, suggesting tha t processing is 
more complete than in the adrenal gland. This is supported by the fa c t th a t 
peptides o f higher m olecular weight reacting w ith  antibodies directed against 
BAM-22P, BAM-12P, and peptide E are more abundant in the adrenal medulla than 
in the hypothalamus or s tria tum  (Giraud e t al., 1984). I t  should be stressed, 
however, tha t th is may re fle c t differences in turnover or rates of transla tion  o f 
pre-proenkephalin.
1.3.1.4 Central Distribution of Proenkephalin Products
[M e t] Enkephalin and [Leu] enkephalin were f ir s t  isolated from  the brain and 
shown to possess opioid a c tiv ity  (Hughes e t al., 1973). This was followed by 
imm unocytochem ical studies demonstrating a s im ilar d is tribu tion  pattern  fo r both 
[M e t]-a n d  [Leu]-enkephalin-conta in ing nerves (Elde £ t  al., 1976) and the
n
existence of many enkephalinergic neuronal systems (H okfe lt et al., 1977a; 
Khachaturian et al., 1983). Evidence fo r separate neuronal systems fo r 
proopiomelanocortin and proenkephalin products was provided by the d iffe ring  
d istribu tion  of 8-endorphin and the pentapeptides (Watson e t al., 1978; Bloom et 
al., 1978). In the numerous studies o f proenkephalin d is tribu tion  in the centra l 
nervous system, or CNS, i t  has consistently been noted tha t enkephalin-containing 
nerves often exist alongside dynorphin-containing nerves (Khachaturian et al.,
1983). Whether or not co-storage o f the respective precursors occurs is unknown.
To date, most im m unocytochem ical studies of CNS proenkephalin-containing 
neuronal systems are in agreement concerning the widespread occurrence o f these 
peptides (see Table 2). They are found in s im ila r d is tribu tion  ra tios  to those 
achieved fo llow ing com plete processing o f the precursor molecule (Boarder et al., 
1982; Ikeda et al., 1982). The use of biochem ical tools, such as co lchicine which 
inhib its m icrotubular axial transport of nerve ce ll products, has fa c ilita te d  the 
detection o f enkephalin-containing ce ll bodies. Table 3 illu s tra te s  the widespread 
d istribu tion  o f proenkephalin products in the CNS.
One of the major enkephalin neuronal systems of the brain is found in the 
basal ganglia, where the possib ility  o f in teractions w ith  dopaminergic nerves has 
been investigated (van Ree et al., 1986; Sivam et al., 1986). W hilst the early work 
employed antibodies specific  only fo r the pentapeptides, more recent studies have 
used antibodies specific fo r both the heptapeptide and octapeptide and have 
confirm ed s im ila r d is tribu tion  patterns fo r [M e t] enkephalin, [Leu ] enkephalin,
Table 3: Central Distribution of Proenkephalin Products in the Rat
Brain Area Density Reference
F ore-brain
Basal ganglia * * * * * Boarder et al., 1982; 
Yang et al., 1983; 
Stern et al., 1979
Hippocampus * * M cGinty et al., 1984
Amygdala * * McGinty et al., 1984
Cortex * Boarder, et al., 1982; 
Yang et al., 1983
Cerebellum * Boarder et al., 1982
Hypothalamus * * * Cuello, 1983; 
P ittiu s  et al., 1983
Thalamus * * * * Cuello, 1983
Mid-brain
C o llicu li * * * A k il et al., 1984
Periaqueductal gray * * A k il e t al., 1984
Interpeduncular nucleus * * * A k il e t al., 1984
Hind-brain
Pons * * * Cuello, 1983; A k il, 1984
Medulla * * * P ittiu s  et al., 1983; A k il, 1984
Parabrachial nucleus * * * * Cuello, 1983; A k il, 1984
Vestibular nucleus * * Cuello, 1983; A k il, 1984
Raphe nucleus * * Cuello, 1983; A k il, 1984
Nucleus tractus solitarius * * * Cuello, 1983; A k il, 1984
Spinal Cord
Dorsal horn * * * * Khachaturian e t al., 1983
Spinal trigem ina l nucleus * * * Khachaturian e t al., 1985; 
Iadorola et al., 1986
Key: * * * * *  _ very dense
* * * *  _ dense
* * *  - medium
* *  - ligh t
*  - sparse
[M et] enkephalyl-arg^-phe^ and [M et] enkephalyl-arg^-g ly^-leu^ (Rossier et al., 
1980; Ikeda e t al., 1983; P ittiu s  e t al., 1983; Boarder et al., 1982). This widespread 
CNS d is tribu tion  suggests tha t proenkephalin products have the po tentia l to 
in fluence a wide varie ty  o f brain functions (A k il et al., 1984; Copolov, 1985).
1.3.2 Release of Proenkephalin Products
To establish the physiological relevance o f a puta tive  hormone or 
neuro transm itte r, i t  is generally accepted tha t i t  is necessary to  demonstrate 
release o f the compound under appropriate conditions.
Evidence fo r the release o f [M e t ] -  and [Leu ]-enkepha lin  from  nerve 
term ina ls has come from  biochem ical and pharmacological studies jn  v itro  w ith  
brain tissue slices (Bayon jet al., 1978) and synaptosomes (Henderson e t al., 1978). 
The release has been shown to be calcium-dependent and the ra tio  o f [M e t ] -  
enkephalin to [Leu] enkephalin is approxim ate ly 4:1. This ra tio  of the two opioid 
pentapeptides is the same as tha t produced fo llow ing complete processing o f the 
proenkephalin molecule.
More recent studies have demonstrated the concom itant release o f 
[M e t] enkephalyl-arg^-phe^ and [M e t] enkephaiyl-arg^-g ly^-leu^ w ith  the 
pentapeptides from  ra t s tr ia ta l slices jn  v itro  (Patey e t ai., 1983; Patey e t a l.,
1985) and ra t spinal cord jn  vivo (Iadarola e t al., 1986; Tang et al., 1983). In a ll 
cases, the ra tio  o f the four released peptides was close to tha t found in the 
proenkephalin molecule. In the periphery, most a tten tion  has been focused on the 
release o f proenkephalin products from  the adrenal medulla, which is the m ajor 
source o f opioid peptides.
Early studies demonstrated tha t s tim u la tion  of the adrenal gland jn  vivo 
(Clement-Jones e t al., 1980) or perfused gland in v itro  (Viveros et al., 1980) evoked 
the release o f catecholamines and enkephalins in to the adrenal vein. Enkephalins
were shown to be present in axon term inals o f the splanchnic nerve, as w e ll as in 
the adrenal m edullary chrom affin  cells (Schultzberg et al., 1978), thus confusing 
the orig in  o f the c ircu la ting  enkephalins. In v itro  studies using adrenal ch rom affin  
cells demonstrated the calcium-dependent release of opioid peptides fo llow ing 
n ico tin ic  stim u la tion  (L iv e tt et al., 1981). This suggested tha t n ico tin ic  cholinerg ic 
receptors mediated the release o f opioid peptides. This was substantiated by in vivo 
evidence demonstrating the release o f high and low molecular weight proenkephalin 
products fo llow ing n ico tin ic  cholinerg ic receptor s tim ula tion (Hanbauer e t al., 
1982).
Fu rthe r studies suggested tha t the nature o f the released proenkephalin 
products depended upon the stimulus. I t  has been demonstrated, using the perfused 
adrenal gland, tha t e ither acetylcholine or a depolarising concentration of 
potassium chloride results in the release o f high molecular weight peptides, 
whereas splanchnic nerve stim u la tion  releases mainly low m olecular weight, 
com plete ly processed peptides (Chaiminade et al., 1984). Additional support fo r 
this mechanism comes from  more recent investigations (Vindrola et a l., 1988) and 
con flic ts  w ith  the earlie r suggestion tha t opioid peptide release is mediated solely 
by n ico tin ic  receptors. These studies demonstrated tha t in perfused adrenal glands, 
s tim u la tion  of muscarinic cholinerg ic receptors resulted in the release o f 
adrenaline and low m olecular weight opioid peptides, whereas s tim u la tion  of 
n ico tin ic  cholinerg ic receptors resulted in the release of noradrenaline and high 
m olecular weight, p a rtia lly  processed opioid peptides.
The existence o f opioid receptors on ch rom affin  cells has been dem onstrated 
(Costa et al., 1981), although th e ir physiological significance is uncerta in. The 
receptor shows characteris tics of the cr-receptor (see Section 1.4.1) and i t  was 
o rig ina lly  hypothesised tha t the receptor may "recognise" the released peptides and 
function as an autoreceptor. S tim ula tion o f the receptor selective ly blocks the
release o f catecholam ines induced by nicotine, but not the release induced by a 
high potassium concentration (Kumukura e t al., 1980). This issue has been fu rth e r 
com plicated by the observation tha t w h ils t opioid peptides produce a dose- 
dependent inh ib ition  of n icotine-stim ula ted release o f catecholamines from  
chrom affin  cells, the action is not reversed by naloxone, suggesting tha t i t  is not 
opioid receptor mediated (Dean et al., 1982). Consequently, the role o f chrom affin  
cell opioid receptor remains unclear.
1.3.3 Metabolism of Proenkephalin Products
Research in to  the physiological and pharmacological actions of opioid 
peptides has been hampered due to the very e ff ic ie n t mechanisms leading to th e ir 
degradation. Shortly a fte r the enkephalins were discovered, i t  was observed tha t 
they were hydrolysed almost im m ediate ly when brought in to  contact w ith  e ithe r 
brain tissue in vivo or brain tissue slices in v itro  (Schwartz, 1983). Extrem ely rapid 
inactiva tion  o f proenkephalin products also occurred fo llow ing intravenous 
adm in istra tion, w ith  reported ha lf-lives ranging from  4 seconds to 2 minutes fo r 
[M et] enkephalin (Dupont et al., 1977; Hambrook e t a l., 1976; Weinberger e t al., 
1986; Clement-Jones e t al., 1980) and 45 seconds fo r [M et] enkephalyl-arg^-phe^ 
(Chou et al., 1983). In v itro  studies have also demonstrated the degradation o f 
enkephalins and shorter peptides fo llow ing incubation w ith  isolated tissue 
preparations, w h ils t la rger peptides such as 8-endorphin and dynorphin A are much 
more resistant to enzym atic breakdown (M cKnight e t al., 1983; C orbe tt et al.,
1982).
The a c tiv itie s  o f various peptidases have been studied by determ ining which 
fragments o f individual proenkephalin products appear f ir s t  in the presence o f brain 
tissue. F igure 4 indicates the enzymes responsible fo r the degradation of 
proenkephalin products and the inh ib itors tha t have been employed to  attenuate or 
abolish th e ir a c tiv ity .
1.3.3.1 Aminopeptidases
Aminopeptidases were the f irs t  enkephalin-hydrolysing enzymes to be 
identified  when i t  was realised th a t large amounts of tyrosine were released by the 
breakdown of [M e t ] -  or [Leu ]-enkepha lin , both in vivo and jn  v itro . The 
heterogeneous patte rn  o f in h ib ition  by several reagents on d iffe re n t subcellular 
fractions suggests th a t the enkephalin-hydrolysing aminopeptidase a c tiv ity  is not 
due to a single enzyme. The aminopeptidases involved include the aminopeptidase 
M il, found extensively in the brain and lung (Hersh, 1985), and the w idely 
d istributed aminopeptidase N, fo rm erly  designated aminopeptidase M (Gros et aj.,
1985). A l l aminopeptidases appear to be metallopeptidases o f which the most 
potent inh ib ito r cu rren tly  available is bestatin, a compound o f bacteria l orig in 
(Barclay and Ph illips, 1980). A m asta tin  and purinom ycin are also capable of 
s ign ifican tly  inh ib iting  the actions o f aminopeptidases (Aoyagi e t aj., 1978; Hersh, 
1981). There is considerable evidence to support the action o f aminopeptidases in 
enkephalin degradation, both in vivo and jn  v itro  (C ha ille t et aj., 1983; Chan jst aj., 
1987; Gaddis et aj., 1987; M cKnight et aj., 1983; Reggiani e t a j., 1984). W hilst 
bestatin has proved useful as an aminopeptidase inh ib ito r, there is cu rren tly  no 
aminopeptidase in h ib ito r tha t approaches the potency w ith  which phosphamidon or 
thiorphan in h ib it the reactions o f endopeptidase-24.11 (see Section 1.3.3.4).
1.3.3.2 D ipep tidy l Aminopeptidases
2 3D ipeptidy l aminopeptidases hydrolysing the gly -g ly  amide bond are also
present in the brain (Gorenstein et aj., 1981), although no selective inh ib ito rs  fo r
these enzymes are available. I t  appears tha t d ipeptidyl aminopeptidases are not
p rim arily  involved in enkephalin metabolism. In a study o f the hydrolysis of [M e t ] -
1 2enkephalin by ra t s tr ia ta l slices, i t  was shown tha t the fragm ent ty r  -g ly  
represented only 2% of the hydrolysis products formed in the absence o f any
1 2
inh ib ito rs  (de la Baume et a l., 1983). The level o f ty r  -g ly  doubled in the presence 
of bestatin and thiorphan, ind ica ting tha t d ipeptidyl aminopeptidases are 
unaffected by inh ib itors o f aminopeptidase and endopeptidase 24.11 a c tiv ity .
1.3.3.3 Angiotensin Converting Enzyme
One of the major cleavage points o f the enkephalin molecule is between the 
gly^-phe^ amide bond and th is is mediated by two d iffe re n t types o f degrading 
enzymes. The f irs t  o f these is angiotensin converting enzyme, ACE (EC 3.4.13.1), 
which is w idely d istribu ted in mammalian tissues. Its major location is considered 
to be the lung, where i t  catalyses the inactiva tion  of bradykinin and the hydrolysis 
of angiotensin I to yie ld the vasoactive peptide angiotensin II (Soffer, 1976). The 
hydrolysis of the gly^-phe^ bond o f enkephalin jn  vivo appears to be a function  of
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ACE (Erdos e t al., 1978), although i t  is possible that i t  also has a ro le in the 
processing of proenkephalin (Demmer and Brand, 1983). An in h ib ito r o f ACE, the 
antihypertensive agent captopril, has been widely used in experiments investigating 
enkephalin breakdown. C aptopril has been found to have considerable po ten tia ting  
e ffec ts  on the a c tiv ity  o f proenkephalin products, both in vivo and in v itro  (Geh et 
al., 1986; Lentzen et al., 1984; D i N ico lantanio et al., 1983; Shvarts and Faerm ark, 
1987; M cKnight et al., 1983). This provides strong evidence tha t ACE has the 
a b ility  to  degrade proenkephalin products, although how s ign ifican t th is is in the 
overall metabolism of the peptides is uncertain.
1.3.3.4 Endopeptidase-24.11
The other m ediator o f cleavage a t the gly^-phe^ amide bond is 
endopeptidase-24.11 (EC 2.4.24.11) or "enkephalinase". Considerable discord 
surrounds the nomenclature o f th is enzyme. De la Baume et al. (1983) and others 
have used the term  "enkephalinase". This has been critic ised  (Turner e t a l., 1983)
since the enzyme does not act exclusively on enkephalins and is w idely d is tribu ted 
in many mammalian tissues which do not contain endogenous enkephalins. In view 
o f these critic ism s, endopeptidase-24.11 w ill be used to re fe r to th is enzyme.
Endopeptidase-24.11 was f ir s t  purified  from  the kidney, where i t  is 
pa rticu la rly  abundant (K err and Kenny, 1974). I t  has since been isolated from  brain, 
spinal cord, lung, in testine and many other sites (Llorens and Schwartz, 1981). The 
peptide bonds hydrolysed are those involving the amino groups of hydrophobic 
residues (phe, leu, ile , val, ty r, trp), ind ica ting tha t the enzyme has a broad 
sp ec ific ity . The observation by Schwartz et al. (1981) tha t the enkephalin analogue 
[M e t] enkephalinamide was a re la tive ly  poor substrate led to the assumption tha t 
the enzyme functioned as a peptidyl dipeptidase requiring a free a-carboxyl group 
at the C-term inus fo r hydrolysis to occur. This is not the case since enkephalins 
containing C -te rm ina l extensions, such as [M et] enkephalyl-arg^-phe^, are 
hydrolysed at the gly^-phe^ bond as rap id ly as the pentapeptide, [M et] enkephalin 
(Marks et al., 1982).
Phosphamidon and thiorphan are potent inh ib itors o f the hydrolysing action of 
endopeptidase-24.11 and there is m vivo and jn  v itro  evidence to demonstrate the 
enkephalin pro tective  action of these inh ib ito rs  (Giros et al., 1987; Mendelsohn et 
al., 1983; Roques et al., 1980; M cKnight e t al., 1983).
1.3.3.5 Summary
The metabolism of proenkephalin products is a consequence o f combined 
widespread enzyme actions a t specific  cleavage points of the peptide molecule. 
This appears to be due to the actions o f a bestatin-sensitive aminopeptidase and of 
endopeptidase 24.11, although experim enta l evidence also supports a ro le  fo r ACE.
The problem of enzym atic degradation of opioid peptides is counteracted in 
receptor binding assays by perform ing them a t 0°C, or by using stable enkephalin
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analogues. However, w ith  stable analogues the s truc tu ra l m odifications o ften  result 
in changes in potency and receptor s e le c tiv ity  (see Section 1.4). The am idation o f 
[Leu] enkephalin, a 6-receptor p re fe rring  agonist, to form  [Leu] -
enkephalinamide results in a more peptidase resistant enkephalin analogue th a t has 
p re fe re n tia l a c t iv ity  at p-receptors (Paterson a t al., 1983). Consequently the use o f 
enkephalin analogues to m im ic the endogenous opioid peptides has severe 
lim ita tions .
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Enkephalin-degrading Enzymes And Their Inhibitors.
Dipeptidyl aminopeptidase Endopeptide 24-11 (Thiorphan) 
'Enkephalinase
N terminal
TYR— GLY—GLY-^HE— MET--ARG---PHE
C terminal
/
/
/
Aminopeptidase Angiotensin-converting enzyme 
(Bestatin) (Captopril)
Figure 4: The sites o f enzyme degradation a representative proenkephalin
product, [M e t]  enkephalyl-arg -phe . The main known cleavage sites 
are shown in bold arrows, dotted arrows represent pu ta tive  cleavage 
sites. The commonly employed inh ib ito rs  o f each enzyme are shown in 
brackets.
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1.4 MULTIPLE OPIOID RECEPTORS
There are several reasons to suggest the existence of m u ltip le  opioid 
receptors. Many endogenous opioids possessing w idely d iffe rin g  structures and 
varying numbers o f amino acid residues have been characterised. This, coupled w ith  
the wide varie ty  o f known physiological responses produced by opioids, suggests 
tha t the existence o f a single type o f receptor is unlikely.
The term  opioid receptor is one tha t has become a m a tte r o f controversy 
over recent years. A t  present, the most w idely used c r ite r ia  fo r c lassifica tion of 
an opioid action is tha t of reve rs ib ility  by the opioid antagonist, naloxone. 
A dd itiona lly , the drug-receptor in teractions should be stereospecific, shown by the 
agonist response being com plete ly blocked by low concentrations o f (-) , but not (+), 
isomers o f opioid antagonists.
1.4.1 Opioid Receptor Subtypes
In the mid-1960's, Portoghese (1966) proposed a m u lt ip lic ity  o f opioid 
receptors based on data from  the relationship between the m olecular s tructure  o f 
opioid drugs. Since then, three subtypes o f opioid receptor named mu, delta and 
kappa have been characterised through pharmacological and biochem ical 
techniques and are universally accepted.
1.4.1.1 Pharm acological Evidence
The f ir s t  real evidence fo r the existence of m u ltip le  opioid receptors was 
obtained by M artin  e t al. (1976) in pharmacological experiments perform ed on 
chronic spinal dogs. They found tha t d iffe re n t natura l and synthetic  opioids 
exhibited very d iffe re n t pharmacological profiles when studying e ffe c ts  on heart 
rate, respiration, body tem perature, nociceptive reflexes and pupil size. Moreover, 
the opioids were unable to substitute fo r each other in the prevention o f
w ithdraw al symptoms in dogs chron ica lly trea ted  w ith  one particu la r opioid. Based 
on these findings, M artin  concluded tha t the existence of three opioid receptors 
had been demonstrated. He named them a fte r  the prototype drugs used in the 
study; mu (y) a fte r  morphine, kappa (k) a fte r  ketocyclazocine and sigma (a) a fte r  
SKF 10,047 (N -a lly l normetazocine). However, there are now considerable doubts 
as to the existence of the sigma receptor (see Section 1.4.1.4). His c lass ifica tion  
was supported by fu rth e r neurophysiological and behavioural investigations using 
both natura l and synthetic opioid alkaloids (Simon and H ille r, 1984).
The receptor se lectiv ities  o f the endogenous opioid peptides has large ly been 
determ ined through the use o f isolated tissue bioassays. Early studies showed th a t 
compared to  the opioid alkaloids, the enkephalins and peptidase resistant 
enkephalin analogues only produced a sm all inh ib ition  o f the e le c tr ica lly -s tim u la ted  
contraction  o f the longitud inal muscle of the guinea-pig ileum. This trend was 
reversed when observing the same e ffe c t in the mouse vas deferens (Lord e t al., 
1977). Both responses were reversed by naloxone. However, ten tim es the 
concentration o f naloxone was required to antagonise the e ffe c t o f the enkephalins 
on the mouse vas deferens, compared to tha t required to antagonise the e ffe c t of 
morphine on the guinea-pig ileum  (Lord e t al., 1977).
These studies suggested tha t d iffe re n t classes of receptors predominated in 
the two jn  v itro  bioassay systems. The receptor type present in the guinea-pig 
ileum  was designated y because of its  pharmacological resemblance to  M artin 's  y -  
receptor, w h ils t the receptor in the mouse vas deferens was termed delta  ( 6).
O ther isolated tissue preparations have since been used to assay opioid 
agonists and antagonists and the opioid receptor profiles of several w idely used 
bioassay tissues have been established. The guinea-pig ileum possesses y -  and k- 
receptors (Holzer e t al., 1983) and the mouse vas deferens possesses m ostly 6 - 
receptors, but also some y -  and k-receptors (Lord et al., 1977) Only k-recepto rs
have been demonstrated in the rabb it vas deferens (Oka et a l., 1981) and the 
hamster vas deferens possesses only 6 -receptors (M cKnight e t al., 1984). The ra t 
vas deferens probably only possesses y -receptors, although this is a m a tte r o f some 
controversy (Smith et a l., 1983; L iao e t al., 1981; Whster et a l., 1979).
1.4.1.2 Biochem ical Evidence
Receptor binding assays have provided fu rthe r characterisation of receptor 
subtypes. Two m ajor approaches are involved in studying the binding o f opioids to 
a receptor subtype. F irs t, the k in e tic  parameters of the in te rac tion  o f a labelled 
opioid w ith  a binding site, or equ ilibrium  dissociation constant, and the maximum 
number o f binding sites can be determ ined by d irec t analysis o f saturation curves. 
Secondly, the a ff in ity  o f unlabelled opioids may be estimated as an inh ib ition  
constant. This Js determ ined from  th e ir  a b ility  to displace the binding of labelled 
ligands w ith  known characteris tics. In addition, the subclassification o f binding 
sites is fu rthe r supported by the results o f experiments where unlabelled opioids 
se lective ly p ro tec t the binding sites of labelled ligands from  a lky la tion . The use o f 
radioreceptor assays to study opioid receptors has recently been reviewed (Leslie, 
1987). A fundamental c r it ic is m  of th is technique is tha t the binding characteris tics  
o f a drug fa il to  indicate whether i t  possesses agonist or antagonist a c tiv ity . I t  is, 
therefore, only a powerfu l too l i f  used in conjunction w ith  isolated tissue bioassays 
or in vivo experiments which demonstrate agonist or antagonist a c tiv ity .
1.4.1.3 Further Subdivisions
There are suggestions tha t the mu, delta and kappa c lass ifica tion  of opioid 
receptor subtypes is an over s im p lica tion , Pasternak (1986) has proposed tha t two 
types o f mu-receptors exist, y^ , and y 2> based on the mechanisms underlying the 
respiratory depression produced by opioids. In addition, there are also suggestions
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fo r subtypes o f kappa receptors based upon discrepancies in results from  binding 
studies using kappa receptor agonists (Lah ti et al., 1985; C lark e ta l. ,  1988).
1.4.1.4 O ther Spurious Receptor C lassifications
As mentioned earlie r (Section 1.4.1.1), there are considerable doubts as to the 
existence of M artin 's sigma receptor. Further work in to the orig ina lly  defined 
sigma receptor has shown th a t e ffec ts  mediated through the receptor are not 
reversed by the opioid antagonist, naloxone, suggesting tha t they are not opioid 
receptor mediated (Zukin and Zukin, 1981). The receptor appears to  be the same 
en tity  as the phencyclidine (PCP) receptor which has been proposed to mediate the 
psychom im etic! e ffec ts  o f PCP and re lated drugs. Evidence fo r th is is 
demonstrated by the displacement o f PCP from  its  binding site by opioids of the 
sigma type (Zukin and Zukin, 1981).
A f i f th  receptor type, the epsilon (e) receptor has been proposed fo llow ing 
the in te rp re ta tion  o f the pharm acological e ffects  o f 8-endorphin in the ra t vas
it
deferens (Wuster et al., 1979). This designation has been made p rim a rily  on the 
basis of the re la tive  agonist e ffe c ts  o f various opioids re la tive  to  8 -endorph in .' 
Thus, because morphine, which is considered to be a prototype p agonist, had no 
agonist e ffe c t i t  was concluded th a t the p -receptor was not involved in m ediating 
the response (Schulz et al., 1979). The observation tha t [M e t]  enkephalin was an 
extrem ely weak agonist in th is tissue preparation s im ila rly  led to the conclusion 
tha t 6 -receptors also played no s ign ifican t part in the modulation o f the 
e le c tr ica lly  evoked tw itch  response. The lack of a c tiv ity  of morphine and 
[M e t] enkephalin can be explained by the evidence demonstrating th a t morphine is 
only a p a rtia l agonist a t p-receptors (Smith, 1984) and tha t the ra t vas deferens is 
only sensitive to high a ff in ity  agonists (Smith and Ranee, 1983). Studies
dem onstrating tha t the ra t vas deferens possesses powerfu l peptidases, which 
rapid ly breakdown opioid peptides, explains the low a c tiv ity  o f [M e t] enkephalin in 
this preparation. When peptidase inh ib ito rs  were used, the agonist potency of 
[M e t] enkephalin increased by two orders o f magnitude (M cKnight et al., 1983).
1.4.2 Receptor Selectivities of Endogenous Opioid Peptides
1.4.2.1 Proopiom elanocortin Products
t
Although 8 -endorphin was discovered almost 10 years ago, its  receptor 
se lec tiv ity  p ro file  has not yet been fu lly  c la rifie d . In guinea-pig brain, 8-endorphin 
shows a s ligh t binding se lec tiv ity  fo r y -  over 6 -recep to r sites, w ith  neglig ible 
a f f in ity  fo r k-s ites (K os te rlitz  and Paterson, 1985). I t  exhibits no opioid a c tiv ity  on 
the rabb it vas deferens, a preparation consisting solely of k-opio id receptors 
(Rezvani et al., 1983). In the mouse vas deferens, 8 -endorphin shows no se le c tiv ity  
fo r y -  over k-and 5-receptors as revealed by receptor inactiva tion  experiments 
using an a lky la ting  agent (Goldstein and James, 1984). I t  is possible th a t 8 - 
endorphin in te racts  w ith  e -receptors in the mouse vas deferens, although the 
existence o f these receptors is a m a tte r o f conjecture (see Section 1.4.1.4). There 
is evidence tha t, in addition to y -  and 6-sites, 8 -endorphin in teracts w ith  a d is tin c t 
population o f binding sites in the brain, which may be the putative e-receptor, 
however th is is highly dubious (A k il et al., 1981). In the ra t vas deferens bioassay, 
8 -endorphin^_27 is more potent than its  parent peptide, 8 -endorphin2_-j2> or 
fu rth e r C -te rm ina l shortened cleavage products (Schulz e ta l. ,  1981). A lthough part 
o f th is potency may be a ttribu ted  to the p re fe re n tia l inactiva tion  of the shorter 
peptides by enzym atic degradation, there appears to exist an in tr in s ica lly  high 
potency o f 8 -endorphin^ an<^  8-endorphin^ preparation. S im ila r
observations have been made in binding studies (A k il e t al., 1981).
The sm aller C -te rm ina l peptides, [M e t] enkephalin, a - and y-endorphin have 
lower binding a ffin it ie s  than the two 8 -endorphin peptides. Consequently, the C-
te rm ina l extended peptide chain in 8 -endorphin, as compared to [M et] enkephalin, 
appears to  increase both the se lec tiv ity  and potency fo r puta tive  6 -receptors and 
the resistance to degrading enzymes. On the other hand, m odifica tion of the N- 
term inus by acety la tion  v ir tu a lly  abolishes binding and opioid a c tiv ity  in the 
preparation (Zakarian and Smyth, 1982; A k il e t al., 1981).
Thus, |3-endorphin j_2 j  and B -e n d o rp h in ^y  in te ra c t p re fe ren tia lly  w ith  y -, 
6 - and possibly the pu ta tive  £-, but not k-opioid receptors (Table 4). N -A ce ty la tion  
of these peptides abolishes the opioid a c tiv itie s  of these peptides and may be 
regarded as a physiological inactiva tion  mechanism.
1.4.2.2 Proenkephalin Products
A clear se le c tiv ity  fo r 6-receptors is exhibited by [M e t ] -  and [L e u ]- 
enkephalin, [M e t] enkephalyl-arg^-phe^ and [M et] enkephalyl-arg^-g ly^-leu^ in 
the mouse vas deferens bioassay (Lord et al., 1977). [ M et] Enkephalyl-arg^-gly^-
g
leu also appears to in te ra c t w ith  k-opioid receptors, as evidenced in mouse vas 
deferens preparations rendered cross-to lerant to k-opio id receptor agonists (Schulz 
et al., 1982). Binding studies show tha t both [M e t] - and [ Leu]-enkephalin  possess 
a high se lec tiv ity  fo r 6 -binding sites in guinea-pig brain (Lord et al., 1977) and in 
mouse brain (Garzon et al., 1983), this is pa rticu la rly  so fo r [Leu ] enkephalin. 
[M et] Enkephaiyl-arg^-phe^ and [ M et] enkephalyl-arg^-g ly^-leu^ exhib it 
comparable a ffin it ie s  fo r y -  and 6 -opioid receptors, w ith  low a ffin it ie s  fo r k- 
receptors (Paterson e t al., 1984).
The la rger peptides derived from  the peptide E domain of proenkephalin, 
peptide E, BAM-22P and BAM-12P, show high a ff in ity  and se lec tiv ity  fo r y-b ind ing 
sites (Garzon et al., 1983). This is also indicated by the high potency of these 
peptides in the guinea-pig ileum, compared to the low potency in the mouse vas 
deferens (Mizuno et al., 1980). In addition, these peptides show considerable
a ff in ity  fo r k-binding sites, about 40-50% of the a ffin itie s  fo r the y-s ites. This is 
also demonstrated by the ir high a c tiv ity  in the rabb it vas deferens (Rezvani et al.,
1983). In contrast, the a f f in ity  o f these peptides fo r 6 -receptors is low  (Garzon et 
al., 1983).
The binding se le c tiv ity  of metorphamide is s im ila r to tha t of the 
aforementioned peptides, ind icating tha t the site se lec tiv ity  does not change 
markedly when peptide E is processed to metorphamide (Weber et al., 1983). In 
contrast, peptide F exhibits about a hundred-fold lower a ff in ity  fo r y-recepto rs  
than the peptides derived from  peptide E. Moreover, peptide F does not have any 
p re fe ren tia l a f f in ity  fo r any o f the three types o f binding sites tested (Garzon et 
al., 1983). I t  is inactive  on the rabb it vas deferens and exhibits a low potency on 
both the guinea-pig ileum and the mouse vas deferens (Rezvani £ t  al., 1983), 
indicating tha t i t  does not have any pa rticu la r a ff in ity  at y - , k- and 6-opioid 
receptors. However, peptide F - and peptide E-derived peptides show substantia l 
potency on the ra t vas deferens, which has led to the suggestion tha t they may
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in te rac t w ith  the proposed e -receptor (H d lt  et al., 1985). As previously mentioned, 
the existence o f th is receptor type is by no means certa in  and these e ffec ts  in the 
ra t vas deferens may re fle c t y -recep to r a c tiv ity .
In conclusion, the in term edia te  processing products o f proenkephalin possess 
d iffe ring  receptor se lec tiv ities  (Table 4). The peptide E re lated peptides in te ra c t 
w ith  y - , k-and possibly 6 -receptors, whereas peptide F appears to exh ib it a c tiv ity  
a t the putative e-receptor only. Complete processing o f proenkephalin in to  the 
enkephalin pentapeptides, heptapeptide and octapeptide is associated w ith  a change 
in the receptor se lec tiv ity  towards 6-opioid receptors, w ith  some y -a c t iv ity  
residing in the heptapeptide and octapeptide.
Table 4: Suggested Receptor Selectivities of Opioid Precursor Products
Opioid Peptide Receptor S e lec tiv ity
Proopiomelanocortin derived
8 -Endorphin y > 6
Proenkephalin derived
[M e t] Enkephalin 6 > y
[Leu ] Enkephalin 6 » y
[M et] Enkephalyl-arg^-phe^ 6 = y > k
[M e t] Enkephalyl-arg^-g ly^-leu^ 6 = y > k
BAM-12P y > k »  £
BAM-22P y > k »  <s
Peptide E y > k »  6
Peptide F y = k = 5
Metorphamide y > k »  5
Prodynorphin derived
Dynorphin A k
Dynorphin A (1-8) k > y = 6
Dynorphin B k
a-Neoendorphin k
8 -Neoendorphin k > 6
Leumorphin k > y
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1.4.2.3 Prodynorphin Products
A ll opioid peptides derived from  prodynorphin have been shown to  exh ib it a 
pronounced se lec tiv ity  fo r k-opio id receptors (K oste rlitz  and Paterson, 1983; 
Goldstein and James, 1984; H ttllt j 3t  al., 1983). A ll these peptides are active  in the 
rabb it vas deferens (Rezvani e t al., 1983; C orbett et al., 1982). In binding 
experiments, dynorphin A appears to  have the highest a ff in ity  and se le c tiv ity  fo r k- 
binding sites, whereas the dynorphin A (1-8) fragm ent has both a lower a ff in ity  and 
se lec tiv ity  fo r k-sites in guinea-pig brain membranes (K os te rlitz  and Paterson,
1985).
Dynorphin A, a-neoendorphin and dynorphin B are selective k-agonists in the 
guinea-pig ileum. Dynorphin A (1-8) and leumorphin appear to in te ra c t w ith  k- and 
y-op io id  receptors, as assessed by d iffe r in g  sensitivites of the peptides to 
antagonism by naloxone (James et a l., 1984). S im ila rly , in the mouse vas deferens, 
dynorphin A, dynorphin B and leumorphin are selective k-agonists, whereas 
dynorphin A (1-8) and 8-neoendorphin are d is tin c tly  less selective fo r  k-receptors 
and appear to in te rac t w ith  6 -receptors, as revealed in a lky la tion experiments 
(Goldstein and James, 1984). In the ra t vas deferens, a ll prodynorphin products are 
v ir tu a lly  inactive, suggesting no a c t iv ity  a t the putative e-receptor (C orbe tt e t al., 
1982).
Thus, the processing of prodynorphin generates a set of opioid peptides tha t 
exh ib it se lec tiv ity  fo r k-opio id receptors (Table 4). Dynorphin A is the most potent 
and selective peptide w h ils t fu rth e r processing in to  dynorphin A (1-8) is associated 
w ith  a change in receptor se lec tiv ity  towards 6 -opioid receptors.
1.4.3 Development of Receptor Selective Ligands
In order to gain an understanding of the functions o f the y -, 6 - and k-opio id 
receptors the development of receptor selective agonists and antagonists is an 
essential requisite. The endogenous opioid peptides often in te rac t w ith  more than 
one receptor type and none has absolute pharmacological spec ific ity  fo r a given 
receptor type (H a lit, 1986).
F urther studies of the in v itro  pharmacological actions of opioid peptides and 
the ir analogues have produced a wealth o f in fo rm ation  concerning s truc tu re - 
a c tiv ity  relationships. This has resulted in fu rth e r knowledge of the functiona l 
chemical group positions tha t influence opioid receptor spec ific ity  (Lenz et al.,
1986). The y -rece p to r se lec tiv ity  of an enkephalin analogue is increased by a
combination o f reducing the number o f amino acids in the peptide, in troduction o f
2 4a lipoph ilic  D-am ino group at gly , and replacing phe by a large lipoph ilic  chain
and hydrophobic amino acids at position 3. D e lta -recep to r se lec tiv ity  is increased
4
by the presence of an arom atic ring at phe , a hydrophilic C-term inus and
2
hydrophilic D-am ino acid a t gly (Lenz et al., 1986).
1.4.3.1 Agonists
Many a ttem pts have been made to synthesise peptides and non-peptides w ith  
high se lec tiv ity  fo r one binding site only.
W hilst morphine and the m orphine-related alkaloids, normorphine, 
dihydromorphine and levorphanol, show a re la tive ly  high se lec tiv ity  fo r the y -
receptor, synthetic  m odified enkephalins have been developed which possess a
2 4 5higher se lec tiv ity . These include [D -A la  , N-Phe , Met(o)ol ] -enkephalin (FK
33824) which exhib its a somewhat higher a f f in ity  fo r y -  than 6 -receptors. This has
r\ A  C
now been superseded by the s truc tu ra lly  s im ila r [D -A la  , MePhe , G ly-o l ] - 
enkephalin (DAGO), which is about tw ice  as potent as morphine and exhibits a high 
se lec tiv ity  fo r y-recepto rs  (K os te rlitz  and Paterson, 1981). In addition, DAGO has 
been shown to  be resistant to the action of peptidases, which is a d is tin c t
experimental advantage. O f the anilino piperidine derivatives, a lfen tan il shows 
greater p -se le c tiv ity  than DAGO (Yeadon and K itchen, 1988).
The attem pts to develop a selective 6 -receptor agonist have resulted in the
synthesis of a range of analogues of [Leu] enkephalin, the endogenous opioid
peptide showing greatest se lec tiv ity  fo r the 6 -receptor. These include [D -5e r , L -
Leu^ ]-enkepha ly l-Thr (David et al., 1982), [D -Thr^, L-Leu^ ]-enkephaly l-Thr
(Zajac et al., 1983) and [D -A la ^ , D-Leu^ ] -enkephalin (DADLE). However, these
substituted peptides were shown to possess a degree o f cross re a c tiv ity  w ith  p-
opioid receptors and so the search fo r a selective 6 -recepto r agonist continued.
This resulted in the synthesis of bis-penicillam ine-contain ing, cyc lic  enkephalin
analogues (Mosberg et al., 1983). The most 6-se lective  of these analogues was
2shown to be [ 2-D -penic illam ine, 5-D -pen ic illam ine] -enkephalin, ([D -P en  , D-
5 2 3Pen ] -enkephalin or DPDPE ) and the s truc tu ra lly  s im ila r [D -Pen , L-Pen ] -
enkephalin. These peptides are also peptidase resistant and possess a fa r superior
se lec tiv ity  fo r 6 -receptors, w ith  v ir tu a lly  no actions a t p-receptors (C orbett e t al.,
1984).
The p ro to typ ic  k-agonists, ketocyclazocine and ethylketocyclazocine, were 
shown to exh ib it high a ffin it ie s  fo r both p - and k-opioid receptors (Vanvoigtlander 
et al., 1982), which provided the impetus to develop a k-recepto r selective agonist. 
U-50, 488H, jtrans-3 ,4 -d ich lo ro -N -m ethy l-N -[2 -(-pyrro lid iny l)-cyc lohexy l] -benzene- 
ace tam ide j, and U-69593, a closely re lated analogue, are compounds tha t have 
been synthesised by Upjohn and have been shown to  possess a high se le c tiv ity  fo r k- 
receptors (Vanvoigtlander et al., 1982; Lah ti et al., 1983). However, in comparison 
to dynorphin A, U-50, 488H only exhibits a fo rt ie th  of the a ff in ity  fo r  k-receptors 
(K oste rlitz  and Paterson, 1985) and so the search fo r a high a ffin ity , selective k- 
receptor agonist continues.
O f the curren tly  available opioid receptor selective agonists, DAGO, DPDPE 
and U-50, 488H are commonly used in in v itro  and in vivo studies to characterise
pharmacological e ffe c ts  mediated through p -, 6 - and k-opioid receptors 
respectively. F u rthe r research e ffo rts  are s t i l l  being directed towards developing 
agonists w ith  superior a ff in ity  and se lec tiv ity .
A
1.4.3.2 Antagonists
The po ten tia l value o f opioid receptor selective antagonists in
pharmacological research is certa in ly  as great as tha t afforded by receptor 
selective agonists, pa rticu la rly  in determ ining a physiological role fo r endogenous 
opioid peptides. Research in this area has been slower than tha t in the quest fo r 
selective agonists. A t  low concentrations, naloxone is re la tive ly  selective fo r  p -
receptors but, i f  concentrations are raised, i t  also acts as an antagonist at the k-
receptor and the 6 -recepto r (K os te rlitz  and Paterson, 1985).
A recen tly  developed 6-receptor antagonist, N ,N -d ia lly l-T y r-A ib -A ib -P he - 
Leu-OH (ICI 174,864) is an enkephalin deriva tive  which has high se lec tiv ity  fo r 6 - 
receptors (C otton et al., 1984). However, its  low potency poses po ten tia l
d iff ic u ltie s  when used jn  v ivo, pa rticu la rly  when system ically administered. There 
are recent reports of a highly selective and potent non-peptide 6 -recep to r 
antagonist, na ltrindo le  (Portoghese et al., 1988). Evidence from  m v itro  bioassays 
indicates tha t th is antagonist possesses superior potency and se lec tiv ity  to  ICI 
174,864. In contrast to peptide antagonists, na ltrindo le  crosses the blood-brain 
barrier, which is advantageous in in vivo studies.
As yet, there are no highly selective k-antagonists and the previously reputed 
selective k-recepto r antagonist, M r2266(a-5,9-d ie thyl-2-(3 -fury lm ethyl)-2 -hydroxy- 
6,7 benzomorphan), has been shown to bind to p -op io id  receptors (K o s te rlitz  and 
Paterson, 1985).
Table 5: Proposed Opioid Receptor Subtypes and their Agonists
Receptor
Type
C haracte ris tic
Classical
Agonist
Puta tive
Endogenous
Peptide
Agonist
Selective 
• Synthetic 
Agonist
Mu (y) Morphine DAGO
Delta (<5) Proenkephalin
products
DPDPE
Kappa (k) Ketocyclazocine Dynorphins U-50, 488H
1.5 CARDIOVASCULAR CONTROL
This section reviews the s truc tu re  and function of the components o f the 
c ircu la tion , the contro l o f blood pressure and the nervous and chem ical 
cardiovascular regulatory mechanisms th a t operate under normal circumstances.
1.5.1 The Heart, Blood Vessels and Circulation
The heart is a hollow muscular organ consisting o f a r ig h t and le f t  side, 
separated by a th ick muscular w a ll, the septum. Each ha lf consists of two 
chambers, an a tria  in to which blood enters from  the veins and a ven tric le  from  
which blood is pumped in to  the arteries. The heart is composed of cardiac muscle 
which has the inherent property o f rh y th m ic ity , the muscle fib res contracting  and 
relaxing a lte rna te ly . This property is developed to the greatest ex ten t in a region 
known as the pacemaker (Hecht, 1965) or s ino -a tria l node. The four chambers o f 
the heart norm ally beat in an organised sequence. In it ia lly  a period, diastole, exists 
when a ll four chambers are relaxed. This is followed by contraction  of the a tria  
(a tr ia l systole) and the contraction  o f the ventric les (ven tricu la r systole). The cycle 
is then repeated. The blood vessels carry blood from  the heart to the tissues and 
back to  the heart. There are three main types of blood vessels; arteries, cap illa ries 
and veins.
The arteries and sm aller a rte rio les are the vessels which carry oxygenated 
blood pumped from  the heart to the tissues. The arte ry  walls contain a high 
proportion o f muscle and elastic tissue (Burton, 1954) which is innervated m ostly by 
sym pathetic nerve fibres. Parasym pathetic nerves to blood vessels are few and are 
found mostly in the sa livary glands and gen ita lia  (Braunwald, 1974). The arte rio les 
are the m ajor site of resistance to blood flow . Small changes in the rad ii o f the 
arterio les results in large changes in the to ta l peripheral resistance and blood 
pressure (re fe r to Section 1.5.2). The arte rio les divide in to sm aller, m uscle-walled 
vessels and these feed in to  capillaries. The capillaries are the sm allest blood
vessels, the lumen being just large enough to allow  the passage of red blood 
corpuscles. The th in  endothelial walls allow  the exchange of gases, nutrien ts and 
m etabolic waste products between the blood and the tissues. The blood is then 
collected from  the capillaries by the venules. The veins and venules re tu rn  the 
deoxygenated blood from  the tissues back to  the heart. Compared w ith  the 
arteries, veins possess a larger lumen and th inner walls. The veins possess a sm all 
amount o f smooth muscle, which is sym pathetica lly innervated.
The c ircu la to ry  system is responsible fo r the transport o f gases, nutrien ts and 
waste products o f metabolism, the d is tribu tion  o f hormones and is also im portan t in 
tem perature regulation. The system can be divided in to two parts, the system ic 
c ircu la tion  and pulmonary c ircu la tion . In the form er, blood is pumped by the le f t  
ven tric le  through the aorta to the arte ries and eventually to the cap illa ries and 
returns via the veins to the r ig h t a trium . In the la tte r, the blood flow s from  the 
rig h t a trium  to the rig h t ven tric le , which pumps i t  through the pulmonary a rte ry  to  
the lung capillaries, where gaseous exchange occurs. The blood then returns to  the 
le f t  a tria  via the pulmonary vein.
1.5.2 The Control of Blood Pressure
Unless otherwise stated, blood pressure refers to the systemic a rte r ia l blood 
pressure which is exerted on the walls o f the arte ries by the blood ejected from  the 
le f t  ven tric le . The pressure is greater during ven tricu la r systole (systo lic pressure) 
than during ven tricu la r diastole (d iasto lic  pressure). The d iffe rence between 
systolic and d iasto lic pressure is re fe rred  to  as the pulse pressure.
Blood pressure is maintained a t a level which allows a blood flow  s u ffic ie n t to  
sustain the m etabolic needs o f the tissues, to  ensure an adequate supply o f blood to  
the brain and to produce the necessary f ilt ra t io n  pressure in the kidney. The blood 
pressure is dependent upon the cardiac output and peripheral resistance 
(Braunwald, 1974).
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1.5.2.1 Cardiac Output
The card iac output is the volume of blood ejected by each ventric le  in one 
m inute and depends upon the heart ra te  and stroke volume. The heart is p rim arily  
contro lled by cardiac innervation, which originates from  the cardiac centre in the 
medulla oblongata of the brain stem. The cardiac centre consists of two 
components, a ca rd iac-inh ib ito ry  centre and a card iac-exc ita to ry  centre (Korner, 
1971), however th is subdivision is not universally accepted. The ca rd iac-inh ib ito ry  
centre is s ituated in the dorsal nucleus o f the vagus nerve and gives rise to a 
continuous vagal or parasympathetic a c tiv ity , known as vagal tone. This slows the 
heart ra te  (Harman and Reeves, 1968) and is term ed negative chronotropism. The 
cardiac- exc ita to ry  centre controls the sym pathetic outflow  to the heart. Un like 
parasym pathetic outflow , the sym pathetic ou tflow  is not continually active. An 
increase in heart rate, positive chronotropism, is produced fo llow ing sym pathetic 
nerve s tim u la tion . There are other im portan t mechanisms influencing the heart 
rate and these are described in Section 1.5.3.
The stroke volume is the amount o f blood pumped from  each ven tric le  per 
heart beat. This volume is determined by the force o f cardiac contraction and 
quantity of blood in the ven tric le  at the onset o f systole (Burton, 1963). The exten t 
to which the ventric les contract is la rgely determ ined by the cardiac centre. An 
increase in the force o f contraction, positive inotropism , is produced fo llow ing  
sym pathetic nerve stim u la tion  orig inating from  the ca rd iac -exc ita to ry  centre. A 
decrease in the-fo rce  of-contraction , negative inotropism , is the result o f vagal or 
parasym pathetic nerve stim ula tion orig inating from  the card iac-inh ib ito ry  centre 
(Korner, 1971).
Under normal circumstances, each side o f the heart is able to transfe r a ll the 
blood i t  is given from  its  venous to its  a rte r ia l side. I f  the volume o f blood 
returning to  the heart increases, more ven tricu la r f ill in g  w ill take place during
diastole. Consequently, the ven tricu la r muscle fibres w ill be stretched and, on the 
next systole, w ill produce a more powerfu l contraction. The resultant increase in 
stroke volume transfers more blood to  the a rte ria l side. This property is known as 
"Starling's Law o f the H eart" and is im portant in ensuring tha t the output of the 
two ventric les are matched (Starling, 1918).
1.5.2.2 Peripheral Resistance
The peripheral resistance is the degree o f resistance to blood flow  as i t  
passes around the systemic c ircu la tion . The smooth muscle in the w a ll o f the blood 
vessels, pa rticu la rly  the arte rio les, is in a constant state o f p a rtia l contraction  due 
to continuous sym pathetic a c t iv ity  or sym pathetic tone (Folkow, 1960). This occurs 
in a ll blood vessels, except fo r those found in skeleta l muscle where sym pathetic 
a c tiv ity  produces a re laxa tion  o f the smooth muscle and results in vessel d ila tion  
(Mauskopf et al., 1969).
Sym pathetic tone orig inates from  a co llection  of nuclei in the medulla 
oblongata, in close p rox im ity  to the cardiac centre, which is known as the 
vasomotor area (Braunwald, 1974). An increase in the a c tiv ity  o f the vasomotor 
area, or VMA, produces an increase in sym pathetic tone, causing blood vessel 
constriction and resulting in a rise in the peripheral resistance. Conversely, a 
decrease in the VMA a c tiv ity  decreases the sym pathetic tone, causing vasodilation 
and a fa ll in peripheral resistance.
1.5.3 Cardiovascular Regulatory Mechanisms
In mammals, m u ltip le  cardiovascular regulatory mechanisms have evolved to 
ensure maintenance o f a constant blood pressure, to increase blood supply to  active  
tissues and to increase or decrease heat loss from  the body by blood red is tribu tion . 
C ircu la to ry  adjustments are produced by nervous and chem ical contro l mechanisms
th a t change the calibre o f the vessels and vary the heart ra te  and cardiac output. 
Loca l autoregulatory mechanisms also operate to maintain blood flow , despite 
fluctua tions in perfusion pressure.
1.5.3.1 Centra l Nervous System Contro l
The two major brain centres involved in cardiovascular con tro l are the VMA 
and the cardiac centre. Both are situated in the medulla oblongata and are 
influenced by numerous factors.
The a c tiv ity  in the closely situated respiratory centre a ffe c ts  the VMA and 
cardiac centre, resulting in rhy thm ica l fluctua tions in a c tiv ity . During inspiration, 
heart ra te  and blood pressure increase, whereas during expiration, a decrease in 
heart rate and blood pressure occurs (Braunwald, 1974). Impulses from  the 
hypothalamus, which occur when the body temperature rises, cause an increase in 
heart ra te  (Herd, 1970). This also produces an inh ib ition o f sym pathetic ou tflow  to  
the blood vessels, resulting in vasodilation and occurs as p a rt o f the heat 
dissipation mechanism. Impulses from  the cerebral cortex have d iffe re n t e ffec ts . 
Excitem ent and anger produce an increase in heart ra te  and blood pressure, 
whereas g rie f and fear cause a decrease in both. Many sensory nerves, pa rticu la rly  
those associated w ith  pain, m odify the a c tiv ity  of the VMA and card iac centre. 
M ild degrees o f pain cause an increase in blood pressure and heart ra te , whereas 
severe pain produces a decrease in blood pressure and heart ra te  (Herd, 1970).
1.5.3.2 Baroreceptors
The baroreceptors are s tre tch  receptors in the walls of blood vessels and the 
heart. The carotid  sinus, situated at the b ifu rca tion  of the common ca ro tid  
arteries in to  the in terna l and external caro tid  arteries, and ao rtic  arch receptors 
are the best documented (G lick and Covell, 1968). S tretch receptors are also
located in the walls of the rig h t and le f t  a tria , a t the entrance of the superior and 
in fe r io r vena cava and pulmonary vein, in the w a ll o f the le f t  ven tric le  and in the 
pulmonary c ircu la tion . These receptors are stim ulated by distension o f the 
structure  in which they are located. Nerve impulses run in the vagus and 
glossopharyngeal nerve from  the baroreceptors to  the VMA and cardiac centre. As 
the pressure on the baroreceptors rises, due to a rise in blood pressure, the nerve 
impulse a c tiv ity  to the VMA and cardiac centre increases. Conversely, i f  the 
pressure on the baroreceptors decreases, due to a fa ll in blood pressure, the nerve 
impulse a c tiv ity  to the VMA and cardiac centre decreases (K ircheim , 1976; Herd, 
1970). An increase in nerve impulse a c t iv ity  inhib its the sym pathetic ton ic  
discharge from  the VMA and excites the ca rd iac-inh ib ito ry  centre. Thus, a rise in 
systemic a rte ria l pressure results in vasodilation, bradycardia, a decrease in 
cardiac output and a decrease in blood pressure. However, a decrease in nerve 
impulse a c tiv ity  increases the sym pathetic ton ic discharge of the VMA and inh ib its  
the vagal tone produced by the cardiac centre. Therefore, a fa ll in system ic 
a rte ria l pressure results in vasoconstriction, tachycardia, an increase in cardiac 
output and an increase in blood pressure (K irche im , 1976; Herd, 1970).
In the a tria , two types o f s tre tch  receptor exist, those tha t discharge during 
a tr ia l systole and those tha t discharge la te  in diastole (Hakumaki, 1968). The re fle x  
c ircu la to ry  adjustments in itia ted  by increased discharge from  these receptors are 
s im ila r to  those described previously. The a tr ia l baroreceptors are part o f a re fle x  
mechanism tha t combats excessive rises in venous pressure and venous re tu rn . In 
addition, ac tiva tion  o f pulmonary stre tch  receptors resulting from  distension o f the 
pulmonary vascular bed causes re flex  bradycardia and systemic hypotension (G lick 
et al., 1969). The location of the receptors involved is uncertain.
Most vascular beds have an in tr in s ic  capacity to compensate fo r m oderate 
changes in perfusion pressure by producing changes in vascular resistance so tha t
blood flow  remains re la tive ly  constant. This capacity is w ell developed in the 
kidney and has also been observed in the mesentery, skeletal muscle, the liv e r and 
brain (Rodbard, 1971).
1.5.3.3 Chemoreceptors
The chemoreceptors are sensitive to changes in the oxygen and carbon 
dioxide tensions in a rte ria l blood. The most im portan t chemoreceptor is the caro tid  
body, which is located close to the carotid  sinus baroreceptor. The main action of 
the chemoreceptors is to increase respiration when there is e ithe r a fa ll in oxygen 
tension or increase in carbon dioxide tension (Purves, 1975). When stim ulated they 
decrease the a c tiv ity  of the VMA, which results in an increased sym pathetic 
outflow  and vasoconstriction (Braunwald, 1974). S tim ula tion o f the chemoreceptors 
also inh ib its  the a c tiv ity  of the ca rd iac-inh ib ito ry  centre, resulting in an increase 
in heart ra te  and cardiac output. These actions cause a rise in blood pressure. The 
chemoreceptors are also stim ulated by a reduction in blood flow , such as th a t 
which occurs during haemorrhage (Purves, 1975).
1.5.3.4 Chemical Contro l
The heart and blood vessels respond to  a varie ty  of chem ical substances 
including peptides, hormones, neurotransm itters, m etabolites and ions.
Angiotensin II is probably the most im portan t endogenous peptide w ith  regard 
to cardiovascular function. An inadequate blood flow  to the kidneys in itia te s  the 
release o f the enzyme renin from  the kidneys. Renin cleaves a plasma pro te in , 
angiotensinogen, to release a decapeptide angiotensin I (Peach, 1977). This is 
enzym atica lly degraded to  angiotensin II, an octapeptide w ith  extrem ely potent, 
widespread vasoconstrictor a c tiv ity . The activa tion  of the renin-angiotensin 
system, in response to a fa ll in blood pressure, is an extrem ely im po rtan t 
mechanism in cardiovascular homeostasis (Braunwald, 1974).
Several peptides called kinins have been isolated from  blood and tissue fluids. 
The best documented kin in is bradykinin which produces a pow erfu l vasodilation 
and increase in blood vessel perm eability . L i t t le  is known about the functions of 
the kinins in the c ircu la tion . Their extrem ely powerfu l, widespread e ffec ts  suggest 
tha t they may play a role in regulating blood flow  in in flam ed tissues (Walaszek, 
1970).
Vasopressin (or an tid iu re tic  hormone) is a nonapeptide secreted by the 
posterior p itu ita ry  gland. I t  is a pow erfu l vasoconstrictor, although the amounts 
released under norm al circumstances do not have any e ffe c t on cardiovascular 
function (Montani e t a l., 1980). During conditions such as haemorrhage, however 
c ircu la ting  levels o f vasopressin are increased (Zerbe, 1982) and the resulting 
vasoconstrictor a c tiv ity  may play an im portan t role in cardiovascular contro l by 
maintaining a rte ria l blood pressure in these circumstances.
Noradrenaline, in addition to being released from  sym pathetic nerve 
term inals, is released w ith  adrenaline from  the adrenal medulla. Noradrenaline 
produces vasoconstriction in almost a ll vascular beds and adrenaline has s im ila r 
effects in most, but not a ll, vascular beds. Both noradrenaline and adrenaline 
produce positive chronotropic and inotrop ic e ffec ts  although the more marked 
pressor response to noradrenaline results in baroreceptor s tim u la tion  so tha t the 
resulting re flex  bradycardia often obscures the tachycardia (Weiner, 1980).
H istam ine is released from  mast cells and basophils in response to m inor 
in jury and is involved in mediating in flam m atory responses. I t  has pow erfu l 
vasodilator e ffe c ts  on the arte rio les and increases cap illa ry  perm eab ility , resulting 
in a leakage o f flu id  and plasma proteins in to  the tissues. I t  has neglig ib le e ffe c ts  
on the heart (Owen, 1977).
Prostaglandins, which are released from  most tissues in to the blood stream, 
possess positive inotrop ic e ffec ts . Members of the prostaglandin E and 
prostaglandin A series lower blood pressure through vasodilation, whereas members 
of the prostaglandin F series produce vasoconstriction, resulting in an increase in 
blood pressure (Higgins and Braunwald, 1972).
M etabolites resulting from  the a c tiv itie s  of tissues are generally vasodilator 
substances. Carbon dioxide and other products of metabolism, such as potassium 
ions, adenosine and la c tic  acid, are released from  the active  muscle cells in to  the 
blood stream. This results in vasodilation and an increase in blood flow  through the 
vascular bed (Johnson and Hendrick, 1975).
1.6 CARDIOVASCULAR EFFECTS OF ENDOGENOUS PEPTIDES
Peptide research has become one of the fastest growing areas in 
neurobiology. Several b io log ica lly active, endogenous peptides have been isolated 
and characterised in recent years and the number o f these peptides is growing a t a 
considerable ra te . This includes c ircu la ting  and p itu ita ry  hormones, hypothalam ic 
releasing factors, gut hormones and other miscellaneous peptides, including the 
opioid peptide fam ily . Most o f the peptides appear to be produced from  the 
cleavage of large precursor polypeptides. Cleavage by processing enzymes can 
produce a m u lt ip lic ity  of b io log ica lly  active  substances. I t  would appear th a t the 
spectrum o f peptides and the ir diverse bio log ica l actions may exceed the number 
and function  o f a ll the other chem ical messengers.
Numerous endogenous peptides exert e ffec ts  upon the cardiovascular system. 
Cardiovascular a c tiv ity  is a dominant feature  o f the biological actions o f some 
peptides (e.g. angiotensin II, bradykinin and vasoactive in testina l polypeptide) but 
fo r others the cardiovascular actions can o ften be overshadowed by o ther e ffe c ts  
o f the peptide (e.g. gastrin, oxytocin and thyrotropin-re leasing hormone). I t  is 
beyond the scope of this section to review  a ll the known cardiovascular e ffe c ts  o f 
endogenous peptides. Emphasis has been placed on the ways in which peptides may 
a ffe c t cardiovascular function, w ith  a closer examination o f those peptides 
possessing potent cardiovascular e ffec ts .
1.6.1 How Peptides A ffec t Cardiovascular Function
Peptide e ffec ts  on the cardiovascular system can be exerted in several ways. 
These may be:-
(i) An action w ith in  the CNS.
(ii)  D ire c t actions on the heart and/or vasculature.
( iii)  In te ractions w ith  other endogenous agents a ffecting  cardiovascular 
function.
(iv) A ctions on other determ inants of cardiovascular function.
1.6.1.1 Peptide E ffec ts  on Centra l Cardiovascular Control
In the CNS, neuropeptides can a ffe c t cardiovascular function by serving as 
neurotransm itters w ith in  the contro l areas th a t regulate cardiovascular function. 
These areas include the card iac-exc ita to ry  and -in h ib ito ry  centres, the nucleus 
tractus so lita rius o f the medulla (which receives baroreceptor and chem oreceptor 
in form ation), the VMA and preganglionic autonomic nerves (Ganong, 1984). In some 
centra l nerves peptides appear to be the only transm itte rs  but in many others they 
are co-transm itte rs , in particu la r w ith  monoamines (H bkfe lt et a l„  1980a). There is 
clearly a m u lt ip lic ity  o f peptide function w ith in  cardiovascular con tro lling  
pathways. For example, in the nucleus tractus so litarius, eleven neuropeptides have 
been id en tified  (Ganong, 1984). L ike ly  candidates fo r a role in cen tra l 
cardiovascular contro l include angiotensin II, gastrin, neuropeptide Y, opioid 
peptides, oxytocin, substance P, som atostatin, vasoactive in testina l polypeptide 
and vasopressin. Peptide function in cen tra l cardiovascular contro l has been 
reviewed in several recent artic les (R e ttig  et _al., 1982; Lang et al., 1983; Ganong,
1984).
1.6.1.2 D ire c t E ffec ts  of Peptides on the H eart and Vasculature
Many peptides exert d irec t actions on the heart, e ither chronotropic or 
inotrop ic e ffec ts , or on the vasculature, by vasoconstrictor or vasodilator actions.
These peptides may be c ircu la ting  in the bloodstream fo llow ing cleavage 
from  a precursor peptide, as in the case of angiotensin II and bradykinin, or as a
paracrine secretion such as vasopressin, oxytocin and secretin. The presence of a 
number o f vasoactive peptides has been demonstrated in the walls o f blood vessels 
where they are capable o f exerting a d irec t influence on vascular tone. Peptide 
innervation is generally more prevalent in arteries than in veins, and examples of 
peptides found in the vasculature and the ir vasoactiv ity  is shown in Table 6 . Many 
of the peptides present in blood vessel walls are also present in the heart where 
they may exist in cardiac nerves, conducting tissue or in the coronary vessels.
1.6.1.3 In te ractions and Co-existence o f Peptides w ith  O ther Vasoactive 
Hormones and N eurotransm itters
Interactions between peptides and other hormones or neurotransm itters may 
occur in the CNS, in sym pathetic and parasympathetic nerves or d irec tly  on the 
vasculature or cardiac muscle. This can result in e ither opposing or po ten tia ting  
e ffects. An example o f th is is the s tim ula tion o f the release of catecholamines and 
vasopressin by angiotensin II (Regoli et al., 1974), or the po tentia tion  o f the actions 
of vasoactive in tes tina l peptide and acetylcholine when both are co-released 
(Lundberg and H bkfe lt, 1983).
The co-existence of peptides w ith  catecholamines and acetylcholine, as well 
as other neurotransm itters, is a frequent occurrence w ith  im portan t physiological 
im plications. This m ultip lies the possibilities fo r in teractions, only a few of which 
have been investigated. The co-existence o f enkephalins w ith  catecholamines in 
the adrenal medulla (Yang et a l., 1980) and the association of ca lc iton in  gene- 
related peptide w ith  substance P in nerve plexuses around blood vessels are 
examples o f th is phenomenon.
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1.6.1.4 Peptide Actions on Other Determinants of Cardiovascular Function
Besides acting d ire c tly  on the heart and blood vessels or through CNS contro l 
centres, peptides are capable o f in fluencing cardiovascular function by in te racting  
w ith  any or several of the m ajor determ inants o f cardiovascular function. These 
include the autonomic nervous system, vascular c o n tra c tility , cardiac and renal 
function, the renin-angiotensin system and catecholamine release. For example, 
angiotensin II exerts cardiovascular e ffec ts  through d irec t actions on the 
vasculature and heart, through cen tra lly  mediated e ffects  and by s tim u la ting  the 
release of catecholamines and vasopressin (Peach, 1977). Bradykinin exerts a d irec t 
e ffe c t on the vasculature, stim ulates the chemoreceptors, attenuates the e ffec ts  
of sym pathetic nerve a c t iv ity  and stim ulates the release o f catecholam ines 
(Walaszek, 1970). Thus, the overall cardiovascular e ffec ts  o f peptides may 
represent a summation of actions on several d iffe re n t determ inants of 
cardiovascular function.
1.6.2 Endogenous Peptides with Potent Cardiovascular Effects
I t  is beyond the scope of th is thesis to review the cardiovascular e ffec ts  o f 
a ll the endogenous peptides. The cardiovascular e ffects  o f the peptides known to 
possess a role in cardiovascular function are summarised in Table 6 together w ith  
substance P, a tr ia l n a tr iu re tic  fac to r, ca lc iton in  gene-related peptide, 
neuropeptide Y and vasoactive in testina l polypeptide, a ll o f which have been shown 
to possess potent cardiovascular a c tiv ity . The evidence im p lica ting  a ro le of the 
endogenous opioid peptides in cardiovascular function is presented in Section 1.7.
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1.7 EVIDENCE FOR A ROLE OF OPIOID PEPTIDES IN CARDIOVASCULAR
REGULATION
1.7.1 Historical Perspectives
The e lucidation o f the s tructure  of morphine a t the turn  o f the 19th century 
was fo llowed by intensive pharmacological research on natura l and synthetic opioid 
compounds. One o f the earliest reported observations on the b io logical a c tiv ity  of 
opioids, besides analgesia, was the demonstration o f potent card iorespiratory 
effects produced by morphine and other opioid alkalo ids (Bernard, 1864; 
Gscheidlen, 1869).
In the second ha lf o f the 19th century, more detailed reports on the 
cardiovascular and resp ira tory e ffec ts  of morphine claim ed tha t the natura lly  
occurring opioid was a powerfu l depressor agent (Jackson, 1914; Schmidt and 
Livingstone, 1933; Van Egmund, 1911). Most of the subsequent research conducted 
over the fo llow ing century was aimed at c la rify ing  the mechanisms involved in the 
biological actions o f opioids. The more recent discovery of endogenous opioid 
peptides led to a resurgence o f in te rest in opioid and cardiovascular in teractions. 
This has resulted in several lines of evidence suggesting a role fo r endogenous 
opioid peptides in cardiovascular contro l and is reviewed in the fo llow ing sections.
1.7.2 Opioid Receptors and Peptides in Areas of Cardiovascular Control
1.7.2.1 D is tribu tion  of Opioid Receptors
Simantov et al. (1978) claimed tha t opioid receptors were present in guinea- 
pig and ra t heart fo llow ing the demonstration o f stereospecific  binding o f [ ^ H ] -  
naloxone and [^ H ] -dihydromorphine to cardiac membranes. The low level o f 
saturable opioid binding (3-10%), re la tive  to the to ta l binding, rendered th is  
evidence fa r from  convincing. Stronger indications fo r the existence o f opioid 
receptors in cardiac tissue -were demonstrated by the stereospecific binding o f
[^H ]-d ip reno rph ine , which binds to p -, 6 - and k-opioid receptors, to ra t cardiac 
muscle. The amount o f stereospecific binding obtained, expressed as fm o l/m g  
tissue, was comparable w ith  values obtained fo r opioid receptor binding in the brain 
(Pert and Snyder, 1973) and suggested the presence of opioid receptors in ra t 
cardiac muscle (Burnie, 1981). The displacement o f bound [^H ]-d ip renorph ine  from  
the le f t  a trium  by dermorphin provided fu rth e r evidence fo r the existence o f opioid 
receptors in cardiac membranes (Krumins, 1987). Investigations in to  the subtype of 
opioid receptor present in ra t heart have shown tha t DADLE (a mixed p: 6 agonist) 
and ethylketocyclazocine (a mixed k:p agonist), b u t . not DAGO (a p se lective 
agonist), compete fo r [^ H ] -diprenorphine binding sites in the rig h t a trium  and 
ven tric le  (Krumins et al., 1985). This indicates tha t the opioid receptor in cardiac 
tissue is like ly  to be e ither the <5- or k - subtype.
In contrast to the above evidence supporting the existence o f cardiac opioid 
receptors, autoradiographic techniques have fa iled to detect [^H ]-n a lo xo n e  
binding in ra t and cat heart (Dashwood and Spyer, 1986). Thus, the existence o f 
opioid receptors in the heart is a m a tte r o f conjecture and is fu rth e r confused by 
the d isparity in the lite ra tu re  from  studies o f opioid e ffects  on m v itro  cardiac 
preparations (see Section 1.7.3). The presence of opioid receptors in the rabb it 
mesentery and aortic  membrane preparations has been demonstrated in binding 
studies using [^H ]-e to rp h in e  (Sun and Zhang, 1985). Displacement o f etorphine 
binding by the k-agonist dynorphin (1-13), but not by DADLE or MEAP (m ixed y :s  
agonists), suggests tha t the receptors are of the k-subtype. However, the low 
density o f these receptors raises the question as to the physiological s ign ificance of 
these findings.
In the CNS, opioid receptors have been shown to be densely d is tribu ted  in 
p rox im ity  to cardiovascular contro l areas in the brainstem and hypothalamus, 
im p lica ting  a possible role in centra l cardiovascular regulation (A tweh and Kuhar, 
1977; Goodman et al., 1980).
1.7.2.2 Distribution of Opioid Peptides
The d is tribu tion  of opioid peptides in cardiac tissue and in parasympathetic 
and sym pathetic nerves has been described in Section 1.3.1. The significance o f 
proenkephalin products in parasym pathetic and sym pathetic nerves is unclear but, 
i t  may be tha t they possess modulating actions i f  co-released w ith  noradrenaline 
and/or acetylcholine (Hughes et a l., 1977; Bastiaensen and de P o tte r, 1987). The 
presence o f opioid peptides in autonomic ganglia (Tang et al., 1983; Lundberg et 
al., 1980) raises the poss ib ility  o f in terference w ith  ganglionic transmission, 
presynaptic inh ib ition  being a common mechanism of opioid action (North and 
Egan, 1983).
The widespread d is tribu tion  o f proenkephalin products in the heart (see 
Section 1.3.1.2) suggests tha t opioids have the potentia l to a ffe c t cardiac 
performance, coronary c ircu la tion  and re flex  mechanisms, as w ell as modulating 
chronotopic and ino trop ic  responses to  other hormones or neurotransm itters.
The measurement o f opioid peptides in plasma has been hampered by rapid 
enzymatic degradation (see Section 1.3.3). The expectation is tha t the c ircu la ting  
concentrations of opioid peptides are low. Radioimmunoassay has detected 
c ircu la ting  8 -endorphin, [M e t]-a n d  [Leu]-enkephalin , [M e t] enkephalyl-arg^-phe^ 
and dynorphin A (Ciement-Jones et al., 1980; Chou et a i., 1983; Ryder and Eng, 
1981; Spampinato and Goldstein, 1983) and has also shown th a t blood from  the 
adrenal vein is a t least ten tim es more enriched w ith  enkephalin than blood from  
the fem oral vein (Lang et a l., 1982). This, combined w ith  the fa c t tha t the adrenal 
venous e ffluen t goes almost d ire c tly  in to  the rig h t a trium  via the vena cava, means 
a re la tive ly  high plasma enkephalin concentration reaches the heart. Since the 
lung is a rich source o f peptidases, the actions o f enkephalins may be lim ite d  to the 
cardiopulmonary system due to rapid peptide degradation (Holaday, 1983).
In the CNS, proenkephalin products and 8 -endorphin have been shown to be 
present in cells densely d is tribu ted in neuroanatomical nuclei which are involved in 
the autonomic regulation o f the cardiovascular system (Elde et al., 1976; H bkfe lt e t 
al., 1977; A tweh and Kuhar, 1977; Goodman et al., 1980).
1.7.3 Pharmacological Evidence for a Role of Opioid Peptides in 
Cardiovascular Regulation
Furthe r indications fo r an opioid role in peripheral cardiovascular function 
stem from  studies w ith  in v itro  cardiac and vascular preparations. C hronotropic 
and ino trop ic e ffects  have been studied using isolated a tria  or whole hearts and a 
varie ty  o f vascular preparations have been used to determ ine whether opioids 
possess vasodilator or vasoconstrictor a c tiv ity . These preparations have included 
cut spira l strips of the aorta and po rta l vein, and perfused vascular beds, such as 
the mesenteric vessels, hind lim b and ear arteries.
Much work investigating the e ffe c ts  o f the peptides has been conducted over 
the last decade, although reports o f the e ffec ts  o f opioid alkaloids and synthetic  
opioids on cardiac and vascular tissue jn  v itro  f irs t  appeared around 60 years ago. 
In 1933, Schmidt and Livingston showed tha t morphine produced potent dose- 
dependent, negative chronotropic and ino trop ic e ffec ts  on isolated perfused hearts 
from  dogs, cats, rabbits and guinea-pigs. This work was fo llow ed by the 
demonstration tha t morphine reduced the negative chronotropic response to vagal 
stim u la tion  in ra t, rabb it and guinea-pig a tria  in v itro  (K os te rlitz  and Taylor, 1959). 
In contrast, Kennedy and West (1967) showed tha t morphine had no e ffe c t on rabb it 
a tr ia l responses to e ither sym pathetic s tim u la tion  or exogenous noradrenaline and 
acetylcholine. More recent work is in agreement w ith  Schmidt and L iv ingston and 
has shown tha t morphine has d irec t negative chronotropic and ino trop ic  e ffe c ts  on 
rabb it a tr ia  (Grundy, 1971) and heart (Vargish, 1987).
Synthetic opioids have also been used to  investigate opioid e ffects  on cardiac 
tissue in v it ro . I t  has been shown tha t methadone increases the chronotropic 
response of guinea-pig a tria  to sym pathetic nerve stim ulation (M ante lli et al.,
1986) and tha t levallorphan exerts negative chronotropic effects on the rabb it 
heart (M ontel and Starke, 1973). There are con flic ting  reports of the e ffe c t of 
naloxone on the isolated ra t heart. In one report, naloxone produced an increase in 
coronary pressure and exerted negative chronotropic and inotropic e ffec ts  (Ventura 
et al., 1987). A second report showed tha t both (-) and (+) naloxone exerted positive 
inotrop ic e ffec ts  tha t were unaffected by morphine pre treatm ent (Sagy et al.,
1987), suggesting tha t naloxone may have non-opioid e ffects  on cardiac 
con trac ta b ility .
In add ition to investigating the e ffec ts  o f morphine on the heart o f various 
species, Schm idt and Livingston (1933) also examined the action of morphine on 
various vascular beds in the dog and cat. Morphine was found to exert a potent 
vasodilatory e ffe c t on the vascular beds in skin and muscle, whereas a cons tric to r 
action predominated in the abdominal viscera. In the perfused ra t mesentery, 
morphine produced a naloxone-reversible vasodilation o f the te rm ina l a rte rio les  
w ith  no e ffe c t on the muscular venules (A ltu ra  j i t  al., 1978). S im ilar e ffec ts  were 
exerted by levorphanol and meperidine. Morphine, pentazocine, cyclazocine and 
levallorphan a ll produced a naloxone-reversible contraction of the ra t ao rtic  s trip  
(Lee and Berkow itz, 1976). In addition to the d irec t e ffects  of morphine and 
synthetic opioids on the vasculature, morphine and nalorphine reduced the 
vasoconstrictor response to noradrenaline in the rabb it ear arte ry, po rta l vein and 
aortic  s trip  (Grundy, 1971).
W hilst there is considerable evidence th a t morphine and synthetic opioids 
exert d ire c t and modulating e ffec ts  on cardiac and vascular tissue in v it ro , the 
m a jo rity  of recent studies have focused on the e ffec ts  o f the endogenous opioid
peptides. Tables 7 and 8 summarise the reported in v itro  e ffec ts  o f opioid peptides 
on cardiac and vascular preparations respective ly.
Studies in whole animals have resulted in a series o f observations 
demonstrating tha t opioids can produce hypertension or hypotension and 
tachycardia or bradycardia, depending upon the opioid, site o f in jection, species 
studied and the presence or absence of anaesthetics. Tables 9 and 10 summarise the 
cardiovascular e ffe c ts  o f opioid peptides in the ra t and other species. The 
cardiovascular e ffe c ts  of non-peptide opioids, such as morphine, etorphine, 
ethylketocyclazocine and fentanyl, are described below.
In the urethane-anaesthetised ra t, the intravenous adm in istra tion of morphine 
results in a fa ll in blood pressure and heart ra te  (Evans et al., 1952; Fennessy and 
R attray, 1971), which has been shown to be naloxone-reversible (Wei et al., 1980). 
In the chloralose-anaesthetised ra t, a biphasic response is produced fo llow ing 
morphine adm in istra tion, consisting of an in it ia l rise then a fa ll in heart ra te  and 
blood pressure (Bolme et a l., 1978). This demonstrates the influence tha t d iffe re n t 
anaesthetics have on the response. There are con flic ting  reports on the e ffects  o f 
morphine in the conscious ra t. A decrease in heart ra te  and blood pressure has been 
observed (Stein, 1976) and a naloxone-reversible increase in heart ra te  and blood 
pressure has also been reported (Gomes et al., 1976). There is a s im ila r d isparity in 
the lite ra tu re  concerning the e ffec ts  of morphine in the pithed ra t. Fennessy and 
R attray (1971) describe an increase in blood pressure accompanied by a decrease in 
heart ra te , w h ils t Feuerstein and Zukowska-Grojec (1987) report no e ffec ts  on 
e ither heart ra te  or blood pressure. The peripheral adm in istra tion o f morphine in 
the conscious rabb it (May et al., 1987), anaesthetised ca t (Feldberg and Wei, 1981), 
and anaesthetised dog (Ward et al., 1972) results in a decrease in heart ra te  and 
blood pressure in a ll species.
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The in trac is te rna l adm in istra tion o f morphine in the anaesthetised ra t 
produces a biphasic response, w ith  an in it ia l rise in heart ra te  and blood pressure 
followed by a fa ll (B e lle t et al., 1980), w h ils t in jection in to  the preoptic nucleus 
results in an increase in heart ra te  and blood pressure (Feuerstein and Faden, 1982). 
A s im ila r trend is exhibited in the anaesthetised cat. In trac is te rna l adm in istra tion 
results in a decrease in heart ra te  and blood pressure, whilst 
in tracerebroven tricu la r adm in istra tion produces an increase in heart ra te  and blood 
pressure (Feldberg and Wei, 1981). This illus tra tes  the im portance o f the pa rticu la r 
area o f the CNS in to  which the drug is administered.
Etorphine produces a decrease in heart rate and blood pressure in both 
urethane- and pentobarbita l-anaesthetised rats (Dashwood et al., 1983; Roquebert 
and Delgoulet, 1988), w h ils t in the pithed ra t, only a decrease in heart ra te  occurs 
(Roquebert and Delgoulet, 1988). S im ila rly , the p ro to typ ic  kappa agonist, 
ethylketocyclazocine decreases the heart ra te  and blood pressure o f the urethane- 
anaesthetised ra t (G autre t and Schm itt, 1984), but decreases only the heart ra te  in 
the pithed ra t. In the anaesthetised rabb it, ethylketocylazocine has no e ffe c t 
whether cen tra lly  or periphera lly administered (Petty  and Reid, 1982).
The anilinopiperid ine deriva tive  fentanyl produces a decrease in heart ra te  
and blood pressure in anaesthetised rats (G autret and S chm itt, 1985a) and 
anaesthetised dogs (Laubie et al., 1974). In trac is te rna l adm in istra tion o f fentanyl 
to anaesthetised rats results in an increase in blood pressure (B e lle t e t al., 1980), 
w h ilst in the pithed ra t, fentanyl produces a decrease in heart ra te  (G au tre t and 
Schm itt, 1985a).
The cardiovascular e ffec ts  o f the above opioids and the in fo rm ation  
presented in tables 9 and 10 illus tra tes  the wide d isparity  in the lite ra tu re  
surrounding the cardiovascular e ffec ts  o f opioids. I t  is clear th a t the 
cardiovascular responses to opioids are influenced by several facto rs, including the
species, the presence or absence of anaesthesia and the route of drug 
adm in istra tion.
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Table 9: Cardiovascular Effects of Opioid Peptides in the Rat In Vivo
Peptide Conditions Route of 
A dm in is tra tion
Cardiovascular Actions 
BP E ffe c t HR E ffe c t References
ME An (Ur) 
An (Ur)
An (Pen)
IV
IA
IC
4  NR 
4- then f  NR
t
4N R Wei e t a l., 1980 
Varagic"& 
Stojanovic, 1987 
Elghozi e t al., 1981
An (Chi) IC NR 0 Bolme e t a l., 1978
Con ICV t t Simon e t a l., 1978
Con IV t t Simon e t a l., 1978
Con IV t 0 Thornh ill, 1986
LE An (Ur) 
An (Ur)
An (Pen)
IV
IA
IC
4 NR 
4 then f  NR
t
4  NR Wei e t al., 1980 
V a rag i(f&  
Stojanovic, 1987 
Elghozi e t a l., 1981
An (Ch) IC f  NR 4 NR Bolme e t a l., 1978
Con ICV fN R f  NR Schaz e t a l., 1980
Con IC f  NR fN R Schaz e t a l., 1980
Con IC t t Simon e t a l., 1978
Con IV t o Simon e t a l., 1978
Con IV NR t  NR Schaz e t a l., 1980
Con IV t t Thornh ill, 1986
Con ICV 0 0 Itoh e t a l., 1986
3-End An (Ur) IV 4 NR 4 NR Wei e t a l., 1980
An (Ur) 
An (Ur)
IV
IA
4 NR
4
4 NR Sitsen e t a l., 1982 
Varagic""& 
Stojanovic, 1987
An (Ur) ICV 4 0 P e tty  e t a l., 1981
An (Ur) NTS INJ 4 then  f  NR t  then 4 NR P e tty  e t a l., 1982
An (Ur) ICV 4 nr 4 NR Sitsen e t a l., 1982
An (Pen) IV 4” NR 0 Sitsen e t a l., 1982
An (Pen) ICV 0 4  NR Sitsen e t a l., 1982
An (Chi) IC 4 NR 4  NR Bolme e t a l., 1978
Con ICV 4  NR 4  NR Sitsen e t a l., 1982
Con IV 0 O Sitsen e t a l., 1982
Pithed IV 0 O E im e rl & 
Feuerstein, 1986
Dyn
(1-13)
An (Pen) IV 4N R 4  NR G autre t & Schm itt, 
1985-
An (Pen) POM INJ 4N R fN R Feuerstein & 
Faden, 1982
An (Pen) NA INJ 4 0 Hassen e t a l., 1984
An (Pen) NTS INJ 4 O Hassen a t a l., 1984
Con
Con
Con
ICV
ICV
IV
fN R
t
I
fN R Saunders & 
T ho rnh ill, 1987 
Holaday e t a l., 1984 
Holaday e t a l., 1984
Table 9: Cardiovascular Effects of Opioid Peptides in the Rat (Continued)
Peptide Conditions Route of 
Adm in is tra tion
Cardiovascular Actions 
BP E ffe c t HR E ffe c t References
Dyn
(1-13)
Con ICV f  NR t  NR Saunders & 
Thornh ill, 1987
Pithed IV t 4 G autre t & Schm itt, 
1984
Pithed IV 4 NR 0 G autre t & Schm itt, 
1985
Leumorphin Con ICV 4 0 Itoh et al., 1986
Dermorphin P ithed IV 0 0 Feuerstein &
Zukowska-Grojec,
1987
DAGO An (Ur) IV 4  NR 4  NR M artynova & 
Medvedev, 1986
An (Ur) NTS INJ t t Hassen & 
Feuerstein, 1987
An (Pen) NTS INJ t  NR fN R Hassen et a l., 1982
An (Pen) POM INJ 4  NR f  NR Feuerstein & 
Faden, 1982
An (Pen) NTS INJ + t Hassen & 
Feuerstein, 1987
Con ICV f  NR 4 fN R Feuerstein e t al., 
1983
Con H Y P IN J 4  NR 4 tN R Feuerstein e t al., 
1983
Con HYP INJ t  NR f  NR P fe if fe r  et a l., 1983
Pithed IV O O Eim erl & 
Feuerstein, 1986
DADLE An (Ur) IV 4 NR 4  NR Wei e t a l., 1980
An (Ur) IV 4, NR 4  NR M artynova & 
Medvedev, 1986
An (Pen) NTS INJ t  NR +  NR Hassen e t a l., 1982
An (Pen) POM INJ 4 NR f  NR Feuerstein & 
Faden, 1982
Con HYP INJ t  NR 4 fN R Feuerstein e t al., 
1983
Con H Y P IN J f  NR f N R P fe if fe r  £ t  a l., 1983
Pithed IV 0 0 E im erl & 
Feuerstein, 1986
Table 9: Cardiovascular Effects of Opioid Peptides in the Rat (Continued)
Peptide Conditions Route of 
A dm in is tra tion
Cardiovascular Actions 
BP E ffe c t HR E ffe c t References
DAMEA An (Ur) IV 4 NR O W ille tte  e t al., 1982
An (Pen) IV I 1 Randich & Callahan, 
1986
An (Pen) IC f  th e n | t  th e n | B e lle t e t al., 1980
An (Pen) IC i I Elghozi et aj., 1981
An (Chi) IC I  NR |N R Bolme et al., 1978
Con ICV fN R t Rockhold et a l., 1980
Con IV I  NR ^N R Thornh ill & 
Saunders, 1985
Con IV t Chandra & Dixon, 198
Decerebrate IV I t  NR 4,NR W ille tte  & Sapru, 
1982
DALEA Con IV I  NR I  NR Thornh ill & 
Saunders, 1985
Decerebrate IV I t  n r |N R W ille tte  & Sapru, 
1982
MEA Con IV fN R Thornh ill & 
Saunders, 1985
LEA Con IV I  NR I  NR Thornh ill & 
Saunders, 1985
DAME An (Chi) 
Con
ICV
ICV
|  NR 
t  NR
Yukim ura e t a l., 1981 
Yukim ura e t a l., 1981
DMPEA Decerebrate IV |  NR |N R Sapru e ta l. ,  1981
Key; Refer to page 78
Table 10: Cardiovascular Effects of Opioid Peptides in Other Species In Vivo
Peptide Species and 
Conditions
Route of 
A dm in is tra tion
Cardiovascular Actions 
BP E ffe c t HR E ffe c t References
ME Rabbit;An(Pen) IV 4 NR Ensinger et al., 1984
Rabbit;Con IA 4 NR 4 NR Schadt et a l., 1987
Dog;An(Pen) IV 4 NR 4- NR Koyama et a l., 1984
Dog;Con IV t i Sander e t al., 1982
Cat;An(Ur/Pen) IC t  NR 4 NR Florez & M ediavilla , 
1977
Cat;An(Chl) ICV O 0 Feldberg & Wei, 1981
Cat;An(Chl) IC O 0 Feldberg & Wei, 1981
LE Rabbit;Con
Dog;An(Pen)
IA 4 NR |  NR Schadt e t al., 1987
IV 4 Giles e t a l., 1983
Dog;An(Pen) IV 4 NR |  NR Koyama et al., 1984
Dog;Con IV t t Giles & Sander, 1983
MEAP Rabbit;Con IA 4 NR ^  NR Schadt e t a l., 1987
Dog;Con IV f  NR f  NR Sander & Giles, 1983
MEAGL Rabbit;Con
Dog;Con
IA 4 NR 
f  NR
4- NR 
f N R
Schadt e t a l., 1987 
Sander & G iles, 1985
3-End Cat;An(Chl) IC
ICV
4
O
4
t
Feldberg & Wei, 1981 
Feldberg & Wei, 1981
Dyn
(1-13)
Rabbit;An(Pen) IV 4 NR 4 NR Szabo et al; 1988
DAGO Guinea-pig;
An(Pen)
IV t 4 Rabkin, 1987
DADLE Rabbit;An(Pen) IC O 0 P e tty  & Reid, 1982
Rabbit;An(Pen)
Dog;Con
ICV
IV
O 0
4
P e tty  & Reid, 1982 
Haddad & Lasala, 198
Cat;An(Chl) IC 4 Feldberg & Wei, 1981
DAME Cat;Con ICV t 0 Schaz et a l., 1980
Key: R efer to page 78
Key to  Tables 7, 8 , 9 and 10
BP - Blood Pressure, HR - H eart Rate
ME - [M e t] enkephalin, LE .- [L e u ] enkephalin, MEA - [M e t ]  enkephalinamide, 
LEA - [Leu ] enkephalinamide, 8-End-8  - endorphin, Dyn -Dynorphin, DAGO - [D - 
A la^,M ePhe^,G ly-ol^] enkephalin, DADLE - [ D -A la^,D -Leu^ ] enkephalin, DAMEA 
- [D -A la^,M e t^  ] enkephalinamide, DALEA - [D -A la^ ,D -Leu^] enkephalinamide, 
DMPEA - [D -M e t^ ,P ro ^] enkephalinamide
Con - Conscious, An - Anaesthetised, (Ur) - Urethane, (Pen) - Sodium 
pentobarbita l, (Chi) -Chloralose, (Iso) - Isoflurane
IV - Intravenous adm in istra tion, IA - In tra a rte ria l adm in istration, ICV - 
In tracerebroventricu la r adm in istra tion, IC - In trac is te rna l adm in istra tion, SC - 
Subcutaneous adm in istra tion, NTS INJ -In jec tion  in to  nucleus tractus solitarius, 
POM INJ - In jection  in to  nucleus preoptic medialis, NA INJ - In jection in to  nucleus 
ambiguus, HYP INJ - In jec tion  in to  hypothalamus
f -  Increase, Decrease, -ve - Negative, +ve - Positive, NR - Naloxone
reversible, NI -Naloxone insensitive
A IM  OF STUDY
There is accum ulating evidence to suggest tha t endogenous opioid peptides 
are capable of modulating cardiovascular a c tiv ity . There are inconsistencies in the 
reports o f these e ffec ts , which are dependent upon species, anaesthesia, route of 
adm in istration and ligand studied (Holaday, 1983). Endogenous opioid peptides and 
receptors have been shown to possess a widespread d is tribu tion  in both the centra l 
nervous system and the peripheral tissues involved in cardiovascular function. 
These include the heart, sym pathetic ganglia, vascular smooth muscle and the 
adrenal gland.
The present study was aimed at studying the cardiovascular e ffec ts  of the
smaller peptide fragm ents o f the proenkephalin molecule in the ra t. W hilst there is
already some evidence fo r cardiovascular e ffec ts  o f the pentapeptides [M e t ]  -and
[Leu] -enkephalin, there is l i t t le  in fo rm ation  on the cardiovascular e ffec ts  of the
heptapeptide [ M e t] enkephalyl-arg^-phe^ and the octapeptide [M e t] enkephalyl- 
6 7 8arg -g ly  -leu . The role o f proenkephalin products in con tro lling  cardiovascular 
a c tiv ity  in the ra t was investigated using cardiac and vascular tissue preparations 
in v itro , and the urethane-anaesthetised ra t preparation in vivo.
In the m vivo modei, cardiovascular responses to intravenously adm inistered 
proenkephalin products were characterised. In order to e lucidate the mechanisms 
involved in mediating the responses various surgical and pharm acological 
manipulations, such as p ith ing, b ila te ra l vagotomy, atropine p re -trea tm e n t and the 
use of a quaternary opioid antagonist, were employed. The e ffe c ts  o f peptidase 
inh ib ition and m anipulation o f the hypotha lam us-p itu itary-adrenal axis were also 
studied in order to assess th e ir contribu tion  to the cardiovascular responses.
2. METHODS
2.1 ANIMALS
Male W istar albino rats (U niversity o f Surrey) stra in  were used in all 
experiments. Anim als were bred at the University 's An im al U n it and housed under 
a contro lled tem perature o f 22°C , a hum id ity o f 40-43% and on a 12 hour 
ligh t/dark cycle (ligh ts on a t 0700 hrs). Animals had free access to food and water 
prior to experim entation.
2.2 IN  VITRO TISSUE PREPARATIONS
2.2.1 Isolated A tria
2.2.1.1 Tissue Preparation
Rats (200-250g) were k illed  by decapitation and the hearts quickly excised 
and immersed in ice-co ld oxygenated Krebs-Ringer solution (composition:- NaCl, 
118mM; N aH C 03, 24.9mM; D-Glucose, l l . lm M ;  K H 2P 0 4, 1.18mM; MgS04 .7H20 , 
1.64mM; CaC l2 .2H20 , 2.52mM; KC1, 4.7mM). The a tria  were dissected, mounted in 
an organ bath at 30°C (in order to reduce the m etabolic demand of the tissue), 
placed under a resting tension o f 500mg, aerated w ith  95% 02/5% C 0 2 and allowed 
to equilibrate fo r 75 minutes. A tr ia l force and in tegra ted ra te  were recorded using 
an isom etric transducer (Grass model FT03; Grass Instruments, Mass., U.S.A.) 
linked to a polygraph (Grass model 79D).
2.2 .1.2 Measurement o f A tr ia l Responses
Chronotropic and inotropic responses to noradrenaline were measured using 
in te rm itte n t dose-response curves w ith  a drug contact tim e o f 1 m inute and a 4 
m inute in te rva l between drug additions. Noradrenergic and cholinergic nerve 
stim ulation responses were studied by obtaining fie ld  stim u la tion  responses in the 
presence o f ly M  atropine and lp M  propranolol respective ly. A tr ia  were pre­
incubated w ith  antagonists fo r 15 minutes. F ie ld  stim u la tion , across linear
platinum  electrodes (0.3mm dia. x 6.5cm length, 0.5cm apart), was provided by 
tra ins of square wave pulses from  a stim u la to r (Grass model S88). These trains 
were of 4 seconds duration, 40V and 1-20 Hz pulses o f 2ms w idth. Responses to 
each given s tim ula tion frequency were obtained in tr ip lica te .
The e ffe c t of each proenkephalin product upon a tr ia l responses to 
noradrenaline and fie ld  stim u la tion  were studied in separate experiments. In a ll 
experiments a tria  were pre-incubated w ith  peptidase inh ib ito rs  (bestatin, lO yM ; 
captopril, 10pM and leucyl-leucine, 2mM) fo r 30 minutes and the inh ib itors were 
maintained throughout the experiment. Contro l dose-response curves to 
noradrenaline or frequency response curves to fie ld  s tim u la tion  were carried out 
followed by incubation w ith  peptide fo r 15 minutes. For each tissue, one peptide 
was studied fo r its  e ffe c t on responses to exogenous noradrenaline or fie ld  
s tim ulation using four concentrations o f peptide in unpaired experiments. A 40 
m inute period separated each dose-response curve.
For responses to noradrenaline, EC^g values (defined as the drug 
concentration producing 50% of the evoked maximum response) were calculated fo r 
each experiment fo llow ing linear regression analysis of the dose-response curve. 
For noradrenergic nerve stim ula tion, an EF^g value (defined as the percentage of 
the maximum chronotropic response evoked by 10Hz stim u la tion) was derived fo r 
each experiment. For cholinerg ic nerve stim ulation, an EF^ ^ value (defined as the 
percentage o f the maximum chronotropic response evoked by 2.5Hz stim ulation) 
was derived fo r each experiment.
2.2.2 Perfused Mesentery
2.2.2.1 Tissue Preparation
Rats (250-300g) were scruffed and anaesthetised by an in traperitonea l 
in jection of sodium pentobarbitone (60 mg/kg i.p.). A fte r  15 m inutes, or at a tim e 
when a su ffic ien t depth of anaesthesia had been induced, the abdomen was opened,
the superior mesenteric a rte ry  cannuiated and the vascular supply to the mesentery 
removed, as described by McGregor (1965).
The superior (anterior) m esenteric a rte ry  is located v ir tu a lly  opposite the 
rig h t kidney, between the coeliac a rte ry  and the le ft  renal a rte ry  and vein. The 
vessels were cleared and two threads placed under the mesenteric a rte ry. The 
a rte ry  was then tied at the point closest to the aorta. An incision was made in the 
a rte ry  and a polythene cannula (17 gauge, blue luer; Portex L im ited , Hythe), 
primed w ith  Krebs-Ringer solution (see Section 2.2.1.1), was inserted in to the 
vessel fo r a distance o f approxim ately 2.5cm and tied in place. The mesentery was 
removed from  the in testine by cu tting  close to the in testina l border, beginning at 
the lowest point of attachm ent. Any remaining connective tissue was cleared and 
the mesentery and its  vascular supply removed from  the animal which was then 
k illed . The vascular system was flushed w ith  Krebs-Ringer solution and the cannula 
attached to a three-way tap connected to a perfusion apparatus containing Krebs- 
R inger solution. The preparation was placed in a horizonta lly-positioned open- 
ended organ bathf thereby surrounding the tissue w ith  a heated w ater jacke t. The 
mesentery was perfused w ith  aerated Krebs-Ringer solution a t 37°C and at a rate 
o f 2-4 m l/m inute using a p e ris ta ltic  pump (Gilson Minipuls). Perfusion pressure was 
measured using an in -line  pressure transducer (Statham P23 ID ) and recorded on a 
polygraph (Grass model 79D). Drugs were administered, via the three-w ay tap, in 
volumes o f 0 .1ml.
2.2.2.2 Measurement o f Mesenteric Responses to Noradrenaline
Preparations were perfused fo r 60 minutes before dose-response curves to 
noradrenaline were carried out. An in te rva l o f 4 minutes separated drug additions. 
As fo r a tr ia l studies, contro l dose-response curves to noradrenaline were carried 
out w ith  peptidase inh ib itors added to the perfusate (see Section 2.2.1.2).
Modulatory e ffec ts  o f proenkephalin products on responses to noradrenaline 
were studied by perfusing the tissue w ith  opioid peptide 15 m inutes before a
noradrenaline dose-response curve was perform ed. A 40 minute resting period 
fo llowed each dose-response curve. For each tissue, one peptide was studied fo r its  
e ffe c t on the response to noradrenaline using four concentrations o f peptide in 
unpaired experiments.-
2.3 PREPARATORY OPERATIVE PROCEDURES IN VIVO
Cardiovascular and respiratory studies were performed in urethane- 
anaesthetised rats, except fo r the work involving pithed rats. The procedures 
described below were employed in both studies except where indicated.
2.3.1 Anaesthesia
Rats (300-400g) were anaesthetised by an in traperitoneal in jec tion  o f 25% 
w /v urethane solution. The animals were scruffed w hilst 1.5ml urethane solution 
was in jected. A f te r  10 minutes, when the ra t was ligh tly  anaesthetised, a fu rth e r 
dose o f anaesthetic was administered to give a to ta l dose o f 1.5g/kg (or 6m i 25% 
w /v urethane solution/kg). Deep anaesthesia was induced during the proceeding 10- 
20 m inutes, at which point the animal was la id on its dorsal side on a heated 
operating table (Palmer L im ited). A re c ta l therm om eter was inserted and the 
rec ta l tem perature maintained w ith in  37 + 1°C through the use of the heated 
operating table and by varying the position o f two 60w overhead lamps.
2.3.2 Tracheal Cannulation
A patch of skin (approximately 2 x 2  cm) was removed from  the neck region, 
and the trachea exposed by removing the parotid  glands and tearing the surrounding 
muscle. The trachea was cleared fo r approxim ate ly 1cm and a co tton  liga tu re  
passed underneath. An incision was made between two rings o f ca rtilage  and a 
polythene cannula (3.0mm external diam eter) was inserted fo r approxim ate ly 1cm 
and tied in place. In respiratory studies, an adaptor was attached to the cannula to 
fa c ilita te  connection to e ither the ven tila tion  pump or the respiratory m onitoring
equipment.
The tracheal cannulation of rats used in cardiovascular studies was necessary 
to m inim ise the in terference of any possible bronchoconstriction and to connect 
the pithed animals to the ventila tion  pump.
2.3.3 Venous Cannulation
The r ig h t jugular vein was always cannulated fo r drug adm in istra tion and in 
some experiments the rig h t fem oral vein was also cannulated.
The jugular vein is easily located, lying in the superfic ia l fa t surrounding the 
neck muscles. Approxim ate ly 1cm of vein was separated from  the surrounding fa t 
and connective tissue, and two cotton ligatures were placed around the vessel. The 
vein was manually pumped fu ll of blood and tied a t the ros tra l end. A small incision 
was made close to the rostra l tie  and a 10cm polythene cannula (17 gauge, blue 
Luer; Portex L im ited , Hythe) primed w ith  0.9% w /v  s te rile  saline (Travenol 
Laboratories, N orfo lk) was inserted in to  the vein fo r approxim ately 2 cm and tied 
in place. The cannula was attached to a three-way tap through which drugs were 
administered.
The fem oral vessels were located by making a m id-line incision in the inside 
o f the rig h t hind leg and removing a small patch o f skin. The arte ry and vein run 
together superfic ia lly  and are easily iden tified , the vein being the caudal o f the 
two. The fine  connective tissue surrounding the vein was removed and two co tton  
ligatures were placed around the vessel. The end towards the paw was tied, and a 
polythene cannula (19 gauge, green Luer) was inserted in to  the vein via a small 
incision. The cannula was then tied in place and attached to a three-way tap, 
through which drugs were administered.
2.3A  A rteria l Cannulation
The le f t  caro tid  arte ry was always cannulated fo r the recording o f blood
pressure and heart ra te . In pre lim inary studies the le f t  fem oral a rte ry  was also 
cannulated.
The carotid  a rte ries lie  e ither side o f the trachea, deep under the neck 
muscles and run closely w ith  the vagus and the cervica l sym pathetic nerve. The 
nerves were separated from  the le f t  caro tid  a rte ry  and two co tton  ties were placed 
around the vessel. The a rte ry  was tied at a point closest to the head, and an arte ry  
clip used to occlude blood flow  fo r a length o f approxim ate ly 1.5cm. A small 
incision was made in to  the a rte ry  and a polythene cannula (16 gauge, pink Luer) 
primed w ith  heparinised saline (100 un its /m l) was inserted and tied  in place. The 
cannula was connected to e ithe r a pressure transducer fo r experiments involving 
the measurement o f blood pressure and heart rate, or to a three-way tap fo r 
experiments requiring periodic sampling o f a rte ria l blood fo r blood-gas analysis.
The fem oral a rte ry  was located as described fo r the fem oral vein (see Section 
2.3.3), and cannulated in a s im ila r manner, except tha t an a rte ry  c lip  was used to 
occlude the blood flow  w h ils t the cannula (17 gauge, blue Luer) was inserted via a 
small incision in to  the vessel. The cannula was connected to a pressure transducer 
to m onitor a rte ria l blood pressure and heart rate.
2.3.5 Bilateral Vagotomy
The vagus nerve is recognisable as being the largest nerve running para lle l to 
the carotid arte ry. The vagus nerve on each side was separated from  the carotid  
arte ry and cerv ica l sym pathetic nerve concom itant w ith  the a rte ria l and venous 
cannulation procedures. L igatures were placed around both vagi, which were cut 
a fte r responses to opioid agonists had been obtained. The e ffec ts  o f b ila te ra l 
vagotomy were only investigated in cardiovascular studies. In some b ila te ra lly  
vagotomised animals a rte ria l blood samples were taken fo r blood-gas analysis.
2.3.6 Post-surgical Equilibration
Follow ing surgery, exposed tissue was covered w ith  a saline-soaked cotton
wool pad. The animal was then le f t  fo r 30 minutes to overcome the acute 
disturbances in heart ra te  and blood pressure produced by surgical stress. In paired 
experiments which investigated the e ffe c t of b ila te ra l vagotomy on responses to 
opioid agonists, a 15 m inute equ ilib ra tion  period followed sectioning of the vagi 
before opioid agonists were adm inistered. Preparations were rou tine ly  used fo r 2-3 
hours and viable fo r up to 8 hours.
2.4 CARDIOVASCULAR STUDIES
2.4.1 Pithed Rat Preparation
Rats (225-275g) were anaesthetised through ether inhalation and the trachea 
cannulated (see Section 2.3.2). The animals were pithed by the insertion o f a short 
steel tube (13 standard w ire gauge, s.w.g.; 4cm long) through the o rb it and via the 
foramen magnum to the level o f the f ir s t  couple o f vertebrae. Through th is troca r 
a te flon  tube (0.16mm diam eter, 20cm long), w ith  a fine steel tube (26 s.w.g.; 24cm 
long) inside it ,  was quickly passed down the spinal cord. This could be fe lt  at the 
sacral end and completed the p ith ing (Gillespie et al., 1970). The troca r was 
inserted through a rubber bung to prevent excessive bleeding from  the re tina l 
arte ry.
A r t if ic a l ven tila tion  im m ediate ly followed through the use o f an oxygen 
cylinder (99% purity) connected to a small animal respiratory pump (S c ien tific  
Research Instruments) which was set to  deliver 1ml O2/100g body w e igh t a t a rate 
o f 50 strokes/m inute. The caro tid  a rte ry  and jugular vein were cannulated fo r the 
recording of both blood pressure and heart ra te  and fo r drug adm in istra tion  (see 
Sections 2.3.3 and 2.3.4). A 30 m inute equ ilibration period preceded drug 
adm in istration. In some animals a rte ria l blood samples fo r blood-gas measurements 
were taken. Preparations were rou tine ly  viable fo r in excess o f 3 hours.
2.4.2 Cardiovascular Recording Apparatus
The le f t  carotid a rte ry  was cannulated (see Section 2.3.4) and connected to a
blood pressure transducer (Statham P23 ID ). The pulsatile signal from  the 
transducer was displayed on a chart recorder via a polygraph (Grass model 79D) to 
give systolic, d iasto lic and mean a rte ria l blood pressure recordings. This was also 
in tegrated to give a constant measurement o f heart rate by means o f an EKG 
tachograph (Grass model 7P4).
The blood pressure transducer was ca lib ra ted  by applying a series o f known 
pressures through the use of a mercury manometer. The EKG tachograph has its  
own in te rna l ca lib ra tion  which was checked m onthly.
2.4.3 Measurements of Cardiovascular Responses
Drugs were administered as intravenous bolus doses in volumes of 0.1 m l and 
washed through w ith  0.1 ml saline. The maximum evoked changes in heart ra te  and 
blood pressure were recorded. Mean a rte ria l pressure (MAP) was calculated using 
the form ula MAP = diasto lic blood pressure + ^/3 pulse pressure. Resting systo lic, 
d iasto lic , mean a rte ria l blood pressure and heart rate were recorded w ith  the 
e ffe c t o f saline being determined before commencing drug adm in istra tion. Dose- 
cycles consisted of agonists being adm inistered every 4 minutes unless th e ir 
duration o f action exceeded this tim e lim it .  In those cases the agonist was 
adm inistered 1 m inute a fte r heart ra te  and blood pressure had returned to pre-drug 
levels.
A p a rt from  the studies investigating the e ffec ts  o f repeated adm in istra tion  
o f opioid agonists, no more than two dose-response curves were perform ed in a 
single preparation and only one opioid agonist was administered to an ind iv idual 
preparation. Most studies were in the form  o f paired experiments, whereby 
responses to an opioid agonist were observed before and a fte r a trea tm en t (e ithe r 
antagonist adm in istration, b ila te ra l vagotomy or a r t if ic ia l ventila tion).
Unless otherwise stated, antagonists were administered 15 m inutes before 
dosing regimes were repeated.
2.5 RESPIRATORY STUDIES
2.5.1 A rtific ia l Ventilation
Rats were a ir ventila ted (1.5ml/100g body weight, 50 strokes/m inute) fo r 30 
minutes before drug adm in istra tion by a small animal respiratory pump connected 
to the tracheal cannula. In some animals blood-gas analysis was carried out to 
determ ine whether pH, pC 0 2 and p 0 2 were maintained w ith in  normal lim its .
2.5.2 Respiratory Monitoring Apparatus
The trachea cannula was connected to a Fleisch tube pneumotachograph 
(Hugo Sachs E lectron ik , Freiburg, FRG, Model 00) via an adaptor. This was fu rth e r 
connected to a d iffe re n tia l pressure transducer (Grass model PT5) fo r the 
measurement o f the respiratory flow  which was recorded on a polygraph (Grass 
model 79D). The flow  signal was fed in to an EKG tachograph (Grass model 7P4) and 
a polygraph in teg ra to r (Grass model 7P10) to give respiratory frequency and tid a l 
volume respective ly.
The d iffe re n tia l pressure transducer was ca lib ra ted by introducing a series o f 
known pressures by means of a mercury manometer. Each transducer is ind iv idua lly  
calibrated fo r a given d iffe re n tia l pressure resulting from  a certa in  a ir flow  rate . 
The magnitude o f the pen deflection produced by inspiration or expiration allowed 
calcu la tion o f the peak a ir flow .
2.5.3 Measurement of Respiratory Responses to Proenkephalin Products
The proenkephalin products (dose range 30-300pg/kg) were administered as 
0.1ml intravenous bolus doses and washed through w ith  0.1ml saline. The resting 
respiratory frequency and tida l volume were recorded and the e ffe c t of saline 
(0.1ml) was determ ined before commencing drug adm in istration. The maximum 
evoked changes in respiratory frequency and tid a l volume were recorded. Dosing 
regimes were the same as those described in Section 2.4.3. Simultaneous
cardiovascular recordings were also made, as described in Section 2.4.2.
2.6 HALF-LIFE DETERMINATIONS OF LEV ALLORPHAN AND N-M ETHYL
LEVALLORPHAN
Biologica l h a lf- life  was determined by measuring opioid receptor antagonism, 
indexed by the recovery o f depressor responses to [M e t] enkephalin fo llow ing an 
intravenous bolus dose o f antagonist.
H a lf- life  determ inations were made assuming tha t the b io logical response is 
proportional to the plasma concentration of the antagonist. Based on th is 
assumption the response at tim e t, divided by the orig ina l response in the absence 
of antagonist w ill give a measure o f the plasma antagonist concentration at tha t 
tim e. The exponential curve o f plasma antagonist concentration against tim e can 
be transformed in to  a s tra igh t line by taking logarithm s.
The e lim ina tion ra te  constant, K gl, and the h a lf- life , T i ,  o f the antagonist 
were calculated using the form ulas:-
Slope = 
of line
0.69
T i
2
2.7 BLOOD-GAS ANALYSIS
Longitudinal studies o f changes in blood gases, pH, derived bicarbonate 
concentration and base excess were made in urethane-anaesthetised rats, 
a r t if ic ia lly  ventila ted anaesthetised rats, b ila te ra lly  vagotomised anaesthetised 
rats and pithed rats.
K el
2.303
For measurement o f the above parameters, 400gl a rte ria l blood samples were 
w ithdrawn in to a heparinised syringe via a three-way tap connected to the carotid 
a rte ry  cannula. The syringe was capped and the sample vigorously mixed fo r 20 
seconds, then analysed im m ediate ly. A liquots were taken every 30 m inutes over a 2 
hour period, unless otherwise stated. A maximum volume o f 1.6ml o f blood was 
w ithdrawn in to ta l.
Before blood-gas measurements were made, the 1L413 pH/Blood gas analyser 
(Instrum entation Laboratories, Warrington) was calibrated through the use of 
supplied calibrated buffers and gas m ixtures. A fte r  blood-gas analysis, 5p l of 
residual blood was taken in to  a haem atocrit m icrocapilla ry tube and centrifuged in 
a Compur M1100 m icrocentrifuge (Com pur-E lectronic GmbH, Munchen, FDR) fo r 5 
minutes to enable measurements o f packed cell volume to be made.
2.8 ADRENALECTOM Y
The two adrenal glands are small, round organs, loosely attached by means of 
adipose tissue to the an terio r pole o f each kidney.
For the ir surgical removal, a suitable depth of anaesthesia was induced in the 
ra t by ether inhalation. Anaesthesia was maintained during surgery by placing an 
ether-soaked cotton wool pad under the animal's snout. The pad was removed when 
signs of overdosage, such as blueing of the extrem ities and resp ira tory and 
cardiovascular depression, were apparent.
The ra t was placed on its  ventra l surface and a dorsal m id-line  incision (3- 
4cm in length) was made behind the spinal curvature. Blunt-nose scissors were 
inserted subcutaneously through the incision and pushed down each side of the 
animal fo r a short distance and opened several times to spread and tear the 
connective tissue and allow  access to the peritoneal cavity . The skin incision was 
re tracted  to each side w ith  forceps to allow gland removal. Entrance in to the 
peritoneal cavity  on the le f t  side was gained by a small cu t (1.0 -1.3cm  in length)
in to  the muscle, a few m illim e tres  below the spinal muscles and just posterio r to 
the last rib . I f  necessary the opening was widened by inserting blunt-nose scissors 
and expanding. The correct placing o f the incision allowed the spleen to be visib le 
d ire c tly  underneath or s lightly  to the le ft .  The kidney was located and by applying 
pressure to the right-s ide o f the animal, extruded through the peritoneal incision. 
By holding the kidney and grasping the periadrenal fa t the adrenal gland was 
located. By clamping the adipose tissue a t the base o f the adrenal gland and holding 
the surrounding fa t w ith  forceps, the gland could be removed by drawing the 
forceps apart.
On the righ t side, the adrenal gland and anterior part o f the kidney are 
overlain by the peripheral part o f the live r. A fte r  the muscle incision, which was 
made a few m illim e tres fu rthe r down than tha t on the le f t  side, the liv e r  was 
pushed away anterio rly  and the kidney extruded as described above. The process of 
adrenal gland removal is identica l to  th a t fo r the le f t  gland (W aynforth, 1980). A 
single suture was made to close each muscle incision and prevent hern iation. The 
dorsal m id-line incision was closed by clamping w ith  4-5 M ichelle clips.
In sham-adrenalectomised animals, exactly the same procedure was 
perform ed except the adrenal glands were not removed. Adrenalectom ised ra ts 
were maintained on 0.9% w /v sodium chloride solution and the sham- 
adrenalectomised rats on tap water. Success o f the operative procedure was 
confirm ed by post-mortem exam ination and sample plasma corticosterone 
measurements.
2.9 DEXAMETHASONE ADMINISTRATION
The suppression of the hypothalam us-pitu itary-adrenal axis by the steroid 
dexamethasone was studied in naive, adrenalectomised and sham-adrenalectomised 
rats.
In acute studies (24 hours duration), dexamethasone was adm inistered to rats
in th e ir drinking water, at a concentration of 5 x 10~^M, based on the method of 
K itchen (1980). In chronic studies (18 days duration), 5 x 10~^M dexamethasone 
was adm inistered to rats in the ir drinking water. Because the chronic flu id  intake 
of adrenalectomised rats was almost double tha t of sham-adrenalectomised or 
naive rats, i t  was necessary to reduce the concentration of dexamethasone to 2.5 x 
10 '^M . In adrenalectomised rats, the appropriate concentrations o f dexamethasone 
were supplemented to the 0.9% w /v sodium chloride solution on which these 
animals were maintained.
F lu id  in take was monitored throughout the acute and chronic studies, and 
cum ulative in take o f dexamethasone calculated per body weight.
2.10 CORTICOSTERONE ASSAY
Plasma corticosterone was assayed fluo rom e trica lly  by a m od ifica tion  
(K itchen and Rowan, 1984) of the method of Zenker and Bernstein (1958). A r te r ia l 
blood was co llected in to  heparinised tubes and plasma was separated by 
centrifugation  a t 4000g fo r 10 minutes a t 4°C  (Beckman 36 centrifuge). 
Corticosterone (1 m g/m l) was diluted w ith  saline to produce a standard curve from  
0.005-0.5pg /m l. Plasma (200pl) was d ilu ted to 1ml w ith  d is tilled  water and 1ml o f 
standard solutions were used fo r assay. Samples were vortexed w ith  10ml 
ch loroform  fo r 10 seconds. The chloroform  layer (8ml) was then mixed w ith  3ml o f 
an ethanol/concentrated sulphuric acid m ix tu re  (3:7 by volume) fo r 5 seconds. 
Fluorescence was measured in the ethanol/acid layer a fte r 90 minutes using a 
spectro fluorim eter (Perkin Elmer LS-5 Luminescence Spectrometer) set a t an 
excita tion wavelength o f 475nm and an emission wavelength of 525nm w ith  s lit  
widths o f 5.
2.11 STATISTICAL TESTS
Values fo r Student's t- te s t were calcula ted from  the fo llow ing fo rm ula :-
fo r + n2 - 2 degrees of freedom, where x = mean, SEM = standard error of the 
mean and n = the number o f observations.
Values fo r Paired t- te s t were calculated from  the fo llow ing form ula:- 
d
t  = -----------
SEMg
fo r n-1 degrees o f freedom, where d is the mean of the differences (d^ = - y j)
and SEM-. is the standard e rro r of the mean of the differences, d
Analysis o f variance (ANOVA) was carried out using the S ta tis tica l Package 
Programmes by D.S. M inors (Version 1.2, Departm ent of Physiology Stats Package) 
on the Apple computer.
E ffe c t o f tim e, and trea tm ent on blood gases was analysed using two way 
ANOVA followed by a posterio ri examination using Duncan's M u ltip le  Range test 
(Duncan, 1955). These s ta tis tica l analyses were carried out using the SPSS 
(S ta tis tica l Packages fo r the Social Sciences, Pensylvania State U nivers ity , Version 
M, Release 9.1) softw are on the University 's Prim e computer.
2.12 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)
Proenkephalin products were analysed by reverse-phase HPLC using a C-18 p 
Bondapak column (3.9mm x 15cm, Waters Associates, Mass., U.S.A.) eluted w ith  a 
linear ace ton itrile  gradient (15-30% over 30 minutes at lm l/m in )  in 6.25% v /v  
acetic acid/0.25% v /v  ammonia, pH 3.2. Peptides were taken up in the in it ia l 
gradient solvent (lOOpg/ml), in jected onto the column (in jection  volume lOOpl) and 
monitored by u ltra v io le t detection at 280nm. The above procedure is based on the 
separation method o f proenkephalin products o f Bailey and K itchen (1985).
r , 6 7[M e t] Enkephalyl-arg -phe and arg-phe were analysed by reverse-phase
HPLC, performed using a C-18 p Bondapak column (as above) eluted w ith  a linear 
gradient (60% ace ton itrile  in 0 .1% v/v  triflu o ro a ce tic  acid, 30-80% a t lm l/m in ) in
0.1% v/v triflu o ro a ce tic  acid. Peptides were taken up in deionised w ater (4 mg/m l),
r 6 7in jected onto the column (in jection  volume 3pl [M e t] enkephalyl-arg -phe , 20pl
arg-phe) and monitored by u ltra v io le t detection a t 230nm.
N -M ethyl levallorphan and levallorphan were analysed by reverse-phase
HPLC, performed using a C-18 Phenomenex X-Trem  3 column (4.6mm x 230mm)
eluted w ith  a linear ace ton itr ile  gradient (40-80% over 30 m inutes a t 2m l/m in) in 
0.1% v /v  tr ifluo roace tic  acid. N -m ethy l levallorphan and levallorphan were taken 
up in deionised water ( lm g /m l), in jected onto the column (in jec tion  volume 25pl) 
and monitored by u ltra v io le t detection a t 280nm.
2.13 DRUGS AND REAGENTS
The drugs and reagents used in these 
listed below.
Drug/Reagent
Opioid Agonists and Antagonists
[M et] enkephalin*
[Leu] enkephalin*
[M e t] enkephalyl-arg^-phe^*
[Met] enkephalyl-arg^-phe^-leu^*
[D -A la 2, MePhe4 -G ly -o l5]
enkephalin*
[D -Pen2, D-Pen^] enkephalin*
Morphine su lphate** +
U-50, 488H ** +
studies were obtained from  the sources 
Source
Cambridge Research Biochemicals, 
Harston, Cambridge, Suffo lk.
as above
as above
as above
as above
Peninsula Laboratories Europe 
L td ., St. Helens, Lancashire.
May and Baker, Dagenham, Essex.
Upjohn L td ., C raw ley, Sussex.
Naloxone hydroch lo ride** +
Levallorphan ta rtra te  (Lorphan)** +
N -M ethy l levallorphan methane s u lp h a te **4"
O ther Agonists and Antagonists 
Ace ty lcho line  chloride4"
Angiotensin II+
L-A rg inyl-L-phenyla lan ine acetate4"
A trop ine  sulphate4" 
l,I-D im e th y l-4 -p h e n y l piperazin ium 4" 
Diphenhydramine hydrochloride4" 
Hexamethonium bromide+
Sodium nitroprusside+
Propranolol hydrochloride (Inderal)4"
Phentolamine mesylate (Rogitine)+
Noradrenaline b ita rtra te  (Levophed)+
Vasopressin (Pitressin)+
Histam ine acid phosphate+
C im etid ine (Tagamet)*
Peptidase Inhib itors
Bestatin
L-Leucyl-leucine acetate+
* *
C aptopril 
HPLC Reagents
G lacia l acetic acid (Pronalys AR)
Ammonia solution (AnalaR)
A c e to n itr ile  (HPLC grade)
T rifluo roa ce tic  acid
Dupont, Crawley, Sussex.
Roche Products L td ., Welwyn 
Garden C ity , H ertfo rdsh ire .
Sanofi Research, M ilan, Ita ly .
Sigma Chemical Company, Poole,
Dorset.
as above 
as above 
as above 
as above 
as above 
as above 
as above
ICI Pharmaceuticals, M acclesfie ld,
Cheshire.
Ciba Laboratories, Horsham,
Sussex.
Sterling Research Laboratories,
Guildford, Surrey.
Parke-Davis and Co., Pontypool.
Gwent.
McCarthy's L td ., Rom ford, Essex.
Smith, K line and French
Laboratories, Welwyn Garden C ity ,
Hertfordsh ire.
Sigma Chemical Company, Poole, 
Dorset.
as above
E.R. Squibb and Sons L td ., 
Hounslow, Middlesex.
May and Baker, Dagenham, Essex.
BDH Chemicals L td ., Poole, 
Dorset.
Koch L igh t L td ., H averh ill. 
Suffolk.
A ld rich , G illingham , Kent.
Miscellaneous
C orticosterone
Dexamethasone
Tetrodotoxin
Urethane (e thy l carbamate)
Heparin sodium in jection (BP)
Sodium pentobarbitone in jection (BP)
Sigma Chemical Company, Poole, 
Dorset.
as above
as above
as above
CP Pharmaceuticals, Wrexham, 
Clwyd.
May and Baker, Dagenham, Essex.
Notes:
*  Opioid peptides were supplied as the acetate salt. Stock concentrations o f 
opioid peptides were seria lly d iluted w ith  Krebs-Ringer solution ( i f  used in jn  
v itro  studies) or 0.9% w /v saline ( i f  used in jn  vivo studies) and stored in 
p lastic  containers at -20°C fo r up to 3 months.
* *  The drugs were g ifts  from  the indicated sources.
+ The drugs were diluted each day from  stock concentrations stored a t 4 °C ,
apart from  acetylcholine which was fresh ly made up when required. Stock 
solutions were not kept longer than 4 weeks. For use in in v itro  studies, drugs
were d ilu ted w ith  Krebs-Ringer solution and fo r in jn  vivo studies, drugs were
d ilu ted w ith  0.9% w /v sodium chlorde solution. Noradrenaline solutions were
stored in p lastic containers on ice and ascorbic acid added (less than 2pg /m l) 
to  prevent oxidation.
3. RESULTS
3.1 EFFECT OF PROENKEPHALIN PRODUCTS ON ISOLATED ATRIA AND
PERFUSED MESENTERY PREPARATIONS
3.1.1 HPLC Analysis of Opioid Peptides
Reverse-phase HPLC analysis o f batches o f [M e t ]  enkephalin (ME), 
[L e u ] enkephalin (LE), [M e t ]  enkephalyl-arg^-phe^ (MEAP), [ M e t] enkephalyl- 
arg^-gly^-leu® (MEAGL) and [ D -A la^,M eP he^,G ly-o l^] enkephalin (DAGO) was 
carried out to check the pu rity  and id en tity  o f the peptides. R etention tim es were 
compared w ith  reference re ten tion  tim es fo r these peptides and are shown in Table 
11.
Table 11: Characteristic Retention Times of Opioid Peptides
Analysed by Reverse-Phase HPLC
Opioid Peptide Retention Time 
(mins)
Laboratory Standard 
Value (mins)
ME 7.34 + 0.11 7.3
LE 11.70 + 0.08 12.3
MEAP 18.32 + 0.10 18.8
MEAGL 16.13 + 0.14 16.6
DAGO 5.82 + 0.16 5.2*
Each value is the mean + s.e. mean o f 4-6 observations, w ith  varying 
concentrations o f peptide in jected onto the column (23-100 pg /m l) and conditions 
as described in Methods. Laboratory standard values were derived from  e ither 
Bailey and K itchen (1983) or *Yeadon (1988).
3.1.2 Effect of Proenkephalin Products on Isolated
Atria and on Responses to Exogenous Noradrenaline
[M e t ]  enkephalin, [ Leu ] enkephalin, [ M et ] enkephalyl-arg^-phe^, [M e t ]  
enkephalyl-arg^-gly^-leu® (10’ ^ - lC f^M ), or naloxone (10"^M) had no e ffe c t on 
basal ra te  or force of contraction  o f spontaneously beating ra t a tria . S im ila rly , 
incubation w ith  the peptidase inh ib ito rs  (bestatin, 10pM; captopril, lOpM , and 
leucyl-leucine, 2mM) had no e ffe c t on a tr ia l contraction or basal beating rate. In 
addition, proenkephalin products were w ithou t e ffe c t (up to lC f^M ) on a tr ia l force 
or ra te  of beating in the presence of peptidase inhib itors. These lack o f e ffec ts  are 
shown in representative traces, F igure 3.
P re lim inary experiments showed th a t a tr ia l chronotropic or inotrop ic 
responses to exogenous noradrenaline did not change s ign ifican tly  over the course 
of five  successive in te rm itte n t dose-response curves. This was determ ined by 
analysis of variance, ANOVA, of EC^g values fo r repeated curves. Representative 
traces of a tr ia l responses to  exogenous noradrenaline are shown in F igure 6 .
Incubation of a tria  w ith  [ M et ] enkephalin, [ Leu ] enkephalin,
[M e t ]  enkephalyl-arg^-phe^ or [M e t] enkephalyl-arg^-gly^-leu® (10 ^ -10 ^M), in
the presence o f peptidase inh ib itors, had no s ign ifican t e ffe c t on the chronotropic
-9 -7or inotrop ic responses produced by noradrenaline (5 x 10" - 2 x 10 M). This is
shown by both the absolute noradrenaline EC^g values (nM) in the presence and 
absence of proenkephalin products, Table 12, and by the change in noradrenaline 
EC^g values (nM) in the presence and absence o f proenkephalin products, Table 13. 
The calcu la tion o f the EC^g value is described in Methods. There was no s h ift of 
the dose-response curve to noradrenaline by proenkephalin products. The shape of 
the dose-response curve was unchanged and there were no s ign ifican t d ifferences in 
the slopes o f the curves, as determ ined by linear regression analysis.
Representative traces fo r the a tr ia l responses to noradrenaline and the 
e ffects  of the maximum noradrenaline dose in the presence of each proenkephalin
product a t the highest concentration studied are shown in Figure 6 .
There was an indication of a small enhancement o f chronotropic responses to 
noradrenaline in the presence of [L e u ] enkephalin and [M e t] enkephalyl-arg^- 
phe^, although there was no clear dose-relationship over the concentration range 
studied.
Effect of proenkephalin products, naloxone and peptidase 
inhibitors on atrial rate and force of beating.
240
160
bpm
80
500 [ mg L
t
lm m u te  lo V lM E 106M LE 106M MEAP
240
160
bpm
80
500
mg t
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t
10pM Bestatin 10 M Naloxone 
10pM Captopril 
2mM Leucyl-leucine
Figure 5: Representative Traces of the E ffec t of Proenkephalin Products,
Naloxone and Peptidase Inhibitors on A tria l Rate and Force of Beating
Traces show the e ffe c ts  on basal beating ra te  (bpm) and developed tension (mg).
ME = [Met] enkephalin; LE = [Leu] enk^phaliri; MEAP = [M e t] enkephalyl-arg - 
phe and MEAGL = [M e t] enkephalyl-arg -g ly  -leu . Responses to proenkephalin 
products were obtained fo llow ing incubation w ith  peptidase inhib itors fo r 15 
minutes. The e ffe c ts  o f each drug or drug com binations were studied in separate 
preparations. For b rev ity , the e ffec ts  o f the highest concentration of proenkephalin 
products and naloxone only are shown.
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Table 12: Chronotropic (A) and Inotropic (B) Responses of Rat Atria to
Noradrenaline in the Presence and Absence of Proenkephalin 
Products
EC^o Values fo r Noradrenaline (nM)
Peptide Concentration (M)
Peptide -
Q\1o
 
1—1 10"8 10 '7 10"6
A ME 21 + 2.0 24 + 4.2 15 + 2.7 21 + 3.3 14 + 2.5
LE 27 + 3.7 34 + 3.9 20 + 3.4 18 + 3.5 22 + 4.5
MEAP 32 + 3.0 34 + 4.5 22 + 3.7 20 + 3.2 27 + 2.3
MEAGL 25 + 3.1 31 + 3.3 23 + 1.8 20 + 3.7 27 + 3.1
B ME 12 + 3.8 8 + 3.1 14 + 2.0 10 + 2.6 13 + 3.0
LE 9 + 2.7 11 + 1.5 17 + 3.7 10 + 2.3 21 + 3.1
MEAP 17 + 3.7 13 + 1.6 19 + 4.0 22 + 1.6 21 + 2.9
MEAGL 12 + 3.7 19 + 1.9 15 + 3.1 21 + 1.9 18 + 4.1
EC^g values calculated as described in Methods. Each value is the mean + 
s.e. mean of 5 determ inations. The mean basal beating ra te  was 190 + 8 
bpm (n=20), the maximum chronotropic response to noradrenaline was +89 
+ 7 bpm (n=20) and the maximum inotrop ic response was +310 + l lm g  
In=20). One way analysis o f variance (ANOVA) fo r each individual peptide 
versus chronotropic or ino trop ic  responses - no s ign ifican t differences.
Table 13: Chronotropic (A) and Inotropic (B) Responses of Rat A tria  to
Noradrenaline in the Presence and Absence of Proenkephalin 
Products
Change in E-C,-g Values fo r Noradrenaline (nM)
Peptide Concentration (M)
Peptide
ON1o
 
1—1 10 '8 10'7 10"6
A ME +3.1 + 5.3 -6.2 + 4.0 -0.1 + 4.4 - 5.1 + 3.1
LE +7.0 + 6.7 -7.1 + 6.7 -8.4 + 7.0 -10.3 + 6.6
MEAP +1.7+ 6.7 -13.1 + 5.0 -15.1 + 4.9 -  6.7 +  4.2
MEAGL +6.2 +  5.8 -2.0 +  4.3 -1 .2+  1.3 - 2.4 + 4.9
B ME -3.9 + 3.2 +0.9 + 2.5 -1.8 + 1.3 +0.7 + 0.2
LE +1.6 + 3.9 +8.4 + 5.5 +0.8 + 4.7 +1.6+ 4.7
MEAP -3.6 + 3.6 +2.1 + 6.1 +4.4 + 4.4 +3.2+ 5.1
MEAGL +6.9 + 4.4 +5.1 + 4.7 +8.4+ 4.5 +5.9 + 6.6
EC^g values calculated as described in Methods. Each value is the mean + s.e. 
mean o f 3 determ inations. The mean basal beating ra te  was 190 + 8 bpm (n=20), 
the maximum chronotropic response to noradrenaline was +89 + 7 bpm (n=20) and 
the maximum inotrop ic response to  noradrenaline was +310 + l lm g  (n=20). One 
way ANOVA fo r each individual peptide versus chronotropic or ino trop ic  responses 
- no s ign ifican t differences.
3.1.3 Effect of Proenkephalin Products on Atrial Chronotropic Responses to
Noradrenergic and Cholinergic Nerve Stimulation
P re lim ina ry  experiments showed tha t fie ld  s tim ula tion o f isolated a tria  w ith  
tra ins o f square wave pulses (4 seconds duration, 40V, l-16H z, pulses o f 2ms w idth) 
produced stimulus frequency (l-16H z) re la ted  increases in chronotropic responses 
in the presence o f lp M  atropine and stim ulus frequency ( l - 6Hz) re la ted decreases 
in chronotropic responses in the presence o f ly M  propranolol as shown in Figures 7 
and 8 . The appropriate concentrations o f atropine and propranolol were confirm ed 
by th e ir a b ility  to  com pletely antagonise chronotropic responses to exogenous 
acetylcholine and noradrenaline respective ly. Incubation of a tria  w ith  te trodo tox in  
(lOOng/ml) to ta lly  abolished chronotropic responses to fie ld  stim ula tion, as shown 
in Figures 7 and 8 .
Incubation o f a tria  w ith  [M e t ]  enkephalin, [L e u ] enkephalin, 
[M e t] enkephalyl-arg^-phe^ or [M et] enkephalyl-arg^-gly^-leu® (10 ^ -10 ^M) in 
the presence o f peptidase inh ib itors, or naloxone (10"^M), had no e ffe c t on the 
chronotropic responses evoked by noradrenergic or cholinergic nerve s tim u la tion , 
Table 14, as shown by comparison o f the EF^g and EF£ ^ values in the presence and 
absence o f proenkephalin products. The ca lcu la tion o f EF^g and EF£ ^ values is 
described in Methods. There was a lack o f s h ift o f the stimulus frequency-response 
curve to noradrenergic and cholinerg ic nerve stim ulation in the presence o f 
proenkephalin products. The shapes o f the stim ulus frequency-response curve were 
unaltered and there were no s ign ifican t d iffe rences in the slopes o f the curves as 
determ ined by linear regression analysis.
Representative traces showing the chronotropic responses to  m axim al 
stim u la tion  frequencies in the presence of the highest concentration studied o f 
each proenkephalin product are shown in Figures 7 and 8 .
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Table 14: Chronotropic Responses to Noradrenergic (A) and Cholinergic (B)
Nerve Stimulation in the Presence and Absence of Proenkephalin 
Products
Peptide Concentration (M)
Peptide - 10"9 lC f8 10"7 10"6
EF10 (% Maximum Response)
A ME 74 + 3.6 66 + 5.2 72 + 3.9 65 + 6.1 71 + 4,9
LE 65 + 7.2 66 + 5.1 74 + 4.3 78 + 5.2 63 + 6.7
MEAP 72 + 5.2 68 + 3.7 63 + 7.2 72 + 4.9 75 + 5.3
MEAGL 75 + 2.9 71 + 5.8 68 + 5.7 70 + 4.4 67 + 5.9
EF 2.5 (% Maximum Response)
B ME 65 + 6.7 57 + 5.7 68 + 4.4 63 + 4.8 59 + 3.9
LE 59 + 7.1 64 + 4.8 62 + 5.2 67 + 5.2 59 + 5.0
MEAP 64 + 4.5 69 + 4.3 67 + 6.1 60 + 4.4 60 + 5.5
MEAGL 64 + 5.3 62 + 5.3 58 + 3.9 52 + 6.3 66 + 4.7
Values are the mean + s.e. mean of 4 determ inations. The maximum response 
was +79 + 9 bpm (n = 16) fo r noradrenergic nerve stim ula tion and -41 + 9 bpm 
(n = 16) fo r cholinergic nerve s tim u la tion . Absolute data was transposed to 
percentage of maximum response versus stim ulation frequency (Hz). 
and EF~ ^ values calculated as described in Methods. One way ANOVA fo r 
each individual peptide versus noradrenergic or cholinergic nerve stim u la tion  
responses - no s ign ifican t differences.
3.1.4 Effect of Proenkephalin Products on the Perfused Mesentery and on
Responses to Exogenous Noradrenaline
A t  bolus doses up to  10yg, proenkephalin products and naloxone had no e ffe c t 
on mesenteric perfusion pressure nor did perfusion w ith  peptidase inh ib itors, F igure 
9.
P re lim ina ry experiments demonstrated tha t the vasoconstrictor response to 
noradrenaline did not change s ign ifican tly  over the course of five  successive 
in te rm itte n t dose-response curves, as determ ined by one way ANOVA o f FD,-g 
values fo r repeated curves.
Perfusion o f the mesentery w ith  [M e t] enkephalin, [L e u ]  enkephalin, 
[M e t] enkephalyl-arg^-phe7 or [M e t] enkephalyl-arg^-g ly7-leu8 (10~9 -10~8M), in 
the presence o f peptidase inh ib itors, had no s ign ifican t e ffe c t on the m esenteric 
perfusion pressure or on the vasoconstrictor response to noradrenaline, as shown by 
comparison o f FD^g values in the presence and absence of proenkephalin products, 
Table 15. The calcula tion o f the FD,-g values is described in Methods. There were 
no sh ifts  o f the noradrenaline dose-response curves by proenkephalin products. The 
shapes o f the dose-response curves were unchanged and there were no s ig n ifica n t 
differences in the slopes as determ ined by linear regression analysis. 
Representative traces of mesenteric responses to noradrenaline and the e ffe c t of 
the m axim al noradrenaline dose in the presence o f the highest concentra tion 
studied fo r each proenkephalin product are shown in Figure 10.
Vasodilator responses to bolus doses o f acetylcholine (lOng) were obtained in 
noradrenaline-preconstricted perfused mesentery preparations.
Effect of pro enkephalin products, naloxone and peptidase 
inhibitors on mesenteric perfusion pressure-
5mmHg[ i l i l j p M l M M I  i iiP P i*
1 minute 10pgME 10pg LE 10pgMEAP
r  i_ i r iilllmiiiitAiimLuaii5mm Hg
t t
K)pg MEAGL 10pg Naloxone
5mmHg[ m M W m
Before After
Perfusion with 10 pM Bestatin,10pM Captopril and 
2mM Leucyl-leucine
Figure 9: Representative Traces of the E ffec t of Proenkephaiin Products,
Naloxone and Peptidase Inhibitors on the Perfusion Pressure of the 
Mesentery
Traces show e ffe c ts  on perfusion pressure (mmHg). The regular fluc tua tion  in 
pressure is due to the pe ris ta ltic  pumping of the perfusate. Responses to  
proenkephaiin products were obtained fo llow ing  perfusion w ith  peptidase inh ib ito rs  
fo r 15 minutes. The e ffe c t of each drug, or com bination o f drugs as in the case o f 
the peptidase inh ib itors, were studied in separate preparations. For brev ity , only 
the e ffec ts  o f t he highest dose j 3f  proenkephaiin products or naloxone studied are 
shown (dose range studied lOng -  lOpg).
Table 15: Pressor Responses of the Perfused Rat Mesentery to
Noradrenaline in the Presence and Absence of Proenkephaiin 
Products
ED50 Values fo r Noradrenaline (nMoles)
Peptide Concentration (M)
Peptide - 10"9 1—1 0
1 00 10"7 10"6
ME 6.7 + 0.7 7.6 + 0.9 5.7 + 0.7 7.3 + 1.1 6.0 + 0.7
LE 8 .1 + 1.1 8.3 + 1.2 8.5 + 1.2 7.2 + 0.7 7 .5+  1.3
MEAP 9.2+  0.7 9 .6+  1.2 8.8 + 1.4 10.2 + 0.8 9.1 + 1.0
MEAGL 6.5 + 1.2 5 .7+  1.2 5.0 + 0.5 5.7 + 0.7 4.4 + 0.7
Values are the mean + s.e. mean of 4 determ inations. ED™ values 
calculated as described in Methods. Peptide concentrations re fe r to the 
levels in the perfusate. The maximum pressor response to  noradrenaline 
was +75 + 8mmHg (n=16). One way ANOVA fo r each individual peptide 
versus pressor responses - no s ign ifican t differences.
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3.2 CARDIOVASCULAR STUDIES IN THE URETHANE-ANAESTHETISED RAT
3.2.1 Preliminary Experiments
The heart ra te , systolic and d iasto lic  blood pressures, blood pH, PC^, PCO 2 , 
bicarbonate concentration and base excess did not change s ign ifican tly  over a 2 
hour period. This was shown by heart ra te  and blood pressure m onitoring and blood- 
gas analysis a t 30 m inute in tervals, Table 16.
The cardiovascular response to  noradrenaline was monitored from  both the 
fem oral and carotid  a rte ry  in paired experiments. There was no s ign ifican t 
d iffe rence in the pressor or tachycardia response to noradrenaline whether 
m onitored from  the fem oral or caro tid  a rte ry . The increases in mean a rte ria l 
pressure and heart ra te  to noradrenaline ( lp g /k g ) were +58.2 + 5.1 mmHg, +65 + 10 
bpm (caro tid  a rte ry  recording) and +71.7 + 6.9mmHg, +49 + 16bpm (fem ora l a rte ry  
recording ,|n=5).
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3.2.2 Effects of Proenkephaiin Products
Representative traces o f the cardiovascular responses to each proenkephaiin
product are shown in Figure 11. The changes in d iasto lic pressure were more
marked than the systolic pressure changes fo r a ll the proenkephaiin products.
E ffec ts  o f [M e t] enkephalin, [ Leu ] enkephalin, [M e t] enkephalyl-arg^-phe^ and
6 7 8[M et]enkepha ly l-a rg  -g ly  -leu (30-300yg/kg) on mean a rte ria l pressure and heart 
rate fo llow ing intravenous adm in istration are shown in Figures 12 and 13 
respectively. The responses were produced w ith in  2 seconds of drug 
adm inistration. The duration o f the e ffects  showed v a ria b ility  between 
proenkephaiin products and are shown in Table 17.
The cardiovascular responses to  proenkephaiin products were independent of 
the site o f intravenous adm in istra tion. The changes in heart ra te  and blood pressure 
produced by [M e t] enkephalin (30-300 yg/kg) fo llow ing jugular or fem oral vein 
adm in istration were not s ign ifican tly  d iffe re n t in terms of magnitude or duration 
of response, Table 18. A small saline loading response on the heart was seen 
fo llow ing jugular vein adm in istration. The tim e taken fo r the response to be 
produced was 2-3 seconds longer fo llow ing fem oral vein adm in istra tion compared 
w ith  jugular vein adm in istra tion.
The described cardiovascular e ffec ts  were always produced by 
[M e t] enkephalin, [L e u ] enkephalin and [ M et] enkephaly l-arg^-g ly^-leu^, 
however in the case o f [M e t]  enkephalyl-arg^-phe^, about 23% o f preparations 
studied showed an a typ ica l response which is described in Section 3.2.5.
bpm
400r
200
u 100 fmmHg
y 70 1
[Met] enkephalin
400r
bpm
200 -
lu 100 r mmHg
[Leu] enkephalin
1 T
s 30 75 150 300
400r
bpm
200 
I ,  1 0 0  r
[Met]enkephalyl-arcf-phe7 (a)
bpm
400
2001
u, 100 r ronHg ?()[
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Figure 11: Representative Traces of Cardiovascular Responses to Proenkephaiin
Products
Traces show e ffe c t on heart ra te  (bpm) and blood pressure (mmHg). The saline 
response is shown as s, and the numbers represent doses in pg/kg. The e ffe c ts  o f 
each proenkephaiin product were studied in separate preparations. The two 
responses to [Met] enkephalyl-arg -phe represent the (a) typ ica l and (b) a typ ica l 
response.
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Table 17: Duration of the Cardiovascular Responses to Proenkephaiin
Products
Proenkephaiin
Product
Duration of 
Depressor Response 
(secs)
Duration of 
Bradycardia 
(secs)
ME 126 + 11* 158 + 15*
LE 77 + 18 58 + 13..
MEAP 114+15 1 5 6 + 1 2 *
MEAGL 68 + 14 65 + 19
The responses were produced by 300pg/kg o f proenkephaiin product and 
each peptide was studied in separate animals (n=10 fo r each peptide). 
The duration was measured as the tim e taken fo r the parameter to 
return to the pre-drug level. Student's t- te s t versus LE :- *p<0.05. 
Values represent mean duration + s.e. mean.
Table 18: Comparison of the Cardiovascular Responses to
M et Enkephalin Following Jugular and Femoral Vein
Administration
Jugular Vein 
A dm in is tra tion
Femoral Vein 
Adm in is tra tion
Dose
(yg/kg)
AMAP (mmHg) AHR (bpm) AMAP (mmHg) AHR (bpm)
30 -6.2 + 2.3 -13 + 5 -4.5 + 2.3 -12 + 6
75 -7.5 + 2.2 -20 + 7 -7.0 + 3.6 -23 + 8
150 -10 + 2.1 -27 + 8 -8.3 + 2.7 -27 + 6
300 -10.8 + 2.4 -35 + 8 -10.4 + 3.6 -30 + 7
AMAP = Change in mean a rte ria l pressure, AHR = Change in heart ra te
Values represent the mean + s.e. mean of 4 observations. Each animal 
acted as its  own contro l. Resting heart rate and mean a rte ria l 
pressure:- 343 + 236 bpm, 73 + 6mmHg. Paired t- te s t - no s ign ifican t 
differences.
3.2.3 Effects of Opioid Receptor Selective Agonists
The cardiovascular responses to the classical opioid agonist morphine, the p-
9  lx  5receptor selective agonist [ D -A la  , MePhe , G ly-ol ] enkephalin (DAGO), the 6 -
9 c
receptor selective agonist [D -Pen , D-Pen ] enkephalin (DPDPE) and k-recepto r 
selective agonist U-50, 488H are shown in Figures 14 and 15.
Both morphine (30-150pg/kg) and DAGO (3-30pg/kg) produced a marked dose- 
re lated decrease in heart ra te  and blood pressure. The responses were im m ediate in 
onset and the duration o f the responses was more prolonged than those observed fo r 
the proenkephaiin products. DAGO (30pg/kg) produced a bradycardia and depressor 
response th a t often persisted fo r over 4 minutes.
DPDPE (75-300pg/kg) had no s ign ifican t e ffe c t on heart ra te  or mean a rte ria l 
pressure.
U-50,488H (75-300pg/kg) had no e ffe c t on mean a rte ria l pressure, but 
produced a small, dose-related decrease in heart rate which was not s ta tis tic a lly  
s ign ifican t by ANOVA.
The histam ine antagonists, diphenhydramine (6mg/kg) and c im etid ine 
(6mg/kg), had no e ffe c t on the decrease in heart rate or blood pressure produced by 
morphine (15-75pg/kg). The employed antagonist doses com plete ly abolished the 
depressor e ffe c t o f histam ine (300pg/kg) .
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Figure 14: Representative Traces of Cardiovascular Responses to Morphine and
Receptor Selective Agonists
Traces show e ffe c ts  on heart rate (bpm) and blood pressure (mmHg). The saline 
response is shown as s, and the numbers represent doses in pg/kg. The e ffec ts  o f 
each agonist were studied in separate preparations.
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Figure 15: Cardiovascular Responses to Morphine and Opioid Receptor Selective
Agonists
The e ffe c ts  of each agonist were studied in separate animals. H istograms represent 
in (a) mean change in heart rate + s.e. mean and in (b) mean change in mean 
a rte ria l pressure + s.e. mean; (n = 6-10). Mean resting heart rates and mean a rte ria l 
pressures ranged from  345-369 bpm and 69-78 mmHg. One way ANOVA of the 
e ffec ts  of DAGO and morphine on heart ra te  and blood pressure: p < 0.01.
3.2.4 Effect of Naloxone on Cardiovascular Responses
The intravenous adm in istration o f naloxone (0.1 - 2.5mg/kg) had no e ffe c t on 
mean a rte ria l pressure or heart rate.
Naloxone (1 mg/kg) to ta lly  abolished the cardiovascular response to 
[M e t] enkephalin, [L e u ] enkephalin, [M e t] enkephalyl-arg^-phe^, [M e t] 
enkephalyl-arg^-gly^-leu® (30-300pg/kg), morphine (30-150pg/kg) and DAGO (3- 
30pg/kg), as shown in Figure 16. The small decrease in heart ra te  produced by LJ- 
30, 488H (75-300pg/kg) was unaltered by naloxone (1 mg/kg).
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Figure 16: E ffect of Naloxone on Cardiovascular Responses to Proenkephaiin
Products, DAGO and Morphine
Solid histograms and ve rtica lly  striped histograms represent responses in the 
absence and presence of naloxone respective ly, each animal serving as its  own 
contro l. Each value represents in (a) the mean change in heart ra te  + s.e. mean and 
in (b) the mean change in mean a rte ria l pressure + s.e. mean, n = 3 in both cases. 
F u ll dose-ranges were studied fo r  each agonist although, fo r b rev ity , only highest 
doses are shown (ME, LE, MEAP, M EAGL-300pg/kg, DAGO-30pg/kg, Morphine - 
75yg/kg). Responses were obtained 15 minutes a fte r the adm in istra tion  o f 
naloxone (lm g /kg ). Mean resting heart rates and mean a rte ria l pressures ranged 
from  321-376bpm and 71-83mmHg.
3.2.5 Atypical Responses to \Met] Enkephalyl-arq^-phe^
In about 25% of rats, a markedly d iffe re n t cardiovascular p ro file  to 
[M e t] enkephalyl-arg^-phe^ was exhibited from  tha t described in Section 3.2.2, 
Figure 17. A t  30yg/kg, [ M et] enkephalyl-arg^-phe^ produced a decrease in heart 
ra te  and blood pressure. However, above this dose the bradycardia and depressor 
response became increasingly transien t and were followed by a marked tachycardia 
and pressor response. The decreases in blood pressure and heart ra te  were 
antagonised by naloxone (1 mg/kg) w h ils t the tachycardia and pressor response were 
unaffected, F igure 18. Phentolam ine (300yg/kg) and propranolol (300yg/kg) 
abolished the pressor response and tachycardia respectively. These antagonist doses 
com pletely antagonised the pressor and tachycardia responses to noradrenaline 
( ljjg /k g ).
Intravenous adm in istra tion o f the dipeptide arg-phe (30-300yg/kg) produced a 
dose-related increase in heart ra te  and blood pressure. This was o f a s im ila r 
magnitude and duration to tha t e lic ited  by [M e t] enkephalyl-arg^-phe^, F igure 17. 
The response to arg-phe was unaffected by naloxone, but phentolam ine (300yg/kg) 
and propranolol (300yg/kg) com plete ly antagonised the pressor and tachycardia 
response respectively.
Arg-phe ( i- i0 0 y g )  did not have any vasoconstrictor action in the perfused 
mesentery.
Hexamethonium (12mg/kg) also abolished the cardiovascular responses to arg- 
phe. This dose blocked the cardiovascular responses to  l, l-d im e th y l-4 -p h e n y l 
piperazinium, DMPP, (30-300y g/kg), but did not a ffe c t the cardiovascular 
responses to noradrenaline.
HPLC analysis revealed tha t the samples o f [M e t]  enkephalyl-arg^-phe^ and 
arg-phe were pure, Figure 19.
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Figure 17: Cardiovascular Effects of (a) [ Met] enkephalyl-arq^-phe^ and (b)
Arg-phe
Diagrams represent the mean change in mean a rte ria l pressure + s.e. mean in the 
upper histogram and mean change in heart ra te  + s.e. mean in the lower histogram, 
n = 5 in both cases. The e ffec ts  o f each peptide were studied in separate animals. 
Mean resting heart rates and mean a rte ria l pressures ranged from  340-374bpm and
70-79mmHg.
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Figure 18: E ffect of Naloxone on the Atypical Cardiovascular Response to
[Met] enkephaiyi -arq^-phe^
Diagrams represent the mean change in mean a rte ria l pressure + s.e. mean in the 
upper histogram and the mean change in heart rate + s.e. mean in the lower 
histogram, n = 5 in both cases. Dark histograms and stippled histograms represent 
responses to MEAP in the absence and presence o f naloxone (lm g /kg ) respective ly. 
Numbers shown represent doses (pg/kg). Responses were obtained 15 m inutes a fte r  
the adm in istration of naloxone. Mean resting heart rates and mean a rte ria l 
pressures ranged from  339-367bpm and 69-80mmHg.
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Figure 19: Reverse-Phase FPLC Profiles of (a) [M e t] enkephalyl-arq -phe and
(b)arg-phe
The profiles represent traces produced fo llow ing  the in jection of 5pl MEAP and 
20pl arg-phe onto the column. Conditions of HPLC analysis are detailed in 
Methods.
3.2,6 Repeated Administration of Proenkephaiin Products, DAGO and
Morphine
The cardiovascular responses to the dose range of proenkephaiin products (30- 
300yg/kg), DAGO (1.5-15yg/kg) and morphine (3-75yg/kg) administered three 
times, w ith  a th ir ty  m inute in te rva l between dosing regimes, was investigated. 
Each opioid agonist was studied in a separate preparation.
Repeated adm in istra tion o f [M e t ]  enkephalin, [Leu ] enkephalin, 
[M e t] enkephalyl-arg^-phe^ and [M e t] enkephalyl-arg^-gly^-leu® produced no 
s ign ifican t differences in cardiovascular responses between the f irs t,  second or 
th ird  dose-response curve, Table 19. Repeated adm in istra tion o f DAGO and 
morphine, however, resulted in a s ign ifican t attenuation of the bradycardia and 
depressor response fo r both second and th ird  dose-response curves, Figures 20 and 
21.
Table 19: Effect of Repeated Administration of Proenkephalin Products
Change in Mean A r te r ia l Pressure Change in H eart Rate 
(mmHg) (bpm)
Opioid Dose D R C (l) DRC(2) DRC(3) D R C (l) DRC(2) DRC(3) 
Peptide (yg/kg)
ME 30 -9.5+1.7 -12.1+1.8 -12.0+3.4 -15+5 -15+4 -10+0
300 -15.9+2.6 -18.3+4.0 -20+5.0 -28+9 -25+3 -25+8
LE 30 -5.4+0.8 -5.0+0.8 -5.4+1.2 -10+0 -10+6 -13+4
300 -12.2+1.7 -11.6+1.5 -12.1+1.8 -32+2 -38+7 -38+9
MEAP 30 -10+2.6 -9.8+2.1 -8.3+2.1 -22+4 -25+5 -27+3
300 -16.7+2.1 -14.6+3.3 -13.3+1.8 -47+7 -50+6 -40+6
MEAGL 30 -6.2+3.0 -8.1+3.7 -9.6+3.1 -16+6 -19.4 -12+5
300 -15+4.1 -13.7+3.2 -15.9+4.8 -39+14 -35+9 -32+8
D R C (l) = 1st dose response curve, DRC(2) = 2nd dose response curve, DRC(3) = 3rd 
dose response curve.
Each value represents the mean + s.e. mean of 4 observations. T h ir ty  m inute 
in terva ls occurred between dose response curves. Fu ll dose ranges (30-300pg/kg) 
were studied, however fo r b rev ity  only responses to the highest and lowest doses 
are shown. The e ffects  o f each peptide were studied in separate preparations. 
Mean resting heart rates and mean a rte ria l pressures ranged from  353-380 bpm and
71-85 mmHg.
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Figure 20: E ffec t of Repeated Administration of DAGO and Morphine on Changes
in Heart Rate
Each point represents the mean + s.e. mean of 5 observations. Squares represent 
responses in the f ir s t  dose-response curve (DRC1), triangles represent responses in 
the second dose-response curve (DRC2), and circ les represent responses in the th ird  
dose-response curve (DRC3). Paired t- te s t fo r changes in dose-response curve 
from  orig inal; open and solid stars represent D R C (l) vs DRC(2), and D R C (l) vs 
DRC(3) respective ly, *p<0.05 •„ Mean resting heart rates in the
range 352-371bpm.
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Figure 21: E ffec t of Repeated Administration of DAGO and Morphine on Change
in Mean Arteria l Pressure
Each point represents the mean + s.e. mean of 5 observations. Squares represent 
responses in the f ir s t  dose-response curve (DRC1), triang les represent responses in 
the second dose-response curve (DRC2) and circles represent responses in the th ird  
dose-response curve (DRC3). Paired t-te s t fo r changes in dose-response curves 
from original; open and solid stars represent D R C (l) vs DRC(2) and D R C (l) vs 
DRC(3) respective ly, *p<0.05, ***p<0 .001  . Mean resting mean a rte ria l
pressures in the range 72-81 mmHg.
3.3 EFFECT OF CAPTOPRIL AND BESTATIN ON THE CARDIOVASCULAR
PROFILES OF PROENKEPHALIN PRODUCTS IN THE URETHANE-
ANAESTHETISED RAT
3.3.1 Cardiovascular Effects of Captopril
The intravenous adm in istra tion o f captopril (2mg/kg) produced a sustained 
decrease in mean a rte ria l pressure (-15.7 + 2.3mmHg, n = 4) w ith  an accompanying 
re flex tachycardia. This resulted in a s ign ifican t attenuation of the depressor 
response to sodium nitroprusside, 75yg/kg, (pre captopril -19.7 + 1.5mmHg, post 
captopril -11.5 + 1.6mmHg), morphine, 30yg/kg, (pre captopril -17.2 + 2.2mmHg, 
post captopril -10.5 + 2.1mmHg) and [M e t] enkephalin, 300yg/kg, (pre captopril - 
13.9 + 3.4mmHg, post cap topril -6.9 + 2.3mmHg).
Depressor e ffec ts  o f cap topril were s t il l evident a t 500yg/kg. However at a 
dose of 200yg/kg, no s ign ifican t lowering of mean a rte ria l pressure or attenuation 
of responses to  sodium nitroprusside occurred. This dose of captopril was used to 
study the e ffec ts  on responses to proenkephalin products.
3.3.2 Effects of Captopril on Cardiovascular Responses to Proenkephalin
Products
The duration o f the cardiovascular responses to [M e t] enkephalin,
[M e t ]  enkephalyl-arg^-phe^, [M e t] enkephalyl-arg^-gly^-leu® but not
[L e u ] enkephalin, were s ign ifican tly  potentia ted in the presence of captopril, 200
pg/kg, Figures 22-23. The magnitude o f the responses to a ll four peptides remained
6 7 8unaffected. The potentia tion was most marked fo r [M e t] enkephalyl-arg -g ly  -leu 
where the duration of the bradycardia and the vasodepressor response was 
increased 3-fo ld .
C aptopril (200 pg/kg) had no e ffe c t on the duration of the cardiovascular 
response to morphine, 30pg/kg, (pre captopril-depressor response 135 + 19 seconds, 
bradycardia 177 + 32 seconds; post captopril-depressor response 120 + 29 seconds, 
bradycardia 145 + 25 seconds). C aptopril (200pg/kg) s ign ifican tly  attenuated the 
duration o f the vasopressor response to angiotensin I, 3pg/kg, (pre cap top ril 172 + 
29 seconds, post captopril 75 + 6 seconds).
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Figure 22: E ffec t of Captopril on the Duration of the (a) Bradycardia and (b) 
Depressor Response to [Met| enkephalin
Points represent the mean duration o f the change in heart ra te  + s.e. mean in the 
top diagram and the mean duration of the change in mean a rte ria l pressure + s.e. 
mean in the bottom  diagram, n = 5 in each case. Solid squares and circles represent 
responses to ME in the absence and presence o f captopril respective ly, each animal 
serving as its  own contro l. Responses were obtained 15 minutes a fte r the 
adm in istration o f captopril (200pg/kg). Paired t- te s t:-  *p <  0.05, '.  Mean
resting heart ra te and mean a rte ria l pressure:- 394 + 21bpm, 78 + 6mmHg.
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Figure 23: E ffe c t of Captopril on the Duration of the (a) Bradycardia and (b) 
Depressor Response to 1 Leu] enkephalin
Points represent the mean duration o f the change in heart ra te + s.e. mean in the 
top diagram and the mean duration of the change in mean a rte ria l pressure + s.e. 
mean in the bottom  diagram, n = 3 in each case. Solid squares and circles represent 
responses to LE in the absence and presence o f cap top ril respectively, each animal 
serving as its  own contro l. Responses were obtained 13 minutes a fte r the 
adm in istration o f cap topril (200pg/kg). Paired t- te s t:-  *p  < 0.03. Mean resting 
heart rate and mean a rte ria l pressure:- 363 + 15bpm, 76 + 3mmHg.
a) 240
18 0
*3> 120XJ
60
0J
★ ^1meap+
I . - ' " ' " '
captopril
i j- k
MEAP
3507 / 7 r ~  mDose (pg/kg) •
b)
18 0
150
120-
§90
60
H i MEAP+captopril
■M  MEAP
Dose (pg/kg)
Figure 24: E ffec t of Captopril on the Duration of the (a) Bradycardia and (b)
Depressor Response to [Met enkephaiyl-arq^-phe
Points represent the mean duration o f change in heart ra te  + s.e. mean in the top 
diagram and the mean duration of change in mean a rte ria l pressure + s.e. mean in 
the bottom diagram, n = 5 in each case. Solid squares and circ les represent 
responses to MEAP in the absence and presence o f cap topril respective ly, each 
animal serving as its  own contro l. Responses were obtained 15 minutes a fte r the 
adm inistration o f captopril (200pg/kg). Paired t- te s t:-  *p  < 0.05. Mean resting 
heart rate and mean a rte ria l pressure:- 352 + 24bpm, 75 + 4mmHg.
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Figure 25: E ffect of Captopril on the Duration of the (a) Bradycardia and (b)
Depressor Response to enkephaiyl-arq^-qly^-leu^
Points represent the mean duration o f the change in heart ra te  + S.E. mean in the 
top diagram and the mean duration o f the change in mean a rte ria l pressure + S.E. 
mean in the bottom  diagram, n = 5 in each case. Solid squares and c irc les represent 
responses to MEAGL in the absence and presence o f captopril respective ly, each 
animal serving as its own contro l. Responses were obtained 15 m inutes a fte r  the 
adm in istra tion o f captopril (200yg/kg). Paired t- te s t *  p < 0.05; * *  p < 0.01. Mean 
resting heart ra te  and mean a rte ria l pressure:- 340 + 13bpm, 71 + 4mmHg.
3.3.3 Effect of Bestatin on Cardiovascular Responses to Proenkephalin
Products
Bestatin  (0.5 - lOmg/kg) had no e ffe c t on resting heart ra te  or mean a rte ria l 
pressure. Bestatin  (0.5mg/kg) had no e ffe c t on cardiovascular responses to [M e t] - 
or [ Leu ] -enkephalin. A t  5mg/kg, a po ten tia tion  of the magnitude o f the depressor 
response to [M e t ] -  and [L e u ] -enkephalin was evident, but not s ta tis tic a lly  
s ign ifican t. A t  lOm g/kg, bestatin s ign ifican tly  potentia ted the magnitude o f the 
vasodepressor response to [M e t] - and [L e u ] -enkephalin (300pg/kg), but not th a t 
produced by [M e t]  enkephalyl-arg^-phe^ and [M e t] enkephalyl-arg^-gly^-leu® 
(300jjg/kg), Table 20. There were no indications o f any e ffects  on the bradycardia 
or on the duration of the responses.
3.3.4 Combined E ffect of Captopril and Bestatin on Cardiovascular 
Responses to Proenkephalin Products
The intravenous adm in istra tion of both bestatin (lOmg/kg) and cap top ril 
(200pg/kg) had no e ffe c t on resting heart ra te  or mean a rte ria l pressure.
The combined e ffe c t of captopril and bestatin was to poten tia te  both the 
duration and magnitude o f cardiovascular responses to a ll proenkephalin products 
by a s im ila r degree to tha t achieved fo llow ing the adm in istra tion o f e ithe r 
peptidase in h ib ito r, Table 20.
The com bination o f captopril and bestatin did not modulate the magnitude or 
duration o f the pressor response to vasopressin, 150ng/kg, (pre cap top ril/bes ta tin - 
+12.5 + 1.6mmHg, 82 + 22 seconds; post captopril/bestatin-+15.0 + 1.3mmHg, 92 + 
10 seconds).
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3.4 INVESTIGATIONS INTO THE MECHANISMS INVOLVED IN THE
CARDIOVASCULAR RESPONSES TO PROENKEPHALIN PRODUCTS
3.4.1 Bilateral Vagotomy
The systo lic and diasto lic blood pressure, a rte ria l pH, P O2, bicarbonate 
concentration and base excess did not change s ign ifican tly  over the 90 m inute 
period fo llow ing b ila te ra l vagotomy. However, the heart ra te  was s ign ifican tly  
higher than in the in ta c t urethane-anaesthetised ra t a t equivalent tim e in terva ls 
and the PCO2 was elevated at 90 minutes, Table 21.
3.4.1.1 E ffe c t of B ila te ra l Vagotomy and A trop ine  on the Cardiovascular 
P ro file  o f the Proenkephalin Products, DAGO and Morphine
B ila te ra l vagotomy abolished the cardiovascular e ffe c ts  o f the proenkephalin 
products, DAGO and morphine, Figure 26.
The intravenous adm in istra tion o f atropine, 300 yg /kg , a dose tha t 
antagonised the cardiovascular e ffec ts  o f 10 yg /kg  acetylcholine, resulted in a 
s ign ificant increase in resting heart ra te  (+53 + 14bpm, n=5) but had no e ffe c t on 
mean a rte ria l pressure.
A trop ine  (300 yg/kg) antagonised the bradycardia produced by the 
proenkephalin products, DAGO and morphine but had no s ign ifican t e ffe c t on the 
depressor response, F igure 27.
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Figure 26: E ffect of Bilateral Vagotomy on Cardiovascular Responses to
Proenkephalin Products, DAGO and Morphine
Solid histograms and hatched histograms represent responses before and a fte r 
b ila te ra l vagotomy respective ly, each animal serving as its  own con tro l. Each value 
represents in (a) the mean change in heart ra te + s.e. mean and in (b) the mean 
change in mean a rte ria l pressure + s.e. mean, n = 4 in each case. F u ll dose-ranges 
were studied, although fo r b rev ity , only highest doses are shown (ME, LE, MEAP, 
MEAGL - 300pg/kg, DAGO - 30 pg/kg, morphine - 73 pg/kg). Responses were 
obtained 15 minutes a fte r the transection of both vagi. Mean resting heart rates 
and mean a rte ria l pressures were in the range 325-362bpm and 72-95bpm.
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Figure 27: E ffect of Atropine on Cardiovascular Responses to Proenkephalin
Products, DAGO and Morphine
Solid histograms and stippled histograms represent responses before and a fte r  
atropine adm in istration respective ly, each animal serving as its  own con tro l. Each 
value represents in (a) the mean change in heart rate + s.e. mean and in (b) the 
mean change in mean a rte ria l pressure + s.e. mean, n = 3 in each case. F u ll dose- 
ranges were studied, although fo r b rev ity , only highest doses are shown (ME, LE, 
MEAP, MEAGL - 300pg/kg, DAGO - 30 pg /kg , morphine - 75 pg/kg). Responses 
were obtained 15 minutes a fte r atropine adm in istra tion (300pg/kg). Mean resting 
heart rates and mean a rte ria l pressures were in the range 337-380bpm and 72- 
80mmHg.
3.4.2 Studies in the Pithed Rat
The m onitoring o f cardiovascular parameters and blood gas analysis every 30 
minutes over a 90 m inute period showed th a t, compared w ith  the urethane- 
anaesthetised ra t, the heart rate and systolic and d iasto lic pressures of the pithed 
ra t were s ig n ifica n tly  lower at a ll tim e points. ThePCOg was s ign ifican tly  higher 
a fte r 60 and 90 minutes, w h ils t the PO^ was higher a t a ll tim e points. The pH and 
base excess were not s ign ifican tly  d iffe re n t, however the bicarbonate 
concentration was s ligh tly  elevated, Table 22.
3.4.2.1 Cardiovascular R e ac tiv ity  o f the P ithed Rat Preparation
The pithed ra t was th ir ty  times more sensitive to noradrenaline compared to
the urethane-anaesthetised ra t. S im ilar responses to  acetylcholine (lO pg/kg) were 
obtained in both urethane-anaesthetised and pithed animals. The pithed ra t 
produced a sm aller depressor response to sodium nitroprusside (40pg/kg) compared 
to the urethane-anaesthetised ra t, w ith  no accompanying tachycardia, Table 23.
3.4.2.2 The Cardiovascular E ffec ts  o f Proenkephalin Products, DAGO and
Morphine in the Pithed Rat
The intravenous adm in istra tion o f [M e t] enkephalin, [L e u ] enkephalin, 
[M et] enkephalyl-arg^-phe^, [M e t] enkephalyl-arg^-g ly^-leu^ (30-300pg/kg), 
DAGO (3-30pg/kg) and morphine (3-75pg/kg) had no e ffe c t on the mean a rte ria l 
pressure or heart ra te , F igure 28.
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Table 23: Cardiovascular Responses of the Pithed Rat to Noradrenaline,
Acetylcholine and Sodium Nitroprusside Compared with those of 
the Urethane-anaesthetised Rat
Pithed R at Anaesthetised Rat
Agonist
Change in 
HR (bpm)
Change in 
MAP (mmHg)
Change in 
HR (bpm)
Change in 
MAP (mmHg)
Noradrenaline (+) +93 + 24 +32.1 + 2.7 + 77+ 18 +50 + 5.2
Acety lcho line 
(10 yg/kg)
-24 + 2* -14.7 + 1.5 -38 + 6 -15.2 + 2.2
Sodium N itroprusside 
(40 yg/kg)
0 + 0 * -11.1 + 1.0* +10 + 2 -19.2 + 2.6
+ Noradrenaline dose:- 100 ng/kg in pithed ra t; 30 yg/kg in anaesthetised ra t. 
MAP represents mean a rte ria l pressure, HR represents heart rate.
Values represent the mean change in heart ra te or mean a rte ria l pressure + 
s.e. mean, n=4 in each case. Student's t- te s t *p<0.05 versus values obtained in 
the urethane-anaesthetised ra t.
Mean resting heart rates and mean a rte ria l pressures:- P ithed ra t 245 + 18 
bpm, 58 + 6mmHg; Urethane-anaesthetised ra t 366 + 14 bpm, 76 + 4mmHcj
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3.4.3 Use of the Quaternary Opioid Antagonist, N-Methyl Levallorphan
3.4.3.1 B io log ica l H a lf- l ife  and Potency o f N -M ethy l Levallorphan and
Levallorphan
The b io log ica l h a lf- life  of N -m ethy l levallorphan (NML) and levallorphan was 
determined as described in Methods, using the magnitude of the vasodepressor 
response to [ Met] enkephalin as an index o f plasma antagonist concentration. The 
h a lf- life  o f the antagonist was calculated from  the slope o f the regression line, as 
shown fo r representative plots in Figure 29.
The bio log ica l h a lf- life  of NML was determ ined to  be 78.5 + 11.5 minutes 
(n=4), w h ils t tha t of the parent compound levallorphan was considerably shorter 
w ith  a duration o f 19.8 + 3.0 minutes (n=4).
NML (1 mg/kg) produced no antagonism of the bradycardia and vasodepressor 
response produced by [ M et] enkephalin (300yg/kg). A higher dose of NM L, 
(2mg/kg), produced a s ign ifican t attenuation of the vasodepressor response and 
bradycardia, F igure 30. A t  5mg/kg, NML com plete ly abolished the cardiovascular 
response to [M e t] enkephalin, [Leu ] enkephalin, [M e t]  enkephalyl-arg^-phe^, 
[ M e t ]  enkephalyl-arg^-gly^-leu® (30-300y g/kg), DAGO (1.5 - 15yg/kg) and 
morphine (7.5 -75 yg/kg), Figure 31.
Levallorphan (1 mg/kg) com pletely antagonised the cardiovascular response to 
the proenkephalin products, DAGO and morphine (a t doses stated above).
149
2*303
ke=9-126x1CT3/min
4.  0-693 „r . .ti.= ~ r — =75 minutes.
0 50 100 150 200
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Figure 29: Determination of the Biological H a lf-life  of (a) N -M ethyl Levallorphan
and (b) Levallorphan
The mean of three depressor responses to [M e t] enkephalin (300pg/kg) was defined 
as 1.0. A fte r  levallorphan (200pg/kg) or N -m ethyl levallorphan (5mg/kg), repeated 
dosing w ith  [M e t] enkephalin produced depressor responses whose magnitude 
gradually increased towards the pre-antagonist contro l. The h a lf- life  of the 
antagonist was calcula ted from  the slope of the regression line. The plots are 
representative o f the four determ inations made fo r each antagonist.
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Figure 30: E ffect of N-M ethyl Levallorphan on the Depressor Response to
Met enkephalin
Values represent mean change in mean a rte ria l pressure + s.e. mean, n = 3 in each 
case. Solid circles and squares show responses to ME in the absence and presence of 
NML respectively. Responses were obtained 13 minutes a fte r the adm in is tra tion  o f 
NML (2mg/kg). Paired t- te s t:-  *p<0.05. This is a typ ica l example o f the e ffe c t o f 
NML (2mq/kg) has on cardiovascular responses to proenkephalin products.
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Figure 31: E ffect of N-Methyl Levallorphan on Cardiovascular Responses to
Proenkephalin Products, DAGO and Morphine
Histograms represent in (a) the mean change in heart rate + s.e. mean and in (b) the 
mean change in mean a rte ria l pressure + s.e. mean, n = 4 in each case. Solid and 
diagonally shaded histograms represent responses before and a fte r the intravenous 
adm in istra tion of NML (5mg/kg) respective ly. Responses were obtained 13 m inutes' 
a fte r  the adm in istration of NML. F u ll dose ranges of each opioid agonist were 
studied, although fo r brev ity , only responses to the highest dose studied are shown 
(ME, LE, MEAP, MEAGL - 300pg/kg, DAGO - 30pg/kg and morphine - 75pg/kg). 
Mean resting heart rates and mean a rte ria l pressures ranged from  365-400bpm and 
76-81 mmHg.
3.4.3.2 Non-opioid Cardiovascular Effects of N-Methyl Levallorphan
Reverse-phase HPLC analysis revealed th a t the NML sample was pure.
The intravenous adm in istration o f NML (0.3 - lOmg/kg) produced an 
immediate, dose-related, s ign ifican t decrease in mean a rte ria l pressure and 
increase in heart ra te  which persisted fo r up to  8 minutes, Figure 32. Doses o f NML 
below 0.5mg/kg produced no cardiovascular e ffects . A t  5 and lOmg/kg NM L, the 
evoked tachycardia and depressor response were abolished by propranolol 
(300yg/kg) and phentolamine (300yg/kg) respective ly, Table 24. The employed 
doses of propranolol and phentolamine com plete ly antagonised the cardiovascular 
e ffects  o f lp g /k g  noradrenaline. Both components o f the response were abolished 
by 12 mg/kg hexamethonium, a dose tha t also abolished the cardiovascular e ffec ts  
of lOOy g/kg DMPP.
In the pithed ra t preparation, NML (1-10 mg/kg) produced a tachycardia and a 
pressor response, F igure 32. Both components o f the responses in the pithed animal 
were blocked by hexamethonium (12mg/kg).
NML (lOmg/kg) had no e ffe c t on the cardiovascular responses to 
acetylcholine, 15yg/kg, (pre NML -12.7 + 3.7mmHg, -38 + 12bpm; post NML -16.7 + 
5.5mmHg, -48 + 13bpm, n=5) noradrenaline, 1.5yg/kg, (pre NML +30.9 + 7.2mmHg, 
+30 + lObpm; post NML +28.7 + 3.7mmHg, +25 + 5bpm, n=5) or sodium 
nitroprusside, 30pg/kg, (pre NML -16.2 + 3.0mmHg, +10 + 2bpm; post NML -17.6 + 
4.7mmHg, +12 + 4 bpm, n=5).
However a t lOmg/kg, NML com petitive ly  antagonised the pressor response to 
the ganglion s tim u lan t, DMPP, Figure 33. A t  5mg/kg NML had no e ffe c t on the 
response to DMPP, 75yg/kg, (pre NML +16.8 + 3.1mmHg, +36 + 7bpm; post NM L 
+17 + 2.6mmHg, +40 + 6bpm).
a) Urethane-anaesthetised rat b)Pithed rat
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Figure 32: Cardiovascular Profile of N-Methyl Levallorphan in (a) the Urethane-
anaesthetised Rat and (b) the Pithed Rat
Upper histograms represent mean change in mean a rte ria l pressure + s.e. mean, 
lower histograms represent mean change in heart ra te  + s.e. mean, n = 3 in each 
case. One way analysis o f variance:- p<0.05 fo r e ffe c ts  on mean a rte ria l pressure 
and heart rate in both preparations. Resting heart ra te  and mean a rte ria l pressure:- 
urethane-anaesthetised ra t (366 + 22bpm, 82 + 5mmHg); pithed ra t (203 + 34bpm, 
36 + AmmHg).
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Figure 33: E ffect of N-M ethyl Levailorphan on the Pressor Response to
1,1 Dimethyl -4-Phenyl Piperazinium
Values represent the mean + s.e. mean, n = 5. Solid c ircles and squares show 
responses to DMPP in absence and presence o f NML respectively. Responses were 
obtained 13 minutes a fte r the intravenous adm in istration o f NML (lO m g/kg). Paired 
t - te s t:-  *p<0.05. Mean resting heart ra te  and mean a rte ria l pressure:- 408 + 21bpm 
and 79 + 3mmHg.
3.3 EFFECT OF MANIPULATION OF THE HYPOTHALAMUS-PITUITARY-
ADRENAL AXIS ON CARDIOVASCULAR RESPONSES TO
PROENKEPHALIN PRODUCTS
3.5.1 E ffec t of Manipulation of the Axis on Resting Cardiovascular 
Parameters, Weight Gain and Circulating Corticosterone Levels
3.3.1.1 Adrenalectom y
Twenty four hours a fte r sham-adrenalectomy, the resting heart rates and 
mean a rte ria l pressures were s im ila r to those recorded in unoperated rats. In 
adrenalectomised animals however, the resting parameters were s ign ifican tly  
elevated compared to the sham-adrenalectomised animals, Table 25. The pulse 
pressure was s ign ifican tly  reduced in acutely adrenalectomised rats compared w ith  
sham-operated animals, w ith  a systo lic /d iasto lic  d iffe rence of 27 + 6mmHg (n=5) 
compared to  54 + 8mmHg (n=5). This did not occur in chronica lly adrenalectomised 
rats where systo lic /d iasto lic  differences o f 55 + 7mmHg (n=5) and 49 + 6mmHg 
(n=5) were recorded in sham-operated and adrenalectomised animals respective ly.
In the chronic studies, animals were m onitored fo r 18 days fo llow ing surgery. 
There was no s ign ifican t d ifference in the weight gain of adrenalectomised rats 
compared to  sham-operated animals over th is  period, Table 25. The c ircu la ting  
corticosterone levels in adrenalectomised ra ts were 3-fo ld  lower than those 
recorded in sham-operated animals, Table 25. The resting cardiovascular 
parameters were s im ila r in both sham-operated and adrenalectomised animals, 
Table 25.
3.5.1.2 Dexamethasone Treatm ent
Twenty four hours fo llow ing the adm in istra tion o f dexamethasone, a t a 
drinking w ater concentration of 50pM, the cardiovascular e ffects  o f proenkephalin 
products were investigated. The mean dexamethasone intake over the 24 hour 
period was 2.0 + 0.16mg/kg (n=20), as determ ined by m onitoring flu id  in take. The
c ircu la ting  corticosterone levels o f the rats were markedly lower fo llow ing 
dexamethasone trea tm en t, Table 25. The resting heart rates and mean a rte ria l 
pressures of dexamethasone trea ted rats were not s ign ifican tly  d iffe ren t from  
those o f the con tro l animals, Table 25.
Chronic adm in istra tion o f the same dose o f dexamethasone, 50pM in the 
drinking water, resulted in a rapid weight loss, lethargism  and a general 
deterio ra tion in health w ith in  4-5 days. M aintaining animals on a 10-fo ld lower dose 
s t il l resulted in a considerable weight loss a fte r 18 days, up to 70g fo r a 300g ra t, 
and therefore a 100-fo ld lower drinking w ater dexamethasone concentration 
(0.5pM) was employed in chronic studies. A t  th is dose, the weight increase over 
the 18 day period was s t i l l  s ligh tly  lower fo r dexamethasone trea ted rats compared 
to contro l animals. The mean dexamethasone intake over 18 days, as assessed by 
m onitoring flu id  in take, was 19.45 + 1.87 pg/kg/day (n=12). The c ircu la ting  
corticosterone levels in dexamethasone treated animals were s ign ifican tly  lower 
than in contro l animals, Table 25. There were no s ign ifican t differences in the 
resting cardiovascular parameters o f dexamethasone trea ted rats compared w ith  
contro l rats, Table 25.
3.5.1.3 Adrenalectom y and Dexamethasone Treatm ent
Twenty four hours fo llow ing adrenalectomy and dexamethasone 
adm inistration, 50pM in drinking water, the cardiovascular e ffec ts  o f the 
proenkephalin products were studied. The contro l, sham-adrenalectomised ra ts 
received the same dose o f dexamethasone.
The c ircu la ting  corticosterone levels were s ign ifican tly  lower in 
adrenalectomised rats receiving dexamethasone than in sham-adrenalectomised 
rats receiving dexamethasone, Table 25. The mean in take of dexamethasone over 
the 24 hour period was 2.42 + 0.38mg/kg (n=10) fo r adrenalectomised animals and 
1.99 + 0.19 mg/kg (n=10) fo r sham-operated animals. The resting heart ra te  o f 
adrenalectomised, dexamethasone treated rats was not s ign ifican tly  higher than
tha t of the sham-operated, dexamethasone trea ted rats, however the mean a rte ria l 
pressure was often elevated, Table 25. The pulse pressure was s ig n ifica n tly  reduced 
in adrenalectomised, dexamethasone trea ted rats compared w ith  sham-operated, 
dexamethasone trea ted rats; a systo lic /d iasto lic  d ifference o f 29 + 7mmHg (n=5) 
compared w ith  49 + 5mmHg (n=5). This was also the case in chronica lly 
adrenalectomised, dexamethasone trea ted rats compared w ith  chron ica lly  sham- 
operated, dexamethasone trea ted rats, Table 25.
In the chronic studies, adrenalectomised and sham-adrenalectomised animals 
were maintained on drinking w ater dexamethasone concentrations o f 0.25 pM and 
0.5pM respectively. This d iffe rence in drinking w ater dexamethasone 
concentrations compensated fo r  the increased flu id  intake o f the adrenalectom ised 
animals.
The mean dexamethasone in take over the 18 day period was 21.22 + 1.94 
pg/kg/day (n=14) fo r the adrenalectomised rats and 18.68 + 1.04 pg/kg /day (n=14) 
fo r the sham-operated rats. The sham-adrenalectomised, dexamethasone trea ted  
rats gained almost tw ice  as much weight as the adrenalectomised, dexamethasone 
treated rats over the 18 day period, Table 25. The resting |mean a rte ria l pressure, 
r but not heart rate was s ign ifican tly  higher fo r the adrenalectom ised, 
dexamethasone trea ted rats compared to  the sham-operated, dexamethasone 
treated rats, Table 25.
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3.5.2 E ffect of Adrenalectomy on Cardiovascular Responses to
Proenkephalin Products
3.5.2.1 Acute Studies
The cardiovascular responses to proenkephalin products in sham- 
adrenalectomised rats were s im ila r to those observed in unoperated animals. The 
cardiovascular p ro file  o f the proenkephalin products in adrenalectomised rats was 
markedly d iffe re n t. There was a 3-4 fo ld  potentia tion of the vasodepressor 
response to  [M e t ]  enkephalin, [L e u ] enkephalin, [M e t]  enkephalyl-arg^-phe^ and
/"  7  n
[M et] enkephalyl-arg -g ly  -leu a t a ll doses studied, Figures 34-37. In addition,
preparations responded to a 10-fold lower threshold dose. The magnitude o f the
bradycardia produced by [M e t] enkephalin, [Leu ] enkephalin and [M e t] 
ft 7 Renkephalyl-arg -g ly  -leu was also potentia ted, although this was not as marked 
fo r [L e u ] enkephalin, Figure 35. The durations of the bradycardia and 
vasodepressor response were not s ign ifican tly  altered. In some preparations, a t the 
highest dose o f [M e t] enkephalyl-arg^-phe^, the atyp ica l biphasic response 
described in Section 3.2.5 was produced. W hilst a depressor response was produced 
in 3 out o f 5 sham-operated and adrenalectomised animals, a bradycardia only 
occurred in 1 out of 5 sham-operated animals and 2 out of 5 adrenalectomised 
animals. The remainder showed no change in heart ra te  fo llow ing  
[M e t] enkephalyl-arg^-phe^ adm in istra tion. The tachycardia and vasopressor 
response occurred in 2 out o f 5 sham-operated and adrenalectomised rats. The 
magnitude and duration o f the vasopressor response and tachycardia were s im ila r 
to those observed in previous studies.
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Figure 34: Acute E ffec t of Adrenalectomy on Cardiovascular Responses to
[ M et | enkephalin ”
Points represent in (a) the mean change in heart ra te  + s.e. mean and in (b) the 
mean change in mean a rte ria l pressure + s.e. mean. Solid squares and c irc les 
represent responses in sham-operated and adrenalectom ised rats respectively, n = 3 
in each case. Adrenalectom ised animals were m aintained on a 0.9% w /v sodium 
chioride solution. Student's t- te s t:-  *p<0.05, **p<0.01, ***p < 0 .0 01 . Mean resting 
heart rate and mean a rte ria l pressure:- 357 + 30bpm, 81 + 6 for sham-operated 
rats; 413 + 24 bpm, 92 + 6 fo r adrenalectomised rats.
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Figure 35: Acute E ffec t of Adrenalectomy on Cardiovascular Responses to
Leu] enkephalin
Points represent in (a) the mean change in heart ra te  + s.e. mean and in (b) the 
mean change in mean a rte ria l pressure + s.e. mean. Solid squares and c irc les 
represent responses in sham-operated and adrenalectomised rats respective ly, n = 5 
in each case. Adrenalectom ised animals were maintained on a 0.9% w /v sodium 
chloride solution. Student's t- te s t:-  *p<0.05, **p<0.01, ***p< 0 .001 . Mean resting 
heart rate and mean a rte ria l pressure:- 350 + 17bpm, 81 + 4mmHg for sham- 
operated rats; 412 + 11 bpm, 9 4 + 2  mmHg fo r adrenalectomised rats.
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Figure 36: Acute E ffect of Adrenalectomy on the Depressor Response to
M et] enkephalyl-arq^-phe^
Points represent in the mean change in mean a rte ria l pressure + s.e. mean. Solid 
squares and circles represent responses in sham-operated and adrenalectom ised 
animals respectively, n = 3 in each case. Adrenalectom ised animals were 
maintained on a 0.9% w /v sodium chloride solution. Student's t - te s t:-  *p<0.05, 
**p<0.01, ***p< 0 .001 . Mean resting heart rate and mean a rte ria l pressure:- 340 + 
23bpm, 78 + 3mmHg fo r sham-operated rats; 443 + 3bpm, 98 + 7mmHg fo r 
adrenalectomised rats.
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Figure 37: Acute E ffect of Adrenalectomy on Cardiovascular Responses to
[M e t]  enkephalyl-arq^-qly^-leu*
Points represent in (a) the mean change in heart ra te + s.e. mean and in (b) the 
mean change in mean a rte ria l pressure + s.e. mean. Solid squares and c irc les  
represent responses in sham-operated and adrenalectom ised rats respective ly, n = 5 
in each case. Adrenalectomised animals were maintained on a 0.9% w /v sodium 
chloride solution. Student's t- te s t:-  *p<0.05. Mean resting heart ra te  and mean 
a rte ria l pressure: 349 + 27bpm, 79 + 5mmHg fo r sham-operated rats; 422 + 12bpm, 
87 + 6mmHg fo r adrenalectomised rats.
3.3.2.2 Chronic Studies
The cardiovascular responses to [M e t] enkephalin and [M e t] enkephalyl- 
arg^-phe^ were unaffected 18 days a fte r  adrenalectomy. However, the 
vasodepressor responses to [M e t] enkephalyl-arg^-gly^-leu® and [Leu] enkephalin 
(300 pg/kg) were potentia ted, Figures 38 and 39. A ll sham-operated and 4 out o f 3 
adrenalectomised rats produced a dose-related tachycardia fo llow ing 
[M et] enkephalyl-arg^-phe^ adm in istra tion. The remaining adrenalectomised ra t 
produced a bradycardia. 2 out o f 5 adrenalectomised rats, and 1 out of 5 sham- 
operated ra ts produced a vasodepressor response to  [M e t] enkephalyl-arg^-phe^, 3 
out of 5 adrenalectom ised rats and 2 out of 5 sham-operated rats produced a 
biphasic response to [M e t] enkephalyl-arg^-phe^. The 2 remaining sham-operated 
rats exhibited a pressor response. The magnitude of the responses were s im ila r to 
those observed in previous studies.
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3.5.3 Effect of Dexamethasone Treatment on Cardiovascular Responses
to  Proenkephalin Products
3.5.3.1 Acute Studies
A cu te  dexamethasone trea tm ent had no s ign ifican t e ffects  on depressor 
responses to  [M e t] enkephalin, [Leu ] enkephalin, [M e t] enkephalyl-arg^-phe^ or
/* *7 Q
[M e t] enkephalyl-arg -g ly  -leu , although there were indications of a ttenuation of 
responses to [L e u ] enkephalin in dexamethasone treated rats, Figure 40. The 
bradycardia responses to proenkephalin products were not s ign ifican tly  a ltered,
although there were indications o f an attenuation of responses to [M et] enkephalin
f\ 7 Rand [M e t]  enkephalyl-arg -g ly -leu .
[M e t] Enkephalyl-arg^-phe^ produced heterogenous e ffects  on heart ra te  in 
contro l and dexamethasone treated rats. In stero id trea ted animals, 3 out o f 5 ra ts  
produced a decrease in heart ra te  and the remaining 2 preparations produced an 
increase in heart ra te . In the contro l rats, 2 out o f 4 produced an increase in heart 
rate and the remaining 2 preparations produced the atyp ica l biphasic response 
described in Section 3.2.5.
3.5.3.2 Chronic Studies
Chronic dexamethasone trea tm ent attenuated cardiovascular responses to a ll 
proenkephalin products, however th is e ffe c t was not always s ta tis tic a lly  
s ign ifican t, Figures 41-44. The response to [M e t] enkephalyl-arg^-phe^ was 
variable. A l l con tro l animals produced a decrease in heart ra te  and blood pressure. 
In dexamethasone treated rats, 2 out o f 5 animals fa iled to respond to 
[M e t] enkephalyl-arg^-phe^ and in the other preparations a bradycardia was 
observed a t doses ranging from  3-75 pg/kg. A t  150 and 300 pg/kg, an increase in 
heart ra te  was produced. A t a ll doses this was accompanied by a decrease in blood 
pressure.
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Figure 40: E ffec t of Acute Dexamethasone Treatment on Cardiovascular
Responses to Proenkephaiin Products
Histograms represent in (a) the mean change in heart ra te + s.e. mean and in (b) the 
mean change in mean a rte ria l pressure + s.e. mean. Blank histograms represent 
responses in untreated animals (n = 4), crossed histograms represent responses in 
dexamethasone trea ted animals (n = 5). Numbers shown ind icate doses (pg/kg). The 
e ffects  o f each peptide were studied in separate preparations. The chronotropic 
response to MEAP is described in Section 3.5.3.1. Student's t- te s t *p<0.05. Rats 
received a 50pM dexamethasone concentration in the drinking w ater. Mean resting 
heart rates ranged from  339-354 bpm fo r ste ro id -trea ted  animals and 310-417 bpm 
fo r contro l animals; mean resting mean a rte ria l pressures ranged from  80-91 mmHg 
for stero id-trea ted animals and 69-81 mmHg fo r contro l animals.
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Figure 41: E ffec t of Chronic Dexamethasone Treatm ent on Cardiovascular
Responses to 1 M et | enkephalin
Points represent in (a) the mean change in heart ra te  + s.e. mean and in (b) the 
mean change in mean a rte ria l pressure + s.e. mean. Solid squares and circ les 
represent responses in con tro l (n = 3) and dexamethasone trea ted animals (n = 5) 
respectively. Dexamethasone trea ted rats were maintained on a drinking water 
concentration o f 0.3 yM  dexamethasone. Mean resting heart ra te  and mean a rte ria l 
pressure:- 347 + 16 bpm, 78 + 5mmHg in steroid trea ted rats; 363 + 12 bpm, 81 + 
6mmHg in contro l rats.
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Figure 42: Effect of Chronic Dexamethasone Treatment on Cardiovascular 
Responses to |Leul enkephalin
Points represent in (a) the mean change in heart ra te  + s.e. mean and in (b) the 
mean change in mean a rte ria l pressure + s.e. mean. Solid squares and c irc les 
represent responses in con tro l (n = 3) and dexamethasone trea ted  ra ts  (n = 5) 
respective ly Dexamethasone trea ted  rats were maintained on a drink ing water 
concentration of 0.3 pM dexamethasone. Student's t- te s t:-  *p<0.05, **p<0 .01 , 
***p< 0 .001 . Mean resting heart ra te  and mean a rte ria l pressure:- 360 + 10 bpm, 73 
+ 2 mmHg in steroid treated rats; 370 + 10 bpm, 83 + 6 mmHg in con tro l ra ts.
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Figure 43: E ffect of Chronic Dexamethasone Treatment on Cardiovascular
Responses to fMetl enkephalyl-arg^-phe^
Points represent the mean change in mean a rte ria l pressure + s.e. mean. Solid 
squares and circ les represent responses in con tro l (n = 3) and dexamethasone 
treated rats (n = 3) respectively. Dexamethasone trea ted  rats were maintained on a 
drinking w ater concentration o f 0.5 pM dexamethasone. Chronotropic responses to 
MEAP in con tro l and stero id-trea ted rats are described in Section 3.5.3.2. Mean 
resting heart ra te and mean a rte ria l pressure:- 352 + 14 bpm, 68 + 6 mmHg in 
ste ro id -trea ted  rats; 353 + 39 bpm, 73 + 3 mmHg in contro l rats.
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Figure 44: E ffe c t of Chronic Dexamethasone Treatm ent on Cardiovascular
6 7 8Responses to [Met | enkephaiyl-arq -gly -leu
Points represent in (a) the mean change in heart ra te  + s.e. mean and in (b) the 
mean change in mean a rte ria l pressure + s.e. mean. Solid squares and circ les 
represent responses in contro l (n = 3) and dexamethasone treated rats (n = 3) 
respectively. Dexamethasone treated rats were maintained on a drinking w ater 
concentration o f 0.5yM  dexamethasone. Student's t- te s t *p<0.05. Mean resting 
heart rate and mean a rte ria l pressure:-420 + 23 bpm, 77 + 5 mmHg in stero id- 
treated rats, 357 + 18 bpm, 72 + 5 mmHg in contro l rats.
3.5.4 Effect of Adrenalectomy and Dexamethasone Treatment on
Cardiovascular Responses to Proenkephalin Products
3.5.4.1 Acute Studies
Twenty four hours fo llow ing adrenalectomy or sham-operation and 
dexamethasone adm in istra tion, 50pM in the drinking w ater, the cardiovascular 
e ffects  of the proenkephalin products were studied.
The magnitude o f the cardiovascular responses to proenkephalin products was 
markedly potentia ted in adrenalectomised, dexamethasone trea ted  rats compared 
w ith  responses in sham-operated, dexamethasone treated rats, F igure 45. Both 
adrenalectomised and sham-adrenalectomised, dexamethasone trea ted  rats 
exhibited a vasodepressor response to [M et] enkephalyl-arg^-phe^, however the 
e ffects  on heart ra te  were more varied. In the adrenalectomised animals, 3 out o f 5 
produced a bradycardia and the remaining 2 preparations produced a tachycardia. 
For the sham-operated group, 3 out of 4 produced a tachycardia and 1 produced a 
bradycardia. The responses were o f a s im ila r magnitude in both groups.
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Figure 45: E ffect of Acute Adrenalectomy and Dexamethasone Treatm ent on
Cardiovascular Responses to Proenkephalin Products
Histograms represent in (a) the mean change in heart rate + s.e. mean and in (b) the 
mean change in mean a rte ria l pressure + s.e. mean. H orizonta lly  striped histograms 
represent responses in sham-adrenalectomised, dexamethasone trea ted  rats (n = 5), 
hatched histograms represent responses in adrenalectomised, dexamethasone 
treated rats (n = 5). Numbers shown ind icate doses (pg/kg). The e ffe c ts -o f each 
peptide were studied in separate preparations. Adrenalectom ised animals were 
maintained on a 0.9% w /v sodium chloride solution; all animals received a drinking 
water dexamethasone concentration o f 50 pM. The heterogeneous responses to 
MEAP are described in Section 3.5.4.1. Student's t- te s t:-  *p<0.05, **p<0.01, 
* * * p < 0.001. Mean resting heart rates and mean a rte ria l pressures ranged from 
378-407 bpm, 89-99 mmHg fo r adrenalectom ised, dexamethasone trea ted  rats and 
344-352 bpm, 72-78 mmHg for sham-operated, dexamethasone trea ted  rats.
3.5.4.2 Chronic Studies
The cardiovascular e ffects  of the proenkephalin products were investigated 
18 days fo llow ing surgery. During this tim e  the adrenalectomised animals were 
maintained on a 0.9% w /v sodium chloride solution containing 0.25pM 
dexamethasone and the sham-operated animals maintained on drinking w ater 
containing a 0.5pM dexamethasone concentration. The cardiovascular e ffec ts  o f 
proenkephalin products were potentia ted in adrenalectomised, dexamethasone 
treated animals compared w ith  sham-operated, dexamethasone treated animals. 
This e ffe c t was most marked and s ta tis tic a lly  s ign ifican t fo r the vasodepressor 
response, F igure 46.
In contrast, a heterogeneous response to  [ M e t] enkephalyl-arg^-phe^ was 
produced in a ll trea tm en t groups. In sham-operated, dexamethasone trea ted  ra ts  a 
vasodepressor response was produced in a ll preparations at doses up to  30pg/kg. 
However a t 75 - 300 pg/kg, 2 out of 5 preparations in each group exhib ited a 
biphasic response. S im ilar responses were observed in adrenalectomised, 
dexamethasone treated rats. A bradycardia was produced in both 
adrenalectomised, dexamethasone trea ted rats and sham-operated, dexamethasone 
treated rats a t doses up to  150 pg/kg. However in both groups a t 300 pg/kg, 3 out 
of 5 ra ts  produced a tachycardia, 1 produced a bradycardia and 1 produced a 
biphasic response. These responses were o f a s im ila r magnitude in both groups.
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Figure 46: E ffect of Chronic Adrenalectomy and Dexamethasone Treatm ent on
Cardiovascular Responses to Proenkephalin Products
Histograms represent in (a) the mean change in heart ra te  + s.e. mean and in (b) the 
mean change in mean a rte ria l pressure + s.e. mean. H orizon ta lly  striped histograms 
represent responses in sham-adrenalectomised, dexamethasone trea ted  rats (n = 5). 
hatched histograms represent responses in adrenalectomised, dexamethasone 
treated rats (n = 5). Numbers shown represent doses (pg/kg). The e ffe c ts  o f each 
peptide were studied in separate preparations. Adrenalectom ised rats were 
maintained on a 0.9% w /v sodium chloride solution containing 0.25 pM 
dexamethasone. Sham-operated animals were maintained on drinking w ater 
containing 50 pM dexamethasone. The heterogeneous cardiovascular responses to 
MEAP are described in Section 3.5.4.2. Student's t- te s t:-  *p<0.05, **p<0 .01 , 
***p< 0 .001 . Mean resting heart rates and mean a rte ria l pressures ranged from  
334-4^5 bpm, 60-99 mmHg fo r adrenalectomised, steroid treated rats and 334-368 
bpm, 70-86 mmHg for sham-operated, steroid trea ted rats.
99996^
3.6 RESPIRATORY STUDIES
3.6.1 Respiratory Effects of Proenkephalin Products
The e ffe c t of [M e t] enkephalin, [L e u ] enkephalin, [M e t]  enkephalyl-arg^-
7 6 7 8phe and [ M et] enkephalyl-arg -g ly  -leu (30-300 pg/kg) on respiratory ra te  and
tida l volume fo llow ing intravenous adm in istration are shown in Figures 47 and 48.
Both [M e t ]  enkephalin and [M e t] enkephalyl-arg^-phe^ produced a s ign ificant,
dose-related, decrease in resp ira tory ra te  and tida l volume which was im m ediate in
onset and lasted no longer than 15 seconds. A t  the highest dose studied, 300 pg/kg,
[M e t] enkephalin and [M e t] enkephalyl-arg^-phe^ produced an apnea of 2-4
seconds duration in 50% o f preparations studied. In contrast, [L e u ] enkephalin and
f\ 7 fl[Met] enkephalyl-arg -g ly  -leu had no s ign ifican t e ffe c ts  on resp ira tory ra te  or
tid a l volume. Simultaneous cardiovascular m onitoring showed th a t a ll
proenkephalin products exhibited typ ica l cardiovascular pro files. A t low doses of
6 7[M e t] enkephalin, [L e u ] enkephalin, [M e t] enkephalyl-arg -phe and
[M et] enkephaly l-arg^-g ly^-leu^, cardiovascular responses were produced w ith  no 
e ffects  on respiratory parameters. The respiratory e ffec ts  o f [M e t] enkephalin 
and [M et] enkephalyl-arg^-phe^ were naloxone reversible.
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Figure 47: E ffect of Proenkephalin Products on Respiratory Rate
Histograms represent the mean change in respiratory rate + s.e. mean, n = 5-7. The 
e ffects  of each peptide were studied in separate preparations. Saline in jec tion  had 
no e ffe c t on respiratory rate . One way ANOVA - ME and MEAP p<0.05; LE and 
MEAGL - not s ign ifican t. Mean resting respiratory rates ranged from  124-164 
breaths/m inute.
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Figure 48: E ffec t of Proenkephalin Products on Tidal Volume
Histograms represent the mean change in tid a l volume + s.e. mean, n = 5-7. The 
e ffects  o f each peptide were studied in separate preparations. Saline in jection  had 
no e ffe c t on resp ira tory rate . One way ANOVA - ME and MEAP p<0.05; LE and 
MEAGL - not s ign ifican t. Mean resting tid a l volumes ranged from  2.1 - 3.2 ml.
3.6.2 Studies in Artificially Ventilated Rats
Cardiovascular recordings and blood-gas analysis were carried out a t 30 
minute in te rva ls  over a 90 m inute period. The heart rate, systolic and diasto lic 
blood pressures, PC^, pH and PCC^ at 30 and 60 minutes were not s ign ifican tly  
d iffe re n t from  those recorded in the spontaneously breathing animal. However, at 
90 minutes the PCC^ was s ign ifican tly  higher, the pH was lower and a reduced base 
excess and bicarbonate concentration were recorded, Table 26.
3.6.2.1 Cardiovascular E ffec ts  o f Proenkephalin Products in A r t if ic ia lly
Ventila ted Rats
Responses to  proenkephalin products were obtained in spontaneously 
breathing animals before a r t if ic ia lly  ven tila ting , each animal acting as its  own 
contro l. Most preparations settled in to  a steady regular breathing rhythm  w ith in  1- 
2 minutes o f connection to the ven tila to r pump, w ith  no indications of distress and 
very l i t t le  a lte ra tion  of resting cardiovascular parameters. Those animals which 
showed signs o f distress were not used.
A r t if ic a l ven tila tion  had no e ffe c t on the depressor response to proenkephalin 
products. There were no s ign ifican t d ifferences in the bradycardia produced by 
[M e t] enkephaiyi-arg^-phe^ and [ M et] enkephalyl-arg^-g ly^-leu^ in a r t if ic ia l ly  
ventila ted compared to spontaneously breathing rats. However, there was a s ligh t 
attenuation o f the bradycardia produced by [M e t] enkephalin and 
[Leu ] enkephalin, F igure 49.
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Figure 49: E ffect of A rtific ia l Ventilation on the Bradycardia Produced by the
Proenkephalin Products
Histograms represent the mean change in heart rate + s.e. mean, n = 4 in each 
case. Dark histograms represent responses in spontaneously breathing rats, stippled 
histograms represent responses in a r t if ic ia l ly  ventila ted rats, each animal serving 
as its  own control. Numbers shown represent doses (jjg /kg). The e ffe c ts  o f each 
peptide were studied in separate preparations. A r t if ic ia l ven tila tion  produced no 
s ign ifican t change in resting parameters. Paired t- te s t:-  *p<0.05. Mean resting 
heart rates and mean a rte ria l pressure ranged from  335-374 bpm and 72-76 mmHg.
4. DISCUSSION
4.1 ISOLATED CARDIAC AND VASCULAR TISSUE STUDIES
4.1.1 The E ffect of Proenkephalin Products on Isolated Atria
The absence of any d irec t e ffec ts  o f proenkephalin products on e ithe r a tr ia l
ra te or c o n tra c tility  accords w ith  the findings of other workers (Eiden and Ruth,
1982; Cherdchu et al., 1987; Maeda et al., 1986; W ille rth  and Thornh ill, 1987). Some 
studies have shown tha t perfusion o f isolated ra t hearts w ith  [M e t] - or [L e u ] -  
enkephalin reduces the heart ra te  and developed tension (Clo et al., 1985; Ventura 
e t al., 1987). However, the lack o f antagonism of these responses by naloxone 
suggests tha t these e ffec ts  may be non-opioid in nature.
The unchanged shape o f the noradrenaline dose-response curve in the 
presence o f proenkephalin products and the absence o f any sh ift of EC,-g values fo r 
chronotropic or inotrop ic e ffects  is strong evidence fo r a lack o f any m odulatory 
e ffec ts  o f proenkephalin products on a tr ia l responses to exogenous noradrenaline. 
The absolute noradrenaline EC,-g values fo r chronotropic and ino trop ic  responses, 
in the presence and absence o f proenkephalin products (Table 12) and the change in 
noradrenaline EC^g values from  contro l dose-response curves (Table 13) were 
compared. This counteracted the possible masking of any s ign ifican t d iffe rences 
due to re la tive ly  high standard errors w ith in  each EC^g value.
The results presented in th is thesis concur w ith  other reports which fa iled  to  
observe e ffe c ts  o f proenkephalin products upon inotrop ic responses to 
noradrenaline (Saunders and Thornh ill, 1985; Parker e t al., 1986; W ille rth  and 
Thornh ill, 1987) or adrenaline (Cherdchu j?t a l., 1987). However, they contrast w ith  
the earlie r work o f Eiden and Ruth (1982) who found tha t the pentapeptides 
[M e t] enkephalin and [Leu ] enkephalin strongly attenuated the m axim al 
chronotropic response to noradrenaline in a naloxone-reversible fashion.
The abo lition o f the a tr ia l responses to cholinerg ic and noradrenergic nerve 
s tim ulation by te trodo tox in , which blocks the conduction o f action potentia ls in 
nerve cells, demonstrated tha t the evoked chronotropic responses were neurally 
mediated and not due to d ire c t e ffec ts  on cardiac muscle. The fa ilu re  to observe 
modulatory e ffec ts  o f proenkephalin products on a tr ia l responses to noradrenergic 
and cholinerg ic nerve stim u la tion  d iffe rs  from  the observed actions o f enkephalin 
analogues which have been shown to in h ib it the cholinerg ic but not the 
noradrenergic responses o f ra t a tr ia  (Wong-Dusting and Rand, 1985). A combination 
o f peptidase inh ib itors, shown to s ign ifican tly  reduce enzym atic degradation jn  
v itro  (M cKnight et al., 1983), were used in a ll the isolated tissue studies in th is 
thesis. This e lim inates the possib ility  tha t the lack o f modulation was due to the 
loss o f pharm acological a c tiv ity  through rapid enzym atic cleavage. There is also 
evidence to suggest tha t enkephalin degradation by a tr ia l peptidases is ins ign ifican t 
(Cherdchu et al., 1987).
The question of the existence o f modulating presynaptic opioid receptors
therefore remains open. An im portan t point to consider when comparing the
observations in th is thesis w ith  published results is the d iffe rin g  receptor
sensitiv ities of the enkephalin analogues and the proenkephalin products. For
example, [L e u ] enkephalin, a strongly 6 -p re fe rring  agonist becomes a mixed p:6
2
agonist fo llow ing the substitution of D-alanine at the gly position in the 
enkephalin analogue DADLE (Paterson e t al., 1983).
The d isparity surrounding the e ffec ts  o f opioid peptides on the isolated a tria  
is paralleled by con flic ting  evidence fo r the presence o f opioid receptors in the ra t 
heart (Section 1.7.2).
4.1.2 The Effects of Proenkephalin Products on the Perfused Mesentery 
Preparation
The results obtained demonstrate tha t proenkephalin products exert no d ire c t 
e ffects  on the mesenteric vasculature or any m odulatory actions on the
vasoconstrictor response of the mesentery to  exogenous noradrenaline. This lack of 
e ffe c t cannot be a ttribu ted  to peptide degradation or to the removal of the 
endothelial layer during perfusion. The responsiveness of the preparation to 
acetylcholine, an endothe lium -re lax ing-factor (EDRF) dependent e ffe c t (Furchgott 
and Zawadzki, 1980), confirm s this.
These results contrast w ith  ea rlie r observations o f d ila tion  of mesenteric 
term ina l a rte rio les by opioid alkaloids (A ltu ra  et al., 1978). This may be a 
re fle c tion  of the d iffe ring  opioid receptor sens itiv ities  o f opioid alkaloids compared 
to those o f the proenkephalin products. A lte rn a tive ly , the d ila tion  of m esenteric 
te rm ina l a rte rio les may have very l i t t le  in fluence on the overall perfusion pressure 
in the vascular bed.
There are reports on the e ffec ts  o f [M e t]  enkephalin and [L e u ] enkephalin 
on other vascular tissues from  the ra t such as the ao rtic  s trip , ta il a rte ry, perfused 
lung preparation and porta l vein (Ruth et jal., 1984a; Yamamoto et al., 1984; Illes et 
al., 1987; G illespie et al., 1984). However, some of these e ffec ts  have been shown 
to be insensitive to naloxone indicating tha t non-specific e ffec ts  may preva il in 
v itro  (Yamamoto e t al., 1984; G illespie et al., 1984).
In d irec t supportive evidence fo r the lack o f e ffe c t of proenkephalin products 
on ra t a tr ia l tissue and mesenteric vasculature is provided by the pithed ra t 
studies, where proenkephalin products had no e ffe c t on heart ra te  or mean a rte ria l 
pressure (see Section 3.4.2.2). The absence o f e ffe c t o f proenkephalin products on 
both isolated a tria  and the mesenteric vascular bed, even in the presence o f 
peptidase inh ib itors, m ilita tes  against endogenous opioid contro l in these tissues 
under normal physiological circumstances.
4.2 STUDIES IN THE URETHANE-ANAESTHETISED RAT
I t  is w idely accepted tha t anaesthesia has varying influences on the resting 
function o f the cardiovascular system and its  responsiveness to both exogenous and 
endogenous activa tion . In comparison to other general anaesthetics, urethane 
produces a long-lasting stable leve l o f anaesthesia accompanied by a high degree of 
a c tiv ity  of the autonomic nervous system (Maggi and M eli, 1986). This is 
substantiated by the observation tha t adm in istration o f autonomic blocking drugs, 
such as atropine, hexamethonium, propranolol or phentolamine, produces prom pt 
and marked variations in heart ra te  and blood pressure. I t  appears tha t urethane 
anaesthesia is characterised by the preservation o f cardiovascular reflexes unlike 
tha t produced by sodium pentobarbitone and other anaesthetics (Brezeneoff, 1973).
Urethane exerts no s ign ifican t depression o f heart ra te  or cardiac 
c o n tra c tility  (Sapru and K rieger, 1979). The mean heart ra te  o f the conscious ra t, 
reported to be in the region o f 330bpm (W aynforth, 1980), is w ith in  the range of 
typ ica l resting heart rates recorded in urethane-anaesthetised rats. Urethane 
produces a s light depressant action on vascular muscle c o n tra c tility  (Maggi and 
M eli, 1984), which may explain why the mean a rte ria l pressure in the urethane- 
anaesthetised ra t, usually around 75-85 mmHg, is lower than tha t recorded in the 
conscious ra t, which typ ica lly  ranges from  100-120 mmHg (W aynforth, 1980). 
Another fac to r may be the damage tha t urethane produces in the mesenteric 
vasculature, which results in a leakage of plasma in to  the peritoneal cav ity  (Severs 
et al., 1981). The gradual decrease in mean a rte ria l pressure over a two hour 
period, shown by the long itud ina l study o f resting cardiovascular parameters and 
a rte ria l blood gases (Table 16), may be due to this action o f urethane. A s im ila r 
trend was also recognised by de W ild t e t al. (1983).
There is no evidence to  suggest tha t urethane is an unsuitable anaesthetic fo r 
the study of the cardiovascular e ffec ts  o f opioids, unlike pentobarb ita l anaesthesia 
which reverses the card iostim u la tory actions o f [ Leu] enkephalin in the dog 
(Sander et al., 1982).
By measuring the tachycardia and pressor responses to noradrenaline from  
both the fem oral and caro tid  a rte ry , i t  was shown tha t the measurement o f a rte ria l 
blood pressure via the carotid  a rte ry  and the resultant occlusion o f blood flow  to 
the carotid  sinus on one side o f c ircu la tion  did not a ffe c t the baroreceptor 
function. I f  the baroreceptor function had been impaired, a greater chronotropic 
and pressor response to noradrenaline would have been recorded from  the carotid  
a rte ry  compared to the fem oral vein, because of the animal's reduced a b ility  to 
produce a re flex bradycardia and reduction in vascular sym pathetic tone.
4.2.1 Cardiovascular Effects of Proenkephalin Products
The cardiovascular responses to opioids depends upon several facto rs , namely 
the species, state o f consciousness and anaesthetic used, route  o f drug 
adm in istra tion and the receptor se lec tiv ity  o f the opioid being investigated 
(Section 1.7).
The intravenous adm in istra tion of proenkephalin products in the urethane- 
anaesthetised ra t resulted in an im m ediate dose-related bradycardia and decrease 
in mean a rte ria l pressure. The cardiovascular e ffects  o f the extended [M e t ] -  
enkephalin sequences in the ra t has not previously been reported. A qu a lita tive ly  
s im ila r cardiovascular p ro file  has been described fo r  [ M e t ] -  and [ Leu] - 
enkephalin, as w e ll as 8-endorphin (Wei e t al., 1980; Sitsen e t al., 1982), the
o  c
enkephalin analogues [D -A la  , M et ] enkephalinamide, DAMEA (W ille tte  et al,
1982), [ D -A la2,D-Leu5 ] enkephalin, DADLE, and [ D -A la2, MePhe4 , G ly5-o l] 
enkephalin, DAGO (Martynova and Medvedev, 1986) in the urethane-anaesthetised 
ra t. There is only one known study which does not agree w ith  the observed 
cardiovascular e ffects  produced by the pentapeptides. Varagic and Stojanovic 
(1987) report tha t fo llow ing a caro tid  a rte ry  in jection o f [ M et] enkephalin or 
[Leu ] enkephalin, a dose-dependent biphasic change in blood pressure is produced 
consisting o f an in it ia l marked, short-lasting fa ll followed by a small, long-lasting 
increase in blood pressure. However, the route of drug adm in istra tion employed is
like ly  to have produced a re la tive ly  higher concentration o f peptide at the blood- 
brain ba rrie r and possibly fa c ilita te d  peptide en try in to the centra l nervous system, 
CNS. Consequently the observed response may have been a combination o f both 
peripheral and cen tra l e ffec ts . The penetration o f opioid peptides across the blood- 
brain ba rrie r and the feas ib ility  o f responses being mediated via centra l opioid 
receptors fo llow ing  peripheral adm in istra tion are discussed in Section 4.4.3.1.
The duration of the cardiovascular responses to [ M et] enkephalin and 
[M et] enkephaiyl-arg^-phe^ were s ign ifican tly  greater than those produced by 
[Leu] enkephalin and [ M et] enkephalyl-arg^-gly^leu®, however the magnitude o f 
the responses was s im ila r fo r a ll four peptides. The demonstration tha t s im ila r 
responses, both in magnitude and duration, to  [ M et] enkephalin were produced 
fo llow ing fem ora l and jugular vein adm in istra tion, is evidence against a d ire c t 
loading concentration e ffe c t o f a bolus dose on the heart. This is possible in view o f 
the p rox im ity  o f the rig h t jugular vein and a trium . The latency in response onset 
fo llow ing fem ora l vein adm in istration suggests tha t the response is mediated a t a 
site d ista l from  the fem oral vein. The abo lition  of the responses by naloxone 
(1 mg/kg), a dose recognised as being specific  fo r opioid receptors (Sawynok et al.,
1979), is con firm ation  tha t they are opioid receptor mediated.
4.2.2 Cardiovascular Effects of Opioid Receptor-Selective Agonists
The cardiovascular p ro file  of the proenkephalin products is qu a lita tive ly  
s im ilar to  tha t produced by morphine and the jj- selective agonist DAGO i.e. 
hypotension and bradycardia. This accords w ith  the lite ra tu re  fo r both morphine 
(Fennessy and R a ttra y , 1971) and DAGO (Martynova and Medvedev, 1986). The lack 
of e ffe c t of the 6-receptor selective agonist DPDPE, at the doses studied, is 
evidence against § -receptors being involved in the cardiovascular response to 
proenkephalin products. This is despite the c lass ifica tion  of the pentapeptides as 
de lta -p re fe rring  agonists (Lord et al., 1977). The synthetic enkephalin analogues 
DAMEA and DADLE exh ib it a s im ila r cardiovascular p ro file  to the proenkephalin
products (W ille tte  et al., 1982; Martynova and Medvedev, 1986) and possess agonist 
a c t iv ity  at both p - and 6-receptors. No conclusions can therefore be drawn from  
these studies as to the possible involvem ent o f 6-receptors in the cardiovascular 
response. P ilo t studies demonstrated th a t the cardiovascular responses to 
[ M et] enkephalin (30-150 pg/kg) were abolished by low doses of naloxone 
(O.lm g/kg). This suggests tha t the responses are p-receptor mediated, as naloxone 
shows a higher spec ific ity  fo r p - than 6 -receptors (Sawynok et al., 1979). I t  is 
un like ly tha t the cardiovascular responses to  proenkephalin products in the 
urethane-anaesthetised ra t involve k-receptors as, despite the production o f a 
modest dose-related bradycardia at high doses o f U-50, 488H, the fa ilu re  of 
naloxone to attenuate the response suggests tha t i t  is non-opioid in nature. Thus 
the indications are tha t the proenkephalin products exert the ir e ffec ts  through p - 
receptors.
Investigations using long-acting receptor specific antagonists show tha t the 
hypotensive response to morphine is mediated by both p - and 6-receptors w h ils t 
the bradycardia is mediated by p -receptors  only (Holaday and Ward, 1982). The 
unava ilab ility  o f receptor-se lective  agonists has precluded this type o f study from  
being conducted. However the lack o f any cardiovascular responses to DPDPE 
suggests tha t i t  is unlikely tha t the cardiovascular responses to proenkephalin 
products involve receptor mechanisms s im ila r to those in the above study. From  
the known recep to r-se lec tiv ities  o f the proenkephalin products (Section 1.4.2.2) i t  
is impossible to in fe r whether d iffe re n t opioid receptor subtypes mediate d iffe re n t 
components of the response, although th is  possib ility  cannot be to ta lly  disregarded.
H istam ine may contribute to the cardiovascular response to morphine as i t  is 
known to be released from  mast cells and basophils fo llow ing morphine 
adm in istra tion (Goth, 1973; Ja ffe  and M artin , 1980). However, the cardiovascular 
response to morphine was unaffected in the presence o f c im etid ine  and 
diphenhydramine a t doses su ffic ie n t to  antagonise the modest vasodepressor 
response produced by histam ine. This suggested tha t the cardiovascular response
could not be a ttribu ted  to the action o f histam ine fo llow ing release and concurs 
w ith  Evans et al. (1952) and Fennessy and R a ttra y  (1971).
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4.2.3 The Atypical Response to [ IMIet 1 Enkephalyl-arq -phe
In about 25% o f preparations, the response to [ M et] enkephalyl-arg^-phe^ 
was a typ ica l to those produced by the other proenkephalin products and the 
remaining 75% o f preparations to which [ Met] enkephalyl-arg^-phe^ was 
adm inistered. The antagonism of the naloxone-insensitive tachycardia and pressor 
response, by propranolol and phentolam ine respectively, im plica tes a 
catecholam ine involvem ent in the response. These non-opioid receptor mediated 
e ffec ts  were m im icked by the dipeptide arg-phe and raise the possib ility  o f rapid 
enzym atic cleavage o f the heptapeptide in vivo. HPLC analysis of 
[M et] enkephalyl-arg^-phe^and arg-phe solutions confirm ed th a t ex vivo 
degradation had not occurred. This suggests th a t d iffe re n tia l degrading capab ilities 
may exist w ith in  animals. The observation tha t this a typ ica l response 
predom inantly occurred in l i t te r  mates raises the possibility th a t the genetica lly  
contro lled expression o f a pa rticu la r cleaving enzyme may be the cause o f th is 
a typ ica l response.
The responses to [ M e t] enkephalyl-arg^-phe^ and arg-phe are produced at 
s im ila r doses, however in molar term s alm ost tw ice as much [ M et] enkephalyl- 
arg^-phe^ is required to produce the same magnitude o f response e lic ite d  by arg- 
phe. This may be achieved i f  the degradation o f [M e t] enkephalyl-arg^-phe^ occurs 
at specific  sites resulting in a high local concentration of released arg^-phe^ and 
may result in a s im ila r local concentration to tha t produced by the intravenous 
adm in istra tion and subsequent d ilu tion  o f the dipeptide. The most obvious reason 
fo r the sto ich iom etric  d ifferences in the a b ility  o f arg-phe and [M e t] enkephalyl- 
arg^-phe^ to  produce vasoconstrictor and tachycardia responses is tha t 
physiological antagonism results from  the pharm acologically active  cleavage 
products of [ M et] enkephalyl-arg^-phe^. The generation of arg^-phe^, which
evokes an increase in mean a rte ria l pressure and tachycardia, is accompanied by 
the release o f [M e t] enkephalin, which produces a depressor response and 
bradycardia. Thus, the overall response to  [ M et] enkephalyl-arg^-phe^ is a 
physiological summation o f the two opposing e ffe c ts  and explains why the a typ ica l 
response to the heptapeptide is less than th a t produced by the dipeptide alone.
A typ ica l cardiovascular responses to [M e t] enkephalyl-arg^-phe^ have also 
been observed in the dog (Sander and Giles, 1985) and the breakdown of 
[M e t] enkephalyl-arg^-phe^ to [ M et] enkephalin has been demonstrated in isolated 
tissue preparations (Ronai et al., 1983) and ra t brain synaptosomes (Marks e t al., 
1982; Demmer and Brand, 1983). A more detailed discussion of the possible 
enzymes responsible fo r th is conversion is presented in Section 4.3.1.
I t  is w orthy o f note tha t the last four amino acids of [ Met] enkephalyl-arg^- 
phe^ (i.e. phe^-m et^-arg^-phe^) constitu te  the same sequence as the molluscan 
card ioexc ita to ry  neuropeptide, FMRF amide (Price and Greenberg, 1982). This 
peptide produces a pressor e ffe c t fo llow ing in tracerebroven tricu la r adm in istra tion  
in anaesthetised ra ts (W ille rth  and Thornh ill, 1987). However, HPLC tim e-course 
studies o f the degradation o f [M e t] enkephalyl-arg^-phe^in synaptosomes reveal 
tha t the fastest and most dominant cleavage step was the removal o f the dipeptide 
arg^-phe^, generating [M e t] enkephalin (Marks et al., 1982; Demmer and Brand, 
1983). Cleavage at the gly^-phe^ bond to release phe^-m et^-arg^-phe^ was 
deemed as a m inor enzym atic pathway, in view of the absence of any absorption 
peaks corresponding to phe^-m et^-arg^-phe^ (Demmer and Brand, 1983). In order 
fo r [M e t] enkephalyl-arg^-phe^ to  be converted to FMRF amide extrem ely rapid 
am idation o f the te trapeptide in blood would have to occur, however am idation o f 
C -te rm ina l peptides has been reported (Bradbury et al., 1982). In addition, 
am idating enzymes are responsible fo r the conversion o f peptide F to am idorphin 
(Seizinger et al., 1985) and the generation of metorphamide (Weber e t a l., 1983).
4.2.4 Repeated Administration of Proenkephalin Products
Tolerance is a reduced response to a drug a fte r  its  continued application and 
is a phenomenon associated w ith  opioid adm in istra tion both jn  vivo and jn  v itro  
(M artin , 1983).
The repeated adm in istra tion o f proenkephalin products did not result in a 
reduction o f the bradycardia and depressor response, ind ica ting an absence of 
tolerance development. This con flic ts  w ith  the findings of Varagic and Stojanovic 
(1987) who report a development of tolerance to the depressor responses o f 
[M e t]  enkephalin fo llow ing  repeated adm in istration. Whether the lack o f tolerance 
to the proenkephalin products is a ttribu ted  to th e ir more transien t, modest 
cardiovascular e ffec ts  as compared w ith  DAGO and morphine is uncertain. 
Tolerance rapid ly developed to morphine and p a rticu la rly  DAGO, as indicated by 
the s ign ifican t a ttenuation o f cardiovascular responses. This is in accordance w ith  
the lite ra tu re  (Grundy, 1971; Fennessy and R a ttray , 1971) which reports tha t 
repeated adm in istra tion of high doses of morphine, up to  lOm g/kg, results in the 
production o f a pressor response.
The subcutaneous infusion of morphine over two days resulted in tolerance to 
morphine-induced bradycardia, however centra l infusions of morphine at doses 
su ffic ien t to produce physical dependence and tolerance to  morphine analgesia did 
not result in to lerance to the peripherally mediated bradycardia (Kiang et al.,
1983). This suggests tha t the development o f tolerance to morphine bradycardia 
does not involve centra l mechanisms.
4;3 DEGRADATION OF PROENKEPHALIN PRODUCTS AND THE EFFECT OF
CAPTOPRIL AND BESTATIN
I t  is like ly  tha t the transient, modest, cardiovascular e ffec ts  o f proenkephalin 
products are due to rapid enzym atic degradation fo llow ing intravenous 
adm in istration. I t  has been shown tha t the pentapeptides [ M e t] - and [ Leu] - 
enkephalin are quickly degraded fo llow ing perfusion through the isolated ra t lung 
preparation which suggests th a t pulmonary metabolism may be p a rtia lly  responsible 
fo r enkephalin inactiva tion  (G illespie et al., 1984). This is substantiated by reports 
o f the extrem ely rapid breakdown of [M e t] enkephalin and [M e t]  enkephalyl-arg^- 
phe^ m vivo (Dupont e t al., 1977; Chou et al., 1983; A loyo e t al., 1986), the 
widespread location of enkephalin degrading enzymes and by studies investigating 
the e ffe c t o f peptidase inh ib ito rs  upon opioid responses (Section 1.3.3).
4.3.1 Cardiovascular Effects of Captopril and the Modulation of Responses to 
Proenkephalin Products
The depressor response and accompanying re flex tachycardia to captopril 
(2mg/kg) accords w ith  the findings of Geh et al. (1986), Di N ico lanton io  e t al. 
(1983) and was probably due to the inh ib ition  of angiotensin converting enzyme 
(ACE), which reduces the c ircu la ting  levels of the vasoconstrictor peptide, 
angiotensin II. A captopril dose o f 2 mg/kg was found to s ign ifican tly  reduce the 
resting mean a rte ria l pressure and attenuate the vasodepressor response to sodium 
nitroprusside. Consequently, a low er dose (200pg/kg), w ithou t e ffe c t on resting 
cardiovascular parameters, was employed in these studies. The sp e c ific ity  of the 
lower dose o f captopril was confirm ed by the attenuation o f the duration o f the 
vasopressor response produced fo llow ing the adm in istration o f angiotensin I. This 
was due to the prevention of the conversion of angiotensin I to  angiotensin II by 
ACE.
C aptopril (200pg/kg) produced a po tentia tion of the duration, but not the 
magnitude, o f cardiovascular responses to proenkephalin products. This was most
marked fo r [ M et] enkephalyl-arg^-phe^ and [ M et] enkephalyl-arg^-gly^-leu® and 
less so fo r [M e t ]  - and [ Leu ] -enkephalin. Po ten tia ting e ffects  o f cap topril on the 
duration of cardiovascular responses to  proenkephalin products have been shown fo r 
[M et] enkephalyl-arg^-phe^ in the anaesthetised dog (Hanbauer e t al., 1982) and 
fo r [ M et] enkephalin in the anaesthetised ra t (D i N icolantonio et al., 1983). The 
more marked e ffe c t o f captopril on responses to the heptapeptide and octapeptide, 
compared to  the pentapeptides, agrees w ith  Chou et al. (1984). They demonstrated 
tha t w h ils t captopril o ffered considerable pro tection against the degradation o f 
[ M e t] enkephalyl-arg^-phe^, there was very l i t t le  protection o f the breakdown of
[M e t] enkephalin. S im ilar e ffec ts  have been reported by Patey e t al. (1981) and
Y a n g e ta l.  (1982).
The results described in th is thesis suggest tha t captopril o ffe rs  equal 
p ro tection  against the degradation o f both [M et] enkephaly l-arg^-g ly^-leu^ and 
[ M et] enkephalyl-arg^-phe^. This con flic ts  w ith  the findings of M ellstrom  £ t  al.
(1987) who reported tha t an ACE in h ib ito r, Hoe 498 diacid, had no po ten tia ting
e ffe c t on the antinociceptive actions of [M e t] enkephalyl-arg^-g ly^-leu^ and Patey 
et al. (1983) who reported tha t cap topril had no e ffe c t on responses to 
[ M e t] enkephalyl-arg^-g ly^-leu^ in v itro . However, i t  is inappropriate to equate 
the findings in one isolated tissue preparation w ith  the in vivo s ituation, and there 
may w e ll be differences in the potencies and mechanisms of action o f cap top ril and 
Hoe 498 diacid.
A para lle l enhancement o f the duration of the vasodepressor response to both 
[M e t] enkephalin and DAMEA, a synthetic enkephalin analogue res is tan t to  
degradation, led Geh et al. (1986) to conclude tha t other mechanisms, besides 
enzyme inh ib ition , were responsible fo r the potentia ting  e ffects  o f cap top ril. 
However, the studies conducted in this thesis demonstrate a lack o f m odulation by 
cap topril on responses to morphine, which con flic ts  w ith  the above proposal.
These findings, and other reports in the lite ra tu re  showing po ten tia tion  by 
cap topril o f responses to proenkephalin products (Shvarts and Faerm ark, 1987;
Gillespie e t a l., 1984; Chou et al., 1983), ind icate tha t ACE or peptidyl dipeptide
hydrolase, EC 3.4.15.1, plays a role in the degradation o f proenkephalin products.
ACE is c lassified as a carboxyl term inus d ipeptidy l peptidase and among its  many
9 10actions, cleaves his -leu from  the carboxyl term inus o f angiotensin I and
8 9 6 7sequentially releases phe -arg and ser -pro  from  the carboxyl term inus o f
bradykinin (Soffer, 1976).
Studies investigating the degradation o f proenkephalin products show tha t
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ACE blocks the form ation of ty r  -g ly  -g ly  from  [ Met] enkephalin (G illespie et
al., 1984) and prevents the degradation o f [ M et] enkephalyl-arg^-phe^ to
[ Met] enkephalin and arg^-phe^ (Yang e t al., 1982; Chou et al., 1983). This
2 3suggests tha t ACE cleaves at the gly -g ly  bond o f the pentapeptides, and possibly
the heptapeptide and octapeptide, and a t the m et^-arg^ bond in the heptapeptide. 
L i t t le  work has been conducted on the degradation o f the octapeptide, although i f  
the same p ro tec tive  mechanism o f captopril occurs, as the results obtained in th is  
thesis suggest, then cleavage between arg^-g ly^ would be expected. The more 
marked e ffe c t o f captopril on the extended enkephalins, [ Met] enkephalyl-arg^- 
phe^ and [M e t] enkephalyl-arg^-gly^-leu®, suggests tha t ACE p re fe re n tia lly  
cleaves the m et^-arg^ and arg^-gly^ bond ra ther than the gly^-phe^ bond. This 
would explain the lesser potentia ting e ffe c t of cap top ril on the pentapeptides and 
why the enhancing e ffe c t o f captopril on responses to  [M et] enkephalin were
recorded at higher doses in other studies (D i N ico lantonio et al., 1983). I t  may be
tha t the pentapeptides are more susceptible to degradation at the gly^-phe^ bond 
by endopeptidase 24.11 ra the r than ACE.
In view o f the evidence provided ea rlie r in th is section, i t  is possible th a t the 
proposed cleavage of [M e t] enkephalyl-arg^-phe^ described in Section 4.2.3 may be 
due to  the cleavage o f the heptapeptide by ACE at the m et^-arg^ bond. During the 
study o f the e ffec ts  o f peptidase inh ib itors on the cardiovascular responses, the 
a typ ica l response to [M et] enkephalyl-arg^-phe^ was not produced. Consequently 
the e ffec ts  o f captopril on the atyp ica l response to [M e t] enkephalyl-arg^-phe^
could not be studied. The enhanced expression of an A C E -like  peptidase in some 
rats is a possible explanation fo r the atyp ica l response to [ M et] enkephalyl-arg^- 
phe7.
4.3.2 Modulation of Responses to Proenkephalin Products by Bestatin
•P o tentia tion o f the magnitude of the depressor response to the pentapeptides 
by bestatin indicates tha t aminopeptidase a c tiv ity  may play a s ign ifican t role in 
the degradation o f [M e t] - and [ Leu]-enkephalin . This has been shown in v itro  in 
the guinea-pig ileum  (Geary et a l., 1982), in perfused ra t lungs (G illespie et al.,
1984) and in vivo as assessed by the enhanced antinociceptive  a c tiv ity  of the 
pentapeptides (C ha ille t et al., 1983). However, studies o f the cardiovascular 
e ffec ts  o f [M e t ] enkephalin in the rabb it demonstrate tha t w h ils t bestatin prolongs 
the plasma h a lf- life  o f the pentapeptide, an a ttenuation of the cardiovascular 
e ffects  is also produced suggesting tha t rapid enzym atic degradation is not 
responsible fo r the b r ie f duration o f the cardiovascular response (Gaddis e t al., 
1987).
I t  is o f in te rest tha t the studies in this thesis show tha t bestatin potentia tes 
the magnitude but has no e ffe c t on the duration o f cardiovascular response to the 
pentapeptides, whereas the reverse is true fo r captopril. Whether th is means tha t 
d iffe re n t parts of the peptide are responsible fo r d iffe re n t parameters of the 
response is uncertain. I t  is clear tha t the e ffec ts  produced are specific  as the doses 
used of the two inh ib ito rs  are w ithout d irec t e ffe c t on the cardiovascular system. 
In addition, the po ten tia ting  e ffe c t o f bestatin on the magnitude o f the response to 
[ M et] - and [Leu ] -enkephalin, and prolongation o f the action o f [M e t] enkephalyl- 
arg^-phe7 and [ M et] enkephalyl-arg^-g ly7-leu® by cap topril are both abolished by 
naloxone.
The lack o f e ffe c t o f bestatin on the cardiovascular response to 
[ M et] enkephalyl-arg^-phe7 and [ M et] enkephalyl-arg^-g ly7-leu^ suggests tha t 
d iffe re n t degradative pathways or a ltered cleavage susceptib ilities fo r the
pentapeptides may exist compared to the hepapeptide and octapeptide. This
conclusion is supported by studies w ith  captopril, where the prolongation of the
cardiovascular response to [M e t] enkephalyl-arg^-phe^ and [M et]enkephaly l-a rg^- 
7 8gly -leu is more marked. Reggiani eit al. (1984) have shown th a t thiorphan, an 
endopeptidase 24.11 inh ib ito r, exerts a considerable enhancement o f the analgesic 
e ffec ts  o f [ M et] enkephalin, but has very l i t t le  e ffe c t on the a c tiv ity  of 
[M et] enkephalyl-arg^-phe^. This suggests tha t d iffe re n t catabolic pathways may 
exist.
The lack o f e ffe c t o f bestatin on the heptapeptide and octapeptide con flic ts
w ith  reports o f po ten tia tion  o f [M et] enkephalyl-arg^-phe^ and [M e t] enkephalyl- 
6 7 8arg -g ly  -leu induced antinociception by bestatin (M ellstrom  et al., 1987; Chou et 
al., 1984). This may be a re fle c tio n  o f d iffe ring  concentrations o f aminopeptidase 
enzymes in the brain compared to the periphery (Gros e t al., 1985; Hersh, 1985).
The anatom ical location o f degrading enzymes is im portan t when considering 
th e ir po ten tia l ro le in the in vivo s ituation. The widespread d is tribu tion  o f besta tin- 
sensitive aminopeptidases (see Section 1.3.3.1) and ACE, which is p r im a rily  found 
in the lung (Ben-Harari and Youdim, 1983), is consistent w ith  these enzymes 
possessing a role in enkephalin inactiva tion . I t  is in teresting to note th a t several 
studies demonstrating endopeptidase 24.11 a c tiv ity  and proposing a ro le  in view of 
the location of the enzyme, have used homogenisation procedures to isolate the 
enzyme. This has rendered the enzyme accessible to substrate which would not 
norm ally be the case in s itu  (Llorens and Schwartz, 1981; Mendelsohn e t a l., 1985). 
Thus w h ils t endopeptidase 24.11 has been detected in the lung (Schwartz e t a l., 
1981), thiorphan o ffe rs  no p ro tection  o f [M e t] - and [ Leu ]-enkepha lin  fo llow ing  
the adm in istra tion of the pentapeptides to perfused ra t lungs m v itro  (G illespie j3t 
al., 1984).
4.3,3 The Effect of Both Captopril and Bestatin on Cardiovascular Responses
to  Proenkephalin Products
The studies investigating the e ffe c ts  o f both captopril and bestatin on the
cardiovascular responses to proenkephalin products do not suggest tha t any
synergistic e ffec ts  between the two inh ib ito rs  exists. S im ila rly , Chou et al. (1984)
reported a lack o f synergism between the pro tective  actions o f cap top ril and
bestatin when studying [M e t] enkephalyl-arg^-phe^ induced antinociception.
However, G illespie et al. (1984) suggest tha t ACE and aminopeptidase may be
functiona lly  linked in vivo. They suggest th a t the pentapeptide [M e t] enkephalin is
1 2  3metabolised by ACE to the tripep tide  ty r  -g ly  -g ly  , which is in turn degraded to 
2 3the dipeptide gly -g ly  plus tyrosine. This is supported by the evidence th a t ACE 
does not accept tripeptides as substrates (Das and Soffer, 1973) and th a t cap topril 
attenuated the appearance of tyrosine in the perfusate fo llow ing [ M e t] enkephalin 
adm in istra tion in to  isolated ra t lungs (G illespie e t al., 1984).
Synergism between thiorphan and bestatin in potentia ting [M e t] enkephalin 
induced analgesia has been demonstrated fo llow ing acute stress, w ith ou t which no 
synergistic e ffec ts  occur (Reggiani et a l., 1984). This may be due to a stress- 
induced increase in a c tiv ity  or release o f e ither an aminopeptidase or 
endopeptidase 24.11.
4.4 INVESTIGATIONS INTO THE MECHANISMS INVOLVED IN THE
CARDIOVASCULAR RESPONSES TO PROENKEPHALIN PRODUCTS
4.4.1 The Importance of the Vagus Nerve
4.4.1.1 B ila te ra l Vagotomy
A p a rt from  the increase in heart ra te  due to the abolition of vagal tone, a 
slight hypercapnia a fte r  90 minutes was the only physiological disturbance 
produced fo llow ing  the transection o f both vagi. This did not in te rfe re  w ith  
experim ental design as a ll paired experiments were completed w ith in  60 minutes o f 
b ila te ra l vagotomy.
The vagus carries a ffe ren t nerves from  sites in the periphery to  the CNS. 
Here the nerves te rm inate  in the dorsal nucleus of the vagus in the medulla 
oblongata, the site o f the card iac-inh ib ito ry  centre (Bell e t al., 1980). Vagal 
e ffe ren ts run from  th is nucleus and te rm inate  a t the s inoatria l and a trio ve n tr icu la r 
nodes in a tr ia l tissue. There is very l i t t le  parasympathetic innervation o f the 
ventric les (Bell e t al., 1980).
B ila te ra l vagotomy at the cerv ica l level abolished the bradycardia and 
depressor response produced by the proenkephalin products, DAGO and morphine. 
This im plies th a t vagal a ffe ren ts and/or e ffe ren ts  play a role in m ediating the 
cardiovascular response to the proenkephalin products. This agrees w ith  the 
findings b f Wei et al. (1980) who demonstrated tha t b ila te ra l vagotomy abolished 
the depressor and bradycardia response to [M e t ] -  and [Leu ]-enkepha lin  and 
morphine. In contrast, Fennessy and R a ttra y  (1971) showed tha t the bradycardia 
and depressor response to morphine became a pressor response accompanied by a 
s light bradycardia fo llow ing b ila te ra l vagotomy. This occurred a t extrem ely large 
doses o f morphine (10-100mg/kg) and may re fle c t e ithe r actions at cen tra l sites or 
non-opioid e ffec ts .
Several studies have investigated the cardiovascular e ffec ts  o f enkephalin 
analogues fo llow ing  b ila te ra l vagotomy. W ille tte  and Sapru (1982) demonstrated
tha t the bradycardia and depressor responses produced by both DAMEA and DALEA 
were abolished by b ila te ra l vagotomy, but only i f  the sectioning took place above 
the level o f the cardiac branches. B ila te ra l vagotomy at the level o f the diaphragm 
was w ithou t e ffe c t on the responses (W ille tte  and Sapru, 1982). In contrast w ith  the 
results described in th is thesis and the above findings, Randich and Callahan (1986) 
reported tha t the decrease in heart ra te  and blood pressure produced by DAMEA 
became an increase in blood pressure fo llow ing b ila te ra l vagotomy. However, th e ir 
work was conducted in pentobarbital-anaesthetised rats in which i t  is known tha t 
sym pathetic a c tiv ity  is increased and vagal a c tiv ity  is reduced (Vollm er and Bush,
1980). This may be the cause o f the discrepancy in the observations.
W ille tte  and Sapru (1982) demonstrated th a t the qu a lita tive ly  s im ila r 
cardiovascular responses to the enkephalin analogues DAMEA and DALEA were 
s t il l maintained in the decerebrate ra t, a preparation in which the higher brain 
centres are destroyed leaving the pons and medulla in ta c t (Sapru and K rieger, 
1978). This indicates tha t only the hind brain and not other CNS regions are 
involved in the response, and tha t urethane anaesthesia does not s ig n ifica n tly  
im pair brain stem mechanisms, which con flic ts  w ith  the finding o f Karczewski 
(1973).
The cardiovascular e ffec ts  o f fentanyl, e thylke tocyclazocine and etorphine in 
the b ila te ra lly  vagotomised ra t have been reported in the lite ra tu re . A ll of the 
above opioids produce a bradycardia and depressor response in the urethane- 
anaesthetised ra t. W hilst b ila te ra l vagotomy to ta lly  abolished the cardiovascular 
e ffects  o f fentanyl (G autre t and Schm itt, 1983a), d iffe rin g  e ffec ts  on the responses 
to etorphine and ethylketocyclazocine were produced. B ila te ra l vagotomy 
elim inated the bradycardia produced by etorphine, however the depressor response 
became a pressor response (Roquebert and Delgoulet, 1988). In contrast, the 
cardiovascular response to  ethylketocyclazocine was unaltered by b ila te ra l 
vagotomy (G autre t and Schm itt, 1984).
Both endogenous and synthetic opioids there fo re  produce a decrease in heart
ra te  and blood pressure fo llow ing  peripheral adm in istration in anaesthetised rats, 
but i t  is clear from  manipulations, such as b ila te ra l vagotomy, th a t the mechanisms 
responsible fo r producing the responses are not the same. The evidence suggests 
tha t vagal a ffe ren ts  and/or e ffe ren ts  are involved in m ediating the cardiovascular 
responses to the proenkephalin products.
4.4.1.2 E ffe c t o f A trop ine
The increase in heart ra te  fo llow ing the adm in istra tion o f the muscarinic 
antagonist, atropine, is a ttr ib u te d  to the blockade of vagal tone. P re trea tm en t w ith  
atropine s ign ifican tly  attenuated, or in some cases abolished, the bradycardia 
but not the depressor response produced by the proenkephalin products, DAGO and 
morphine. This suggests tha t the bradycardia is not due to d ire c t e ffec ts  of 
proenkephalin products on the heart. The results raise the possib ility  tha t the 
bradycardia may be due to parasym pathetic e ffec ts  on the heart fo llow ing  vagal 
stim ulation.
The results described in th is thesis accord w ith  Wei e t al. (1980) and G autre t 
and S chm itt (1983a) who also reported tha t atropine s ig n ifica n tly  reduced the 
bradycardia, but not the depressor responses produced by [ M e t] - and [ Leu] - 
enkephalin, morphine and fen tanyl. Fennessy and R a ttray  (1971), however, showed 
tha t both the decrease in heart ra te  and blood pressure produced by morphine in 
anaesthetised rats was s ig n ifica n tly  attenuated by atropine. Thornh ill and Saunders 
(1985) also concluded this when studying the cardiovascular responses to DAMEA 
and DALEA in conscious rats. This suggests tha t e ither the bradycardia contributes 
to the depressor response or tha t both responses are produced by atropine sensitive 
mechanisms. The observation tha t atropine did not s ign ifican tly  attenuate the 
depressor response produced by the proenkephalin products is strong evidence tha t 
the two responses are m anifested independently.
The d iffe re n tia l e ffe c ts  o f atropine and b ila te ra l vagotomy on the 
cardiovascular response to proenkephalin products also im plies tha t both vagal
a ffe re n t and e ffe ren t nerves are involved in the response. The abo lition  o f vagal 
e ffe re n t e ffec ts , through the use o f atropine, a ffec ts  the bradycardia but not the 
depressor response. This suggests tha t vagal e ffe ren t action is not responsible fo r 
the depressor response. However fo llow ing b ila te ra l vagotomy, where both a ffe re n t 
and e ffe re n t nerves are sectioned, the depressor response is abolished which 
indicates tha t vagal a ffe ren ts are involved in the depressor component of the 
response. Vagal a ffe ren ts  may also be involved in producing the bradycardia 
although this is speculation as the a ffe ren t and e ffe ren t involvem ent in th is 
response cannot be dissociated.
4.4.1.3 O ther Studies o f the Mechanisms Involved in the Cardiovascular 
Responses to Opioid Agonists
F u rthe r studies by other workers in to  the mechanisms responsible fo r the 
im m ediate hypotension and bradycardia produced fo llow ing the intravenous 
adm in istra tion o f opioid agonists suggests tha t the response is mediated via opioid 
receptors associated w ith  a type o f pulmonary sensory receptor known as the J- 
receptor (Sapru et al., 1981; W ille tte  e t al., 1982).
Evidence fo r this comes from  recording the nerve a c tiv ity  o f vagal a ffe re n t 
fibres associated w ith  the J-receptors (Painta l, 1977). An increase in a c t iv ity  was 
produced fo llow ing the intravenous adm in istra tion of the enkephalin analogues 
DAMEA and DALEA. This accompanied the im m ediate hypotension and bradycardia 
and was also associated w ith  the cessation o f phrenic nerve a c tiv ity  (Sapru e t al.,
1981). O ther sensory receptors in the lung, s tre tch  and ir r ita n t receptors (G inzel, 
1975) were unaffected by DAMEA and DALEA (W ille tte  and Sapru, 1982). Fu rthe r 
evidence to discount a role fo r  other types o f pulmonary receptors is th a t 
s tim u la tion  o f stre tch or ir r ita n t receptors did not result in bradycardia and 
hypotension (G inzel, 1975). Pulmonary J-receptors were also stim ula ted by phenyl 
diguanidine, PDG (Paintal, 1969). In the urethane-anaesthetised ra t, s im ila r 
bradycardia and hypotensive responses were obtained to morphine and PDG,
however the PDG response was unaffected by naloxone (W ille tte  et al., 1982). The 
antagonism o f the cardiovascular e ffec ts  o f DAMEA and DALEA by naloxone 
demonstrated tha t the response was spec ifica lly  mediated by opioid receptors and 
not due to a non-specific s tim ulation o f pulmonary J-receptors.
The results and subsequent conclusions arising from  the work conducted in 
th is thesis do not co n flic t w ith  the possib ility  of the cardiovascular responses to 
proenkephalin products being produced by opioid receptors associated w ith  
pulmonary J-receptors. In particu la r, the rapid onset o f the bradycardia and 
hypotension produced by PDG, around 1-2 seconds subsequent to intravenous 
adm in istra tion via the jugular vein, is a s im ila r onset tim e fo r the cardiovascular 
response to the proenkephalin products. This tim e  in te rva l re a lis tica lly  re fle c ts  the 
entry o f the peptides in to  the pulmonary c ircu la tion  fo llow ing rig h t jugular vein 
adm in istra tion.
4.4.2 Use of Quaternary Opioid Antagonists to Dissociate Peripheral
from Central Effects
4.4.2.1 E n try  o f Opioid Peptides in to  the C entra l Nervous System
Opioid antagonists such as naloxone and naltrexone are highly lip id-so lub le  
and rapid ly d iffuse across b io logical membranes, including the blood-brain barrie r. 
This property has consistently frustra ted  a ttem pts to confine the actions o f these 
compounds to e ither the CNS or to peripheral tissues (Herz and Teschemacher, 
1971; Kaufman et al., 1975). One approach to th is problem has been to develop 
congeners o f these antagonists bearing an add itional a lky l substituent on the 
nitrogen atom in the ring structure . These quaternary amine derivatives, which 
reta in some antagonist a c tiv ity , are designed to  traverse the blood-brain ba rrie r 
less read ily than th e ir te rtia ry  counterparts due to th e ir re la tive ly  greater p o la rity  
and reduced lip id  so lub ility .
The blood-brain barrie r plays an im portan t ro le in determ ining the 
relationship between the levels of a substance in the CNS and the periphera l
c ircu la tion . I t  has been shown tha t centra lly-m ed ia ted  e ffec ts  o f opioid peptides 
can resu lt fo llow ing  peripheral adm in istra tion (Zadina et al., 1986). Therefore, i t  is 
possible tha t the cardiovascular responses to intravenously administered 
proenkephalin products may have followed as a resu lt of the stim u la tion  o f centra l 
opioid receptors. Four synthetic analogues o f endogenous opioid peptides, DAMEA 
and three synthetic analogues o f 8-endorphin, were found to possess su ffic ie n t 
cerebrovascular perm eab ility  to produce a s ign ifican t brain uptake w ith in  3 to 11 
minutes fo llow ing repeated bolus dosing. There was l i t t le  uptake a fte r a bolus 
in jection i f  the peptide was rapid ly degraded or i f  binding to  plasma prote in 
occurred (Rapoport j3t al., 1979). An im portan t fa c to r to consider is th a t 
in traperitonea lly  adm inistered urethane increases plasma osm olality. This has been 
shown to m arkedly increase the perm eability  of the blood-brain ba rrie r (Severs e t 
al., 1981) and could po ten tia lly  fa c ilita te  the entry o f opioid peptides to the CNS.
The blood-brain ba rrie r exists due to t ig h t junctions between the endothelia l 
cells of the cap illa ry  bed of the brain. A few  areas o f the brain, such as the choroid 
plexus and the c ircum ven tricu la r organs, have fenestrated capillaries but these 
areas are de lim ited  by ependymal cells possessing t ig h t junctions tha t impede 
diffusion to the rest o f the CNS (Weindl, 1973). Substances may cross the blood- 
brain barrie r by one o f three basic ways, namely non-specific mechanisms, 
transmembrane d iffus ion  or saturable transport. Non-specific mechanisms include 
u ltra - f i lt ra t io n  and pinocytosis which are re la tive ly  non-d iscrim inating among 
substances w ith  regard to th e ir physical characteris tics. Transmembrane d iffus ion, 
a non-saturable mechanism, is the most common mode of drug access to the CNS. 
The physicochemical characteris tics of the substance and membrane composition 
are im portan t facto rs  in determ ining the degree o f penetration. The th ird  general 
way in which a substance may cross the blood-brain ba rrie r is by carrie r-m ed ia ted  
transport. This u tilizes  prote in complexes capable o f binding and moving substances 
across the membrane. These systems are lim ite d  in the ra te  at which m ate ria l may 
be transported and so display sa tu rab ility . The transport may or may not be energy
dependent, be able to transfe r substances against a gradient or require co-factors 
fo r maximal a c tiv ity . Generally, th is type o f system tends to be highly specific  fo r 
a group o f closely re lated compounds (Banks and Kastin, 1987).
Early studies on the transport o f opioid peptides from  blood in to  the CNS, 
based on the O ldendorf technique (Oldendorf, 1970), have indicated tha t they have 
l i t t le  access to  the CNS via the blood brain barrie r (C om ford e t al., 1978; Z lokovic 
et al., 1985). However, various cen tra lly  mediated e ffec ts  have been demonstrated 
fo llow ing peripheral adm in istra tion  o f opioid peptides (Zadina e t a l., 1986). The low 
penetration o f opioid peptides in to  the CNS has been a ttr ib u te d  to the absence o f a 
specific transport mechanism (Cornford e t a l., 1978) together w ith  the rapid 
degradation o f the peptide in the blood (Z lokovic et al., 1985; Begley and Z lokovic,
1986). A c r it ic is m  of the O ldendorf technique is tha t i t  measures the brain uptake 
5-15 seconds a fte r an in traca ro tid  in jection. This tim e in te rva l is not suitable fo r 
the assessment o f blood-brain barrie r perm eability  to slow ly penetrating 
compounds (Z lokovic e t a l., 1988).
Evidence fo r transport o f opioid peptides in to the CNS fo llow ing  peripheral 
adm in istration comes from  a study of the brain uptake o f radio labelled 
[L e u ] enkephalin and DADLE in isolated perfused choroid plexuses from  the sheep 
(Z lokovic et al., 1988). These studies concluded tha t peptide transport was due to  
the saturable uptake o f the in ta c t peptide by the choroid epithelium . The higher 
penetration o f the blood-brain barrie r by DADLE was a ttr ib u te d  to the greater 
resistance of the enkephalin analogue to  hydrolysis.
C arrier-m ediated transport o f opioid peptides has been demonstrated a t both 
sides o f the blood-hrain ba rrie r (Z lokovic et al., 1985). In a survey o f eighteen 
peptides, a few were found to have a lower degree o f perm eation than predicted by 
the ir lipoph ilic ities  (Banks et al., 1986). Fu rthe r investigation showed th a t a 
saturable highly specific  bra in-to-b lood transport system exists fo r sm all peptides 
w ith  an N -te rm ina l tyrosine residue, including [ M et] - and [ Leu] -enkephalin, 8- 
casomorphin and dynorphin (1-8) (Banks and Kastin, 1987). I t  appears tha t
b id irectiona l transport at the blood-brain barrier represents an im portan t 
mechanism which, together w ith  enzym atic hydrolysis in the CNS and plasma, 
governs the levels o f opioid peptides in the CNS. Thus, there are indications tha t 
the proenkephalin products may traverse the blood-brain barrie r in both d irections.
4.4.2.2 E ffe c t of N -M ethy l Levallorphan on Cardiovascular Responses to
Proenkephalin Products
Many studies have used quaternary ammonium opioid antagonists to 
d iffe re n tia te  between peripheral and cen tra l e ffects  of opioid agonists (fo r a 
review, see Brown and Goldberg, 1985). O f the currently  available quaternary 
antagonists, N -m ethyl levallorphan (NML) has been reported to be the most 
promising compound in re la tion  to e ffica cy  and peripheral se lec tiv ity  (B ianche tti et 
a l., 1985).
The antagonism by NML (5mg/kg) o f the cardiovascular responses to 
proenkephalin products, DAGO and morphine suggests tha t the responses are 
mediated by peripheral opioid receptors. Evidence tha t N -m ethyl levallorphan does 
not traverse the blood-brain ba rrie r has been provided by studies dem onstrating the 
a b ility  o f the quaternary antagonist to  prevent constipation produced by 
subcutaneously administered morphine, but not tha t produced by 
in tracerebroven tricu la rly  adm inistered morphine (D ragonetti e t a l., 1983; 
B ianchetti et al., 1983). In addition, intravenously administered NML (5mg/kg) had 
no e ffe c t on the cen tra lly  mediated resp ira tory e ffec ts  of a lfe n ta n il whereas 
in tracerebroven tricu la rly  adm inistered NM L antagonised the resp ira tory  depression 
(Yeadon, 1988).
Therefore, i t  is un like ly th a t the observed antagonism of the cardiovascular 
responses to proenkephalin products by NM L is due to a blockade o f cen tra l opioid 
receptors, pa rticu la rly  as a threshold antagonist dose was employed. S im ila r 
antagonism could be achieved w ith  a f iv e -fo ld  lower dose of the parent compound 
levallorphan, indicating a potency loss by the quaternary compound. A s im ila r
trend has been reported in other studies (B ianchetti et al., 1983) and is a ttribu tab le  
to quaternisation o f the parent compound.
4.4.2.3 Non-opioid E ffec ts  o f N -M ethy l Levallorphan
The hypotension and tachycardia produced fo llow ing the intravenous 
adm in istra tion  o f NML are qua lita tive ly  s im ila r responses to those achieved by the 
intravenous adm in istra tion o f naltrexone m ethylbrom ide (W ille tte  et al., 1983) and 
naloxone methobromide (Giles et al., 1983).
The abo lition  o f the NML induced tachycardia by propranolol suggests th a t 
the response is catecholam ine mediated. The antagonism by hexamethonium 
fu rth e r indicates tha t the response may be produced by the release o f 
noradrenaline from  sympathetic nerve endings. The demonstration tha t the 
tachycardia is produced in the pithed ra t suggests tha t s tim ula tion of sym pathetic 
nerves occurs a t peripheral sites i.e. sym pathetic ganglia. W ille tte  et al. (1983) 
proposed tha t the tachycardia produced by naloxone m ethylbrom ide was a ttr ib u te d  
to the antim uscarin ic a c tiv ity  o f the antagonist. This was im plied by the 
a ttenuation o f the bradycardia produced by the muscarinic agonist methacholine. 
The lack of e ffe c t of NML on the bradycardia and depressor response to 
acetylcholine suggests tha t the antagonist is devoid of any antim uscarinic a c tiv ity . 
S im ila rly , NM L does not appear to exert any adrenoreceptor antagonism or 
m odulation o f vascular re a c tiv ity  since responses to noradrenaline and sodium 
nitroprusside are also unaffected.
The antagonistic e ffe c t of NML on the pressor response to DMPP suggests 
tha t i t  blocks n ico tin ic  receptors at a dose o f lOmg/kg, but not a t 5mg/'kg. A 
modest tachycardia was produced by DMPP which was attenuated by NM L, 
however th is was not s ta tis tica lly  s ign ifican t. A s im ila r antagonism of the pressor 
response to DMPP was shown by W ille tte  e t al. (1983), however they reported th a t 
DMPP produced a bradycardia which was also antagonised by naltrexone 
m ethylbrom ide. The reason fo r the d iffe re n t chronotropic responses to  DMPP is
uncertain, however the e ffec ts  o f n ico tin ic  receptor s tim u lan t drugs in the whole 
animal are complex and depend upon the balance between parasympathetic and 
sym pathetic a c tiv ity  a t the tim e of in jection.
The abo lition  by phentolamine and hexamethonium o f the hypotension 
produced by NM L, and the fa ilu re  of NML to lower the mean a rte ria l pressure in 
the pithed ra t indicates tha t the hypotension is neurally mediated. This may be due 
to a reduction of sym pathetic tone through ganglionic blockade. Phentolamine 
pre trea tm ent removes sym pathetic tone in the anaesthetised ra t through a - 
adrenoreceptor antagonism and therefore  any ganglionic blocking e ffec ts  o f NML 
would be w ithou t e ffe c t. S im ila rly , ganglionic blockade in the pithed ra t, in which 
the destruction o f the VMA has abolished sym pathetic tone, would not result in a 
hypotensive response. The increase in mean a rte ria l pressure produced by NML in 
the pithed ra t is like ly  to be secondary to the tachycardia w ith  the lack o f 
baroreceptor function  preventing a re flex  depressor response.
Thus, the experim ental evidence suggests tha t the tachycardia and 
hypotension produced fo llow ing the intravenous adm in istra tion o f NML may be due 
to sym pathetic ganglion s tim ula tion o f cardiac innervating nerves and to ganglionic 
blockade of sym pathetic nerves innervating the vasculature, however th is is merely 
speculation. I t  is unlike ly tha t the cardiovascular e ffec ts  are due to im purities  
since HPLC analysis revealed tha t the drug sample was pure. The a b ility  o f the 
compound to have agonist a c tiv ity  at a pa rticu la r population o f n ico tin ic  receptors 
and antagonistic a c tiv ity  at others is somewhat surprising, but appears to be the 
most obvious in te rp re ta tion  fo r the results obtained. One possible explanation is 
tha t subtypes o f n ico tin ic  receptors exist and the a c t iv ity  p ro file  o f NML d iffe rs  a t 
d iffe re n t receptor subtypes. Cloning studies suggest tha t there are a t least fiv e  
types of n ico tin ic  receptors and i t  has been demonstrated tha t binding pro files  o f 
various toxins d iffe rs  at muscle and neuronal n ico tin ic  receptors (Colquhoun et al., 
1987).
I t  is o f in te rest to note tha t the in it ia l cardiovascular e ffec ts  o f NML are
re la tive ly  short-lived and the pre-drug cardiovascular parameters restored a fte r  5- 
8 minutes. However, the attenuation o f the depressor response to DMPP, 
presumably through ganglion blockade, is apparent 30 minutes a fte r  intravenous 
adm in istra tion of NML. This suggests tha t a c tiv ity  at ganglionic sites occurs a fte r 
the com pletion o f the tachycardia and hypotensive response.
The non-opioid a c tiv ity  of NM L may be of importance in the analysis of 
opioid responses, pa rticu la rly  fo r in vivo systems involving transmission a t n ico tin ic  
ganglia. NML has been shown to be five  tim es more selective fo r p ra ther than 6 
sites (B ianchetti et al., 1985). The results presented in th is thesis show tha t the 
ganglion blocking e ffec ts  o f NM L occur at doses 2-fo ld  higher than these which 
antagonise the p -receptor mediated e ffec ts  of [ M et] enkephalin, however the 
doses required to block <5 -o r k-opio id receptor mediated e ffec ts  are also like ly  to 
block autonomic ganglion transmission.
4.4.3 Studies in the Pithed R at Preparation
The pithed ra t preparation is frequently used to investigate cardiovascular 
responses since the CNS is destroyed and the preparation is devoid of any 
neurogenic re flex  contro l tha t m ight otherwise modulate the prim ary drug e ffe c t. 
The preparation is an invaluable com parative tool as i t  can also be used to 
determ ine whether the response in the in ta c t animal is due to d ire c t e ffe c ts  on the 
heart and vasculature, is cen tra lly  mediated, or is a summation o f cen tra l and 
peripheral e ffects.
The s ign ifican tly  lower heart ra te , systolic, d iasto lic and mean a rte r ia l blood 
pressures recorded in the pithed ra t, compared to resting cardiovascular 
parameters in the urethane-anaesthetised ra t, are s im ilar to other reported resting 
cardiovascular parameters in pithed rats (Grant and McGrath, 1984; E im e rl and 
Feuerstein, 1986). A r t if ic ia l ly  ven tila ting  w ith  100% oxygen resulted in the 
preparation being hyperoxic compared w ith  the urethane-anaethetised ra t and a fte r
60 minutes a s light hypercapnia was also evident. The a rte ria l pH, however, was 
not s ign ifican tly  d iffe re n t from  tha t recorded in the urethane-anaesthetised ra t. 
The a lte rna tive  is to ven tila te  w ith  air, however to keep the pithed ra t preparation 
viable (i.e. not hypoxic), large stroke volumes are necessary. This results in a high 
a rte ria l pH and lowFCO^ due to respiratory alkalosis. I f  the stroke volume is 
reduced to achieve normal pH and PCC>2 values, i t  has been shown tha t ra ts become 
hypoxic and non-viable (G rant e t al., 1985). Thus oxygen ven tila tion  results in a 
normal a rte ria l pH and a s ligh t hypercapnia and hyperoxia, however the preparation 
is viable and the resting physiological and cardiovascular parameters are stable 
over a 90 m inute period.
In in ta c t animals sustained hyperoxia produces small decreases in ven tila tion  
in dogs and rabbits and a s light increase in ventila tion  in man (Dejours, 1975). 
Hyperoxia in in ta c t animals also results in re flex changes in ven tila tion  which 
re c tify  the condition but provoke acid-base disturbances which suggests tha t the 
regulation o f acid-base status appears to  be subordinate. The employed level o f 
ventila tion  of the pithed ra t appears appropriate to m aintain a stable preparation 
in view of the normal a rte r ia l pH, bicarbonate concentration and steady resting 
cardiovascular parameters recorded in these studies, together w ith  the v ia b ility  o f 
the preparation.
The increased sens itiv ity  o f the pithed ra t to noradrenaline is like ly  to be 
due to the massive sym pathetic discharge tha t occurs on pith ing. This results in a 
supersensitivity to catecholam ines (G illespie and M uir, 1967). Despite the resting 
mean a rte ria l pressure and heart ra te  of the pithed ra t being respective ly almost 
20mmHg and lOObpm lower than in the urethane-anaesthetised animal, the s im ila r 
vasodepressor and bradycardia responses to acetylcholine and sodium nitroprusside 
demonstrate tha t comparable responses can s t il l be produced in th is preparation. 
This elim inates the possib ility  tha t a lack o f response to proenkephalin products in 
the pithed ra t is due to the lowered mean a rte ria l pressure and heart rate .
The lack o f e ffe c t of proenkephalin products, DAGO and morphine in the 
pithed ra t accord w ith  the findings o f E im erl and Feuerstein (1986) fo r other 
opioids. They showed tha t DADLE, DAGO, dynorphin A (1-17) and 8-endorphin had 
no e ffe c t on resting heart ra te  or blood pressure, except fo r dynorphin A, which a t 
high doses exerted a b rie f naloxone-insensitive depressor response. S im ila rly , 
dermorphin, an endogenous opioid peptide isolated from  the skins of toads 
(Erspamer and M elch iorri, 1980), and morphine, at doses up to lO m g/kg, had no 
e ffe c t on e ither heart ra te  or blood pressure (Feuerstein and Zukowska-Grojec,
1987).
There is con flic ting  evidence fo r  the e ffe c t of morphine in the pithed ra t. 
Fennessy and R a ttray (1971) showed tha t morphine at doses o f 10-100mg/kg 
produced a decrease in heart ra te  but had no e ffe c t on blood pressure. This 
suggests tha t morphine has a d ire c t depressant action on the heart, an e ffe c t which 
also has been demonstrated m v itro  (Schmidt and Livingston, 1933). However 
because of the high doses used, non-opioid e ffects  are like ly  to be produced. 
Several synthetic opioid agonists, including fentanyl (Gautret and S chm itt, 1983a), 
ethylketocyclazocine (G autret and Schm itt, 1984) and etorphine (Roquebert and 
Delgoulet, 1988) produce a decrease in both heart ra te  and blood pressure in the 
anaesthetised ra t, but only exert a bradycardia in the pithed ra t.
Whether the observed bradycardia is due to d irec t opioid receptor mediated 
e ffec ts  on the heart is uncertain, an issue confused by the discord surrounding the 
existence of cardiac opioid receptors (Section 1.7.2) and the fa ilu re  to dem onstrate 
whether the bradycardia is naloxone reversible. I t  is in teresting to note however, 
tha t a ll the aforementioned agonists possess varying degrees o f se le c tiv ity  fo r  the 
jj- opioid receptor.
4.4.4 Summary
The results from  investigations in to  the mechanisms involved in the 
cardiovascular response to proenkephalin products indicate tha t the response is
m ediated by peripheral opioid receptors. However, i t  appears tha t a cen tra l 
component is essential in the responses as destruction of the CNS through p ith ing 
abolishes the cardiovascular e ffects . The lack o f e ffe c t of proenkephalin products 
in the pithed ra t also suggests tha t the bradycardia and depressor responses are not 
due to  d ire c t actions on the heart, vasculature or autonomic ganglia. The presence 
o f opioid receptors and/or peptides a t these sites (Section 1.7.2) im plicates th a t 
endogenous opioids may possess a role in cardiovascular regulation. The m a jo rity  o f 
the lite ra tu re  and the results presented in th is thesis, indicate tha t i f  th is  is so, i t  
is un like ly to  be due to d irec t e ffec ts  on the heart and vasculature. The lack o f 
e ffe c t o f proenkephalin products on the isolated a tria  and perfused mesentery 
preparation accord w ith  these findings.
As b ila te ra l vagotomy abolishes the cardiovascular response produced by 
proenkephalin products, i t  is like ly  tha t vagal a ffe ren t nerves are responsible fo r 
transm itting  the response from  the periphery to  the CNS. Vagal a ffe ren ts  
term inate  in the dorsal nucleus of the vagus in the medulla oblongata of the hind 
brain. S ituated close to this nucleus is the card iac-inh ib ito ry  centre (Bell e t a l., 
1980) which has in terconnecting nerves w ith  the VMA. The p rox im ity  o f the three 
sites means the possib ility  of vagal a ffe ren ts  exerting e ffects  on the card iac- 
inh ib ito ry  centre, and hence vagal e ffe re n t output, and on the resting blood 
pressure via the VMA is anatom ically feasible.
I t  is speculation tha t the decrease in mean a rte ria l pressure is due to a 
decrease in sym pathetic tone but in view o f the lack of e ffe c t of proenkephalin 
products in the pithed ra t preparation, th is is a like ly  explanation. Fennessy and 
R a ttray  (1971) have suggested tha t the depressor e ffe c t of morphine may be 
vagally mediated, the a ffe ren t pathways being in the vagus nerves and the 
resultant e ffe ren t e ffec ts  consisting o f a com bination of vagal bradycardia and 
decreased sym pathetic m otor tone. A s im ila r mechanism has been proposed fo r the 
depressor e ffec ts  o f DAMEA (Randich and Callahan, 1986). The evidence th a t the 
underlying cause is a reduction in sym pathetic tone is provided by the
demonstration o f a 90% decrease in renal sym pathetic nerve a c tiv ity  during the 
hypotensive response. A decreased sym pathetic tone has also been claimed as the 
mechanism responsible fo r the depressor response to intravenously administered 
etorphine (Roquebert and Delgoulet, 1988), fentanyl (G autret and Schm itt, 1985a) 
and dynorphin (1-13) (G autret and Schm itt, 1985).
4.5 EFFECT OF MANIPULATION OF THE HYPOTHALAMUS-PITUITAR Y -
ADRENAL AXIS ON CARDIOVASCULAR RESPONSES TO
PROENKEPHALIN PRODUCTS
The cardiovascular e ffec ts  o f proenkephalin products were investigated 
fo llow ing acute and chronic manipulations of the hypotha lam us-p itu itary-adrenal 
axis. Responses were studied, (i) 24 hours and 18 days a fte r  adrenalectomy, a 
procedure resulting in the removal o f c ircu la ting  adrenaline, corticostero ids and 
the major source o f proenkephalin, ( ii) 24 hours and 18 days a fte r  trea tm en t w ith  
the steroid dexamethasone, which has been shown to suppress the a c tiv ity  of the 
hypotha lam us-pitu itary-adrenal axis (Jones et al., 1977; Buckingham, 1979) and ( iii)  
24 hours and 18 days a fte r  a combination o f both treatm ents.
4.5.1 E ffec t of Manipulation of the Hypothalamus-Pituitary-Adrenal Axis 
on Weight Gain and Circulating Corticosterone Levels
The level at which the hypotha lam us-pitu itary-adrenal axis is manipulated is 
c r it ic a l in determ ining whether weight gain is a ffected . The rem oval o f the 
adrenocortical hormones and major source o f proenkephalin products through 
adrenalectomy had no e ffe c t upon weight gain, whereas the rem oval o f p itu ita ry  
hormones through hypophysectomy has been shown to s ig n ifica n tly  reduce weight 
gain (K itchen, 1980).
The drinking w a te r concentration o f dexamethasone employed in chronic 
studies was reduced 100-fold from  tha t used in the acute studies as m ainta in ing the 
animals on 50uM dexamethasone resulted in a rapid weight loss, de te rio ra tion  in 
health and death w ith in  10 days. This is like ly  to be due to the widespread adverse 
e ffec ts  o f chronic g lucocortico id  adm in istra tion on carbohydrate and pro te in  
metabolism (Thompsom and Lippman, 1974). Animals maintained on a 0.5pM 
dexamethasone concentration over an 18 day period s t il l exhibited a s ign ifican tly  
lower weight gain compared to contro l animals. This was evident in both naive and
adrenalectomised rats.
O ther studies have adm inistered higher chronic doses o f dexamethasone in 
order to suppress 8-endorphin release from  the p itu ita ry  but the e ffec ts  on weight 
gain during the course o f trea tm en t have not been stated (Khalid et a l., 1982; 
Rossier et al., 1979; Nordin e t a l., 1987). The greater reduction in weight gain o f 
chronica lly adrenalectomised, dexamethasone trea ted rats compared w ith  
chronica lly dexamethasone trea ted  rats suggests tha t adrenalectomy may have an 
e ffe c t on weight gain when combined w ith  chronic g lucocorticoid trea tm ent.
A fou r-fo ld  reduction in c ircu la ting  corticosterone levels in chron ica lly  
adrenalectomised rats, together w ith  post-m ortem  analysis, confirm ed the success 
o f the operative procedure. The stress induced by sham-operation did not produce 
changes in c ircu la ting  corticosterone levels a fte r 18 days), as compared w ith  those 
recorded in contro l, unoperated animals used in the studies investigating the 
e ffec ts  o f dexamethasone (see Section 3.5.1).
The suppressive e ffe c t o f dexamethasone on p itu ita ry  function was re flec ted  
in the large reduction in c ircu la ting  corticosterone levels and was due to the 
suppression o f ACTH release (Rossier e t a l., 1979). Acute adm in istra tion o f 50pM 
dexamethasone suppressed the hypotha lam us-pitu itary-adrenal axis, as indicated by 
s ign ifican t reductions in c ircu la ting  corticosterone levels. A s im ila r suppression 
was also achieved by the chronic adm in istra tion o f 0.5 ijM dexamethasone, since 18 
days a fte r trea tm ent, s im ila r c ircu la ting  corticosterone levels were recorded. The 
suppression o f ACTH and 8-endorphin release by dexamethasone has previously 
been demonstrated (Rossier et al., 1979; Simantov, 1979) as has the concom itant 
release o f 8-endorphin and ACTH from  the p itu ita ry  in equimolar amounts 
fo llow ing stim ula tion by co rtico trop in  releasing fac to r, CRF (Jones e t a l., 1977; 
Buckingham, 1979: Guillem in et al., 1977a).
A lthough c ircu la ting  corticosterone measurements provide an ind ica tion  as to 
whether suppression o f p itu ita ry  function has occurred, several other fac to rs  must
also be taken in to  account when in te rp re ting  the recorded plasma concentrations. 
F irs t, urethane has been shown to s tim ula te  adrenocortical a c tiv ity  by inducing 
CRF release and hence ACTH secretion. The resultant increase in plasma 
corticosterone levels has been shown to be dexamethasone-sensitive (Ham stra et 
al., 1984). I t  is therefo re  possible tha t urethane anaesthesia may have a ltered the 
suppressed corticostero id  levels resulting from  dexamethasone adm in istra tion. 
However, the dexamethasone was adm inistered to the rats over a 24 hour or 18 day 
period and the stim u la tory  e ffe c t o f urethane would have only been prevalent fo r  
an hour before the cardiovascular responses to proenkephalin products were 
investigated. Secondly, the e ffe c t o f handling and in jection stress on the 
c ircu la ting  corticosterone levels must be considered. A tw o -fo ld  elevation in 
plasma corticosterone levels occurs w ith in  2 hours of saline in jection  (Santagostino 
et a l., 1978). Thus, i t  is possible tha t a greater suppression of p itu ita ry  function  by 
dexamethasone is produced than is indicated . by the recorded c ircu la tin g  
corticosterone levels.
4.5.2 E ffec t of Manipulation of the Hypothalamus-Pituitary-Adrenal Axis on 
Resting Cardiovascular Parameters
4.5.2.1 E ffe c t in Adrenalectom ised Anim als
Adrenalectom ised rats were maintained on a 0.9% w /v sodium ch loride 
solution in order to  compensate fo r the removal o f aldosterone, the p rim ary  
hormone responsible fo r the contro l o f w a ter and salt balance (Moses, 1965). Sham- 
operated animals were maintained on tap w ater, as rats maintained on 0.9% w /v  
sodium chloride solution become hypertensive re la tive  to contro l animals drink ing  
tap w a te r due to a salt-induced e levation o f blood pressure (Iaina ^ t  a l., 1980; 
Preuss and Preuss, 1980).
The elevation in resting heart ra te  24 hours a fte r adrenalectom y, in 
comparison w ith  th a t recorded in sham-operated animals, has also been reported 7 
days a fte r perform ing the operative procedure (Gardiner and Bennett, 1983). I t  was
suggested th a t the ensuing tachycardia was due to a com bination o f sym pathetic 
hype ractiv ity  and reduced vagal tone, since in the presence o f propranolol and 
atropine the in tr in s ic  heart rate was lower in the adrenalectomised rats than in the 
controls. This was presumably due to a m anifestation o f post-adrenalectomy 
myocardial depression as reported by Le fe r (1968).
The s ligh tly  elevated mean a rte ria l pressure recorded in acutely 
adrenalectomised rats, compared w ith  sham-operated rats, accords w ith  the 
findings o f Fuentes et al. (1984) but contrasts w ith  Gardiner e t al. (1981). They 
report a systemic a rte ria l hypotension in adrenalectomised rats which had been
maintained on 1% w /v sodium chloride solution. Again, th is was observed 7 days
and not 24 hours a fte r  adrenalectomy. The reported elevation o f mean a rte ria l 
pressure is surprising in view of the removal o f c ircu la ting  catecholamines 
fo llow ing adrenalectomy. I t  is possible tha t the increase in mean a rte ria l pressure 
may be due to increased sym pathetic a c tiv ity , resulting in the production o f an 
enhanced sym pathetic tone. The observed decrease in pulse pressure is like ly  to  be 
due to the aforementioned post-adrenalectomy m yocardia l depression (Le fe r, 
1968). Gardiner and Bennett (1983) have shown th a t the development o f
hypotension 7 days fo llow ing adrenalectomy is reversed to normal levels i f  the 
animals are m aintained on 1% w /v  sodium chloride solution. I t  appears th a t the 
blood pressure is maintained by the autonomic nervous system and ren in-
angiotensin system w ith  no discernable con tribu tion  from  the peripheral 
cardiovascular actions o f vasopressin.
The s im ila r resting cardiovascular parameters in chron ica lly 
adrenalectomised and sham-operated animals demonstrate tha t the in it ia l e levation 
o f resting cardiovascular parameters 24 hours a fte r  adrenalectomy is not sustained 
over an 18 day period. Any stress induced by sham-operation is not re flec ted  in 
a lterations o f resting cardiovascular parameters e ithe r 24 hours or 18 days 
fo llow ing surgery or in changes in c ircu la ting  corticosterone levels compared w ith  
those recorded in contro l, unoperated animals (Section 3.5.1).
Changes in resting cardiovascular parameters have been recorded several 
hours fo llow ing stress inducing procedures, such as surgery or isolation, and have 
been proposed to be due to the increased release o f opioid peptides (Dashwood and 
Feldberg, 1980; Naranjo et al., 1986). During acute stress, 8-endorphin is released 
concom itantly w ith  ACTH from  the anterio r p itu ita ry  o f the ra t (G uillem in et al., 
1977a). Proenkephalin products stored w ith  catecholamines in adrenal medullary 
chrom affin  cells are also released in response to stress (Viveros et al., 1980; Alessi 
et al., 1982). Dashwood and Feldberg (1980) showed tha t in the anaesthetised ca t 
surgical stress results in the release o f opioid peptides, which produce a naloxone- 
reversible bradycardia and a depressor response. This response was evident several 
hours a fte r surgery. In addition, im m obiliza tion stress resulted in a naloxone- 
reversible hypotension (Nordin et al., 1987). This response was also manifested in 
adrenalectomised animals, although not to such an extent as in in ta c t animals, 
suggesting tha t adrenal opioid peptides were not solely responsible fo r the 
hypotensive response. However, they did not state how long the hypotension 
persisted fo llow ing rem oval o f the stressor. In view of the rapid degradation o f 
c ircu la ting  endogenous opioid peptides (Weinberger et a l., 1986; Clement-Jones e t 
al., 1980) i t  is un like ly tha t any im m ediate a lte ra tions in cardiovascular 
parameters, due to stress-induced opioid peptide release, would be sustained over a 
24 hour period.
4.5.2.2 E ffe c t in Dexamethasone Treated Anim als
Suppression o f p itu ita ry  function by dexamethasone trea tm en t did not a ffe c t 
resting cardiovascular parameters in e ither acute or chronic studies, suggesting 
tha t dexamethasone was w ithou t e ffe c t on cardiovascular function. This accords 
w ith  other studies which used ten-fo ld  higher doses to  investigate the e ffe c t o f 
chronic dexamethasone adm in istra tion on cardiovascular responses (Nordin et al., 
1987).
4.5.2.3 E ffect in Adrenalectomised, Dexamethasone Treated Animals
The elevation in heart ra te  and blood pressure in adrenalectom ised rats 24 
hours a fte r  surgery also occurred in adrenalectomised animals which received 
dexamethasone over a 24 hour period. This demonstrates tha t suppression of 
p itu ita ry  function does not influence the development of any sym pathetic 
hype rac tiv ity  produced fo llow ing adrenalectomy. S im ila rly  adrenalectomised rats 
receiving dexamethasone also exhibited a decreased pulse pressure, presumably due 
to the post-adrenalectomy m yocardia l depression observed by L e fe r (1968). The 
re turn  o f the resting cardiovascular parameters to normal levels in the chron ica lly 
adrenalectomised, dexamethasone trea ted rats is s im ilar to th a t observed in the 
chron ica lly  adrenalectomised rats (Section 4.3.2.1).
4.5.3 E ffec t of Manipulation of the Hypothalamus-Pituitary-Adrenal Axis on 
Cardiovascular Responses to [M et] Enkephalin, [ Leu] Enkephalin and 
[M et] Enkephalyl-arq^-qly-leu^
4.3.3.1 Responses in Adrenalectom ised Rats
The marked po tentia tion  o f cardiovascular responses to proenkephalin 
products in rats fo llow ing acute adrenalectomy suggests tha t the a c t iv ity  of the 
hypotha lam us-p itu itary-adrenal axis is c r it ic a l in determ ining the animal's 
responsiveness to opioid peptides. This accords w ith  other studies which have 
demonstrated an increase in sens itiv ity  to  opioid alkaloids fo llow ing 
adrenalectomy. Lewis (1923) f ir s t  noted tha t adrenalectomy increases the 
suscep tib ility  o f ra ts to the le tha l e ffe c ts  o f morphine. Subsequent studies (MacKay 
and MacKay, 1929) confirm ed these findings and indicated tha t the le tha l dose o f 
morphine in adrenalectomised rats was approxim ately ^/4  to * /5  o f the le tha l dose 
in sham-operated controls. Adrenalectom y has also been shown to reduce the 
antinociceptive dose of morphine as assessed by the ta il f lic k  method (M ille r  e t a l., 
1955; Gebhart and M itche ll, 1972; Wei, 1973). In addition, swim stress induced 
analgesia and footshock stress induced analgesia (Marek et a l., 1983; Marek e t a l.,
1982) are markedly potentiated in rats following adrenalectomy.
The increased sensitiv ity  o f the adrenalectom ised rats to proenkephalin 
products may be due to the removal o f the major source o f c ircu la ting  
proenkephalin products, resulting in an im m ediate increase in sens itiv ity  o f the 
animal to  intravenously administered opioid peptides. However, the adrenal gland 
is not the only source o f c ircu la ting  opioid peptides and the involvem ent o f the 
p itu ita ry  gland may also be im portan t in the altered responsiveness o f the 
adrenalectomised animals. Another consequence of adrenalectomy is the rem oval 
of adrenaline and corticosterone, which may play a role in determ ining the 
responsiveness o f the animal to opioids.
I t  has been demonstrated tha t adrenalectom y causes an increase o f p itu ita ry  
proopiom elanocortin mRNA and consequently an augmentation o f ACTH and 8- 
endorphin synthesis (Douglas et al., 1984). This e ffe c t is not evident u n til 3 days 
a fte r adrenalectomy. Up un til 3 days, p itu ita ry  ACTH content is s ig n ifica n tly  
depressed, however a fte r this period substantia l rises in p itu ita ry  ACTH content 
persist fo r  up to 300 days (Gemzell e t a l., 1931; F o rtie r, 1958; K rieger e t a l., 1979). 
The resulting increase in c ircu la ting  3-endorphin levels may be the underlying 
cause o f the decreased potentia tion o f cardiovascular responses to proenkephalin 
products observed 18 days a fte r adrenalectom y. This may also explain why, in a 
study o f morphine-induced bradycardia, adrenalectomy alone did not s ig n ifica n tly  
increase the sensitiv ity  o f the rats to the bradycardia compared to sham-operated 
contro ls (Kiang and Wei, 1984). However, i f  adrenalectomy was fo llow ed by 
dexamethasone infusion over a 24 hour period, which has been shown to decrease 
the elevated levels o f c ircu la ting  and synthesised 8-endorphin (Rossier e t al., 1979; 
Simantov, 1979; Douglas et al., 1984), then the sensitiv ity  o f the animals to 
morphine-induced bradycardia was increased 6 to  10 fold. S im ila rly , animals 
exposed to  cold stress fo r 2 days, a procedure known to increase 8-endorphin 
release from  the p itu ita ry , were 5 tim es less sensitive to morphine than animals 
kept at a room temperature. The desensitisation to morphine produced by cold-
stress was prevented by dexamethasone trea tm en t, indicating tha t increased levels 
o f c ircu la ting  8-endorphin may have resulted in the animal's decreased sens itiv ity  
to morphine (Kiang and Wei, 1984).
4.3.3.2 Responses in Dexamethasone Treated Rats
The lack o f e ffe c t of acute dexamethasone trea tm ent on cardiovascular 
responses to proenkephalin products accords w ith  Kiang and Wei (1984), who 
reported th a t dexamethasone infusion over a 24 hour period had no s ign ifican t 
e ffe c t on morphine-induced bradycardia. A non-s ign ificant attenuating e ffe c t is 
evident in both the bradycardia response to morphine in the ir study and the 
bradycardia and depressor response to  proenkephalin products observed in th is 
thesis, although the large in te r-an im al varia tion  in responses produced in some 
experiments may be responsible fo r masking some s ign ifican t e ffects . The 
suppression o f p itu ita ry  function and the reduction in c ircu la ting  8-endorphin levels 
fo llow ing dexamethasone trea tm ent therefore  does not have an im m ediate e ffe c t 
on the responsiveness o f the animal to opioid peptides.
The attenuation o f cardiovascular responses to proenkephalin products 
fo llow ing chronic dexamethasone trea tm en t is s im ila r to the e ffec ts  o f 
dexamethasone on opioid-m ediated analgesia. Dexamethasone has been shown to 
attenuate the analgesia resulting from  swim stress (Panocka et al., 1987) and fo o t-  
shock (Marek e t a l., 1983) to  the same exten t as the opioid anatagonist naloxone. 
This suggests tha t the reduction in c ircu la ting  8-endorphin levels fo llow ing  
suppression o f p itu ita ry  function may decrease the responsiveness o f the animal to 
the e ffec ts  o f both endogenous and exogenous opioid peptides. I t  is possible, 
however, th a t the decreased responsiveness fo llow ing dexamethasone trea tm en t 
may also be due to e ffec ts  on the adrenal gland. As w e ll as exerting in h ib ito ry  
e ffec ts  upon the hypothalamus and p itu ita ry  gland, dexamethasone has been shown 
to stim ulate the release o f proenkephalin products from  the adrenal medulla 
(LaGamma and Ad ler, 1987). Thus any increased c ircu la ting  levels o f proenkephalin
products may influence the sensitivity of opioid receptors.
/ 4.5.3.3 Responses in Adrenalectom ised, Dexamethasone Treated Rats
In th is study, con tro l sham-operated rats also received dexamethasone in 
order to investigate d ifferences in the cardiovascular responses o f animals which 
had undergone operative stress and then received dexamethasone, compared w ith  
those sham-operated animals receiving tap water.
The marked po ten tia tion  o f the cardiovascular responses to proenkephalin 
products in rats 24 hours a fte r adrenalectomy and dexamethasone trea tm ent, 
compared w ith  sham-operated, dexamethasone trea ted  rats, was s im ila r in 
magnitude to tha t observed in acutely adrenalectomised rats which had not been 
treated w ith  steroid. This suggests tha t dexamethasone was w ith ou t e ffe c t on the 
immediate changes in sens itiv ity  produced fo llow ing adrenalectomy.
I t  has been shown tha t acute adrenalectomy coupled w ith  dexamethasone 
trea tm ent markedly potentia ted the bradycardia induced by morphine, whereas 
individual adrenalectomy or dexamethasone trea tm ent did not. This suggests th a t 
the suppression o f p itu ita ry  function is necessary fo r the development o f the 
increased responsiveness to opioids fo llow ing adrenalectomy (Kiang and Wei, 1984). 
Whether in the adrenalectomised animal the absence o f an increase in sens itiv ity  is 
due to the s tim u la tion  o f 8-endorphin release from  the p itu ita ry  fo llow ing 
adrenalectomy is uncerta in but is possible.
The sustained po ten tia tion  o f the cardiovascular responses to proenkephalin 
products in chronica lly adrenalectomised, dexamethasone trea ted  rats contrasts 
w ith  the observation th a t in chronically adrenalectomised ra ts  the in it ia l 
potentia tion seen in acute studies is not maintained. In adrenalectom ised rats 
treated w ith  steroid, the increased magnitude o f the depressor response and 
bradycardia are s im ila r in both the chronic and acute studies, provided 
dexamethasone is adm inistered throughout. This suggests tha t, in chron ica lly
adrenalectomised rats the fa ilu re  to m aintain the in it ia l hypersensitiv ity  is re la ted 
to some aspect o f p itu ita ry  function , which may involve an increase in 3-endorphin 
release. The increase in p itu ita ry  proopiomelanocortin mRNA and subsequent 
augmentation of ACTH and 3-endorphin synthesis fo llow ing adrenalectomy, which 
is reversed by dexamethasone (Douglas et al., 1984) substantiates this suggestion.
I t  has been observed th a t animals exposed to cold or receiving in jections o f 
CRF, procedures which increase the levels o f c ircu la ting  opioid peptides, possess a 
decreased sensitiv ity  to the cardiovascular e ffects  of morphine. This can be 
prevented by dexamethasone trea tm en t (Kiang and Wei, 1984) and accords w ith  the 
results obtained in th is thesis. The increase in 3-endorphin secretion fo llow ing 
adrenalectomy decreases the hypersensitiv ity  of the animal. The cum ulative e ffe c t 
results in chronically adrenalectomised rats possessing a s im ila r responsiveness to 
proenkephalin products to tha t observed in contro l animals. In contrast, opposing 
e ffec ts  of adrenalectomy and dexamethasone have been demonstrated by Holaday 
et al. (1979). They demonstrated th a t pre trea tm ent of adrenalectomised ra ts or 
mice w ith  dexamethasone abolished the adrenalectomy-induced sensitisation to 
parenteral morphine or 3-endorphin.
4.5.4 E ffect of Manipulation of the Hypothalamus-Pituitary-Adrenal Axis on 
Cardiovascular Responses to [ Met] Enkephalyl-arq-phe^
Unlike the responses to  the other proenkephalin products, the cardiovascular 
e ffec ts  of [M e t] enkephalyl-arg^-phe^ were extrem ely varied and there fo re  are 
discussed separately.
The cardiovascular responses in acute and chronically adrenalectomised rats, 
acute and chronically dexamethasone trea ted rats, and in acute and chron ica lly  
adrenalectomised, or sham-adrenalectomised, dexamethasone trea ted ra ts were fa r 
more heterogeneous than those observed in naive rats. Tachycardia, bradycardia, 
depressor, pressor and biphasic responses were produced. The responses in acute 
and chronically sham-operated rats and in the contro l rats in the dexamethasone
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study showed a s im ila r va ria b ility  to those obtained in naive animals, suggesting 
tha t the heterogeneity in responses was due to the treatm ents ra the r than to 
altered cardiovascular profiles to [M e t] enkephalyl-arg^-phe^ in the lit te rs  
studied. The observation tha t the responses to  [M e t] enkephalyl-arg^phe^ were no 
more variable a fte r  sham-operation suggests tha t the cardiovascular e ffe c ts  o f the 
heptapeptide are unaltered by stress. The in it ia l va riab ility  in responses seen in 
the acute studies persisted and was s t i l l  evident to  the same degree in the chronic 
studies, suggesting tha t a lasting e ffe c t is produced which is not reversed w ith  
tim e.
I t  appears tha t manipulation o f the hypothalam us-pitu itary-adrenal axis,
through e ither adrenalectomy, dexamethasone trea tm ent, or both, results in a
variable response to [M et] enkephalyl-arg^-phe^. Surgical stress does not appear to
be an im portan t fa c to r since there was comparable va riab ility  in responses in
adrenalectomised and dexamethasone trea ted  animals. The mechanism behind th is
%
a lte ra tion  in the response is unclear. However, since the heptapeptide has a s im ila r
6 7 8receptor se le c tiv ity  p ro file  to the octapeptide [M e t] enkephalyl-arg -g ly  -leu 
(Paterson et al., 1984), i t  is therefore  unlike ly to be an e ffe c t a t opioid receptors. 
The most obvious explanation is tha t m anipulation of the hypo tha lam us-p itu ita ry- 
adrenal axis a ffe c ts  the m etabolic fa te  o f the heptapeptide, which has already been 
shown to  be degraded by several cleavage pathways (Yang et al., 1982; Demmer 
and Brand, 1983; Marks £ t  al., 1982). The various peptide fragm ents of the 
degraded heptapeptide may possess d iffe r in g  cardiovascular e ffec ts , like  the 
dipeptide arg-phe (Section 4.2.3), which could explain the va ria b ility  in responses.
4.5.3 Summary
These studies show tha t m anipulation o f the hypotha lam us-p itu itary-adrenal 
axis has profound e ffec ts  upon the cardiovascular responses to in travenously 
adm inistered proenkephalin products. In view of the modest responses o f the 
cardiovascular system fo llow ing the adm in istra tion o f pharmacological ra the r than
physiological doses of proenkephalin products, the action of endogenous opioids 
upon the cardiovascular system may be of a greater significance in circumstances 
tha t resu lt in an a lte ra tion  of the function o f the hypotha lam us-pitu itary-adrenal 
axis and/or subsequent levels o f c ircu la ting  opioid peptides. W hilst the c ircu la ting  
levels o f [M e t] enkephalin are reported to be in the region of 14-140 pg/m l plasma 
(Clement-Jones et al., 1980; Viveros et al., 1980), the dose-ranges employed in th is  
thesis (30-300 pg/kg) are like ly  to result in c ircu la ting  plasma concentrations 
several orders of magnitude higher. However, various types o f stress have been 
shown to d ram atica lly  increase the release and levels o f c ircu la ting  opioid peptides 
(Rossier e t a l., 1977; Viveros et al., 1980). Thus, under stressful circumstances, the 
c ircu la ting  levels o f opioid peptides may reach the levels achieved fo llow ing the 
intravenous bolus dosing o f proenkephalin products used in this study. C erta in  
stress-inducing procedures may also increase the sensitiv ity  of the animal to 
c ircu la ting  endogenous opioid peptides and there is considerable evidence to  
support stress induced potentia tion of opioid e ffec ts  (Appelbaum and Holtzm an, 
1984; Spaggia et al., 1979; Drugan et al., 1982).
The stress o f short-term  isolation and im m obilisa tion has been shown to  
result in hypertensive and hypotensive responses respective ly, both of which are 
reversed by naloxone (Nordin et al., 1987; Fuentes e t al., 1984; Naranjo e t al., 
1986). S im ila rly , hypotensive responses to  haemorrhagic shock (Faden and Holaday, 
1979) and endotoxic shock (Holaday and Faden, 1978) are also reversed by naloxone, 
im p lica ting  th a t endogenous opioid peptides may play a role in m anifesting these 
responses. This complex area is the subject o f a review  by Holaday (1983). There is 
evidence to suggest tha t regulation of opioid receptors may also be part of the 
animals response to stress. Opioid receptor binding was found to be m arkedly 
decreased in a tr ia l tissue 2 hours a fte r haemorrhagic shock, although recovery o f 
binding had occurred w ith in  24 hours (Krum ins e t al., 1983).
The responsiveness of the ra t to morphine has also been shown to be 
modulated through the exogenous adm in istra tion of opioid peptides. The
subcutaneous adm in istra tion  o f dynorphin (1-13) and [ Leu] enkephalin, 30 m inutes 
before morphine adm in istra tion, resulted in sensitisation to  the e ffec ts  of 
morphine, however [M e t] enkephalin was w ithou t e ffe c t (Kiang and Wei, 1984a). 
The m odifica tion  o f morphine sensitiv ity  by dynorphin (1-13) was shown to be tim e 
dependent. A phase o f increased sensitiv ity  was fo llowed by a rapid development o f 
desensitisation in response to the in it ia l e ffe c t. This response was also produced 
fo llow ing the in trace reb roven tricu la r adm in istration o f dynorphin. Thus, i t  appears 
that modulating e ffec ts  on peripheral opioid receptor sens itiv ity  may be mediated 
at centra l sites (G la tt e t al., 1987).
4.6 RESPIRATORY STUDIES
Respiratory depression is an im portan t fa c to r to consider in any study o f the 
cardiovascular actions of opioids. I t  is a potent pharmacological action o f both the 
alkalo id opioids (Ja ffe  and M artin , 1980) and the opioid peptides (Sapru and 
K rieger, 1979; Moss and Friedman, 1978). Furthermore, acute hypoxic stress 
resulting from  respiratory depression has been shown to activa te  the sym pathetic 
nervous system and is associated w ith  elevated levels o f c ircu la ting  catecholam ines 
and subsequent a ltera tions in resting cardiovascular parameters (Sylvester e t al., 
1979; Saito j3t al., 1981).
I t  is not in the scope of th is thesis to conduct a detailed study o f the 
mechanisms involved in the respiratory changes produced by proenkephalin 
products. However, an awareness o f the respiratory e ffec ts  and the possible 
contribu tion tha t they may have on the cardiovascular responses necessitated 
investigation.
4.6.1 Respiratory Effects of Proenkephalin Products
There was a markedly d iffe rin g  e ffe c t o f proenkephalin products upon 
resp ira tory rate and tid a l volume. [M e t] Enkephalin and [M e t] enkephalyl-arg^- 
phe^ produced a dose re lated, naloxone reversible decrease in t id a l volume and 
resp ira tory rate , whereas [Leu ] enkephalin and [M e t] enkephaly l-arg^-g ly^-leu^ 
were w ithout s ign ifican t e ffe c t on e ithe r parameter. The resp ira tory changes were 
im m ediate in onset, like  the cardiovascular responses, however they were o f a 
much shorter duration. The sens itiv ity  of the animals to [ M et] enkephalin and 
[ Met] enkephalyl-arg^-phe^ varied. In 30% of preparations an apnea of a few 
seconds duration was produced.
Q ua lita tive ly  s im ila r resp ira tory responses were produced fo llow ing  the 
intravenous adm in istration of morphine (W ille tte  and Sapru, 1982a), DAMEA and 
DALEA (W ille tte  and Sapru, 1982), and DADLE and DAGO (M artynova and
Medvedev, 1986). These responses were also im m ediate in onset and of a short 
duration, less than 20 seconds in a ll cases. 8-Endorphin, however, was w ithou t 
e ffe c t on respiratory ra te  a t doses which produced a decrease in mean a rte ria l 
pressure and bradycardia (Sitsen e t al., 1982).
The reason behind the d iffe re n tia l resp ira tory e ffects  o f the proenkephalin 
products cannot be a ttribu ted  to d iffe r in g  receptor se lectiv ities. However, i t  is 
in teresting to note tha t [ M et] enkephalin and [ M et] enkephalyl-arg^-phe^ 
generally produce a more prolonged and greater decrease in mean a rte ria l pressure 
and bradycardia. Thus, i t  is possible tha t the respiratory e ffects  are secondary to 
the cardiovascular responses. A dd itiona lly , i f  the opioid receptors m ediating the 
resp ira tory response are a separate population of receptors from  those m ediating 
the cardiovascular response, then the receptors mediating the resp ira tory response 
would appear to  be less sensitive. This is supported by the dem onstration th a t 
[ Leu] enkephalin and [ M et] enkephaly l-arg^-g ly^-leu^ exhibited typ ica l 
cardiovascular pro files in the preparations, but were devoid of any resp ira tory 
a c tiv ity . An explanation of the s ligh tly  enhanced cardiovascular a c t iv ity  and 
resp ira tory actions o f [ M et] enkephalin and [ M e t] enkephalyl-arg^-phe^ is not 
s tra igh tfo rw ard . There is no evidence to suggest tha t i t  can be a ttr ib u te d  to  e ithe r 
d iffe re n tia l , enzym atic degradation compared to [ Leu] enkephalin and 
[ M et] enkephalyl-arg^-g ly^-leu^ or increased e fficacy  at the opioid receptor(s) 
m ediating the responses.
The decrease in respiratory frequency fo llow ing the adm in istra tion  o f 
morphine (W ille tte  and Sapru, 1982a), DAMEA and DALEA (W ille tte  and Sapru, 
1982) has been proposed to be due to the stim u la tion  of opioid receptors associated 
w ith  pulmonary J-receptors (see Section 4.4.1). The stim ula tion o f pulmonary J- 
receptors, in addition to producing bradycardia and hypotension, results in an apnea 
which is re flec ted  by a decrease in tid a l volume and respiratory frequency. These 
three responses, apnea, bradycardia and hypotension, are also produced by phenyl 
diguanidine (Painta l, 1977) and are of a s im ila r magnitude and duration to  those
produced by morphine (W ille tte  and Sapru, 1982a)! I t  is uncertain whether th is 
mechanism is responsible fo r the resp ira tory responses to [M e t] enkephalin and 
[ M et] enkephalyl-arg^-phe^. The d iffe re n tia l e ffec ts  o f proenkephalin products 
upon resp ira tory  and cardiovascular parameters suggest d iffe re n t populations o f 
opioid receptors may be involved.
4.6.2 Studies in the A rtific ia lly  Ventilated Rat
Through the use o f the a r t if ic ia lly  ventila ted  ra t, i t  is possible to e lim ina te  
the influence o f changes in respiratory parameters on the cardiovascular system 
(M ilm er and Clough, 1983).
The long itud ina l study o f the cardiovascular and blood gas changes in the a ir 
ventila ted, urethane-anaesthetised ra t demonstrated tha t, at 60 minutes, the 
resting cardiovascular parameters and blood-gas levels were not s ign ifican tly  
d iffe re n t from  those recorded in the spontaneously breathing, urethane- 
anaesthetised ra t at the same tim e point. However, at 90 minutes, an elevated 
PCC>2 leve l and a decrease in pH, bicarbonate concentration and base excess were 
recorded, ind ica ting the onset of resp ira tory acidosis. The PC ^ level was not 
s ign ifican tly  a ltered, suggesting tha t under ven tila ting  was not the cause o f the 
acidosis. The hypercapnia was w ithou t e ffe c t on the resting heart ra te and mean 
a rte ria l pressure which were not s ign ifican tly  a ltered from  previous resting levels. 
A ll experiments were completed w ith in  60 m inutes o f a r t if ic ia lly  ven tila ting , a t 
which po in t no disruption of resting cardiovascular parameters or blood gas levels 
was evident. Thus, i t  can be assumed tha t any changes in cardiovascular responses 
compared to responses obtained in spontaneously breathing animals were due to the 
e lim ina tion of any accompanying respiratory changes.
4.6.2.1 E ffe c t o f A r t if ic ia l V en tila tion  on Cardiovascular Responses to
Proenkephalin Products
The lack of modulation of the depressor response to proenkephalin products in
a rtif ic a lly  ventila ted  rats suggests tha t the decrease in mean a rte ria l pressure is 
not secondary to  any opioid-induced respiratory changes. S im ila rly , the absence o f 
any s ign ifican t changes in the bradycardia produced by [ M e t] enkephalyl-arg^-phe^ 
or [ M et] enkephaly l-arg^-g ly^-leu^ indicates tha t the decrease in heart ra te  is not 
due to changes in respiration. However, the slight a ttenuation o f the bradycardia 
produced by [M e t] - and [Leu ]-enkepha lin  suggests th a t changes in respiratory 
parameters may contribu te  to the response. This could be explained fo r 
[ Met] enkephalin, in view of the evoked dose-related resp ira tory depression. 
However, the dem onstration tha t [ Leu] enkephalin has no e ffe c t on respiratory 
parameters makes i t  d if f ic u lt  to  in te rp re t why the bradycardia response is 
attenuated in the a r t if ic ia l ly  ventila ted ra t. S im ila rly , the bradycardia produced by 
[M e t] enkephalyl-arg^-phe^ is unaltered in the a r t if ic ia l ly  ventila ted  ra t even 
though the heptapeptide exerts a s ign ifican t depression of resp ira tory ra te  and 
tida l volume. These results fu rth e r suggest th a t the resp ira tory and cardiovascular 
responses are independent o f one another.
The centra l adm in istra tion of morphine produced marked cardiovascular 
responses w ith  no signs of respiratory depression (Conway et al., 1983) which 
substantiates the proposal tha t cardiovascular and resp ira tory responses to opioids 
are independent o f one another. In rats chronica lly treated w ith  naloxone, there 
was no a lte ra tion  o f the respiratory response to  in tra a rte ria lly  adm inistered 
morphine. However, there was a marked sensitiv ity  to the depressor and 
bradycardia response (P fe iffe r et al., 1984), ind icating tha t the responses were 
mediated by d iffe re n t receptor populations.
I t  has also been shown tha t a change in cardiovascular parameters is not 
always associated w ith  a s im ila r change in resp ira tory parameters. The cen tra l 
adm in istration o f the synthetic enkephalin analogues DAGO and DADLE resulted in 
an increase in heart ra te  and blood pressure. However, the resp ira tory ra te  was 
depressed by DAGO but increased by DADLE and the tid a l volume was depressed 
by both peptides (Hassen et al., 1982). A dd itiona lly , the rank order o f potency o f
the fentanyls to depress respiration d iffe rs  from  the rank order o f potency to 
depress cardiovascular param eters (Yeadon, 1988) ind icating tha t d iffe ring  
sensitiv ities of the cardiovascular and respiratory systems to the e ffec ts  of the 
fentanyls exists.
Evidence to suggest tha t the cardiovascular e ffects  of opioids are secondary
to respiratory responses is provided by Elghozi et al. (1981) and B e lle t et al. (1980).
Their studies o f the resp ira tory e ffec ts  of [M e t]  enkephalin, [L e u ] enkephalin,
morphine, fentanyl and DAM EA, fo llow ing low dose in trac is te rna l adm in istra tion in
the ra t, demonstrated tha t each o f these agonists produced a pressor response w ith
slight tachycardia and no s ig n ifica n t change iryP.C^. However, a t higher doses each
agonist produced a biphasic response w ith  a secondary hypotension and a
bradycardia. A marked reduction in PC^ was found during the depressor phase.
This led to the assumption tha t the respiratory depression observed a t high agonist
doses caused the hypotension. W hilst th is may have been the case, the possib ility
exists tha t the biphasic response may have been due to  the summation of
cardiovascular e ffec ts  produced by opioid action at two d iffe re n t receptor
populations in the brain. This e ffe c t may only have been seen a t higher doses due to
the diffusion of the agonist to other areas of the brain. Furtherm ore, the
experiments were conducted in pentobarbital-anaesthetised rats and resp ira tory
be
depression is known to^accentuated by pentobarbita l anaesthesia (Dai et al., 1983; 
Sitsen et al., 1982). This is illus tra ted  by the lack o f e ffe c t of 
in tracerebroven tricu la rly  adm inistered 8-endorphin on resp ira tory parameters in 
conscious rats, w h ils t in pentobarbital-anaesthetised rats s im ila r doses of 8- 
endorphin produced a severe resp ira tory depression, often resulting in death (Sitsen 
et al., 1982).
Thus, as in cardiovascular studies, the anaesthetic used is an im portan t fa c to r 
to consider when in te rp re ting  results. Studies have shown tha t urethane anaesthesia 
does not in te rfe re  w ith  resting resp ira tory functions in various species and th a t 
urethane has a much reduced depressant e ffe c t compared to halothane, enflurane
and sodium pentobarbita l (Maggi and M eli, 1986). As a result of these findings, 
urethane is commonly used in studies investigating the e ffe c t o f drugs upon 
respiration.
4.6.3 Summary
The results o f the resp ira tory studies indicate tha t there is a marked 
d iffe rence in the e ffects  o f proenkephalin products upon resp ira tion. 
[M e t] Enkephalin and [M e t] enkephalyl-arg^-phe^ exert a dose-related resp ira tory  
depression w h ils t [ Leu] enkephalin and [ Met] enkephalyl-arg^-gly^-leu® have no 
s ign ifican t e ffe c t. This fo llows the same order o f potencies fo r the proenkephalin 
products in producing bradycardia and depression of mean a rte ria l pressure in 
term s of magnitude and duration o f e ffe c t. However, the e ffects  on the resp ira tory  
system are not nearly as marked as those on the cardiovascular system.
The studies in the a r t if ic ia lly  ventila ted  ra t suggest tha t w h ils t the 
respiratory depression may contribu te  towards the bradycardia produced by 
[M e t] enkephalin, th is is not the case fo r [ M et] enkephalyl-arg^-phe^. The 
a ttenuation o f the bradycardia produced by [ Leu] enkephalin in the a r t i f ic ia l ly  
ventila ted  ra t is d if f ic u lt  to explain in view of the lack of resp ira tory e ffe c ts  of 
the peptide. Overall, the evidence suggests tha t the cardiovascular and resp ira to ry  
e ffe c ts  o f proenkephalin products are independent o f one another.
CONCLUDING REMARKS AND FURTHER WORK
Previous studies investigating the cardiovascular e ffec ts  o f proenkephalin
products have focused m ainly on the pentapeptides [M e t]  - and [ Leu]-enkephalin
and paid l i t t le  a tten tion  to [ M et] enkephalyl-arg^-phe^ and [ M et] enkephalyl-arg^- 
7 8gly -leu . The resulting lite ra tu re  contains many inconsistencies in the nature of 
these e ffec ts  which are dependent upon species, anaesthesia, route of 
adm in istration and ligand studied (Section 1.7; Holaday, 1983). The work presented 
in this thesis represents the f ir s t  known study o f the m v itro  and jn  vivo 
cardiovascular e ffe c ts  o f the four major processing products o f proenkephalin in 
the ra t.
The lack o f d ire c t and in d irec t e ffects  o f proenkephalin products on isolated 
a tria , the m esenteric vasculature and in the pithed ra t accords w ith  the m a jo rity  o f 
lite ra tu re . This questions the significance o f the presence o f proenkephalin 
products and opioid receptors in the brain areas and peripheral tissues involved in 
cardiovascular regulation. The lack o f e ffe c t m ilita tes  against a role o f endogenous 
opioid peptides in cardiovascular contro l under normal physiological circumstances.
Results from  studies using pithed rats and the quaternary opioid antagonist, 
N -m ethyl ievallorphan, suggest tha t cardiovascular responses to intravenously 
administered proenkephalin products are mediated by peripheral opioid receptors, 
but are also dependent upon centra l nervous system function ing. The mechanisms 
proposed to be responsible in mediating the responses are illu s tra ted  in F igure 30. 
The qua lita tive  s im ila r it ie s  between the responses evoked by the proenkephalin 
products, DAGO and morphine and the lack o f e ffe c t of U-50, 488H and DPDPE 
indicate tha t the e ffe c ts  o f the proenkephalin products are mediated by p-opio id 
receptors. This is despite the c lassifica tion of the pentapeptides, p a rticu la rly  
[ Leu] enkephalin, as being strongly 6-p re fe rring  agonists. The use of recep to r-
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Figure 50: Schematic Diagram Representation of the Proposed Mechanisms
Involved in the Cardiovascular Response to Proenkephalin Products in 
the Urethane-Anaesthetised Rat
Dotted lines represent the stages at which antagonists or surgical procedures have 
been used to dissect the response. Solid lines represent nerves, hatched area 
represents the cen tra l nervous system. C ircu la tin g  proenkephalin products shown as 
open circles.
selective antagonists and the derivation of apparent pA£ values in vivo could be 
employed to c la r ify  th is issue.
The use o f cap top ril and bestatin demonstrates tha t the proenkephalin 
products are subject to rapid enzymatic degradation jn  v ivo , which may be 
responsible fo r the transien t duration and modest size of the evoked cardiovascular 
responses. This suggests tha t a captopril sensitive enzyme, possibly ACE, and an 
aminopeptidase contribu te  towards the degradation o f the peptides. Whether or not 
endopeptidase 24.11 also plays a role in the breakdown o f proenkephalin products 
fo llow ing intravenous adm in istra tion could be determ ined through the use o f 
thiorphan and phosphoramidon in vivo studies.
The "a typ ica l response" to  [M e t] enkephalyl-arg^-phe^, which appears to be 
due to the degradation o f the heptapeptide and generation o f the pharm acologically 
active dipeptide, may represent a phenomenon responsible fo r the inconsistencies 
in the lite ra tu re  on the cardiovascular e ffec ts  o f endogenous opioid peptides. 
G enetically contro lled d iffe re n tia l expression o f peptidases may be the mechanism 
behind this response, and i f  this is so, i t  has widespread im plica tions fo r the 
b iological functions and ac tiv itie s  o f the many peptides found throughout the 
mammalian body. I t  is tem pting to speculate tha t such a phenomenon may be,, 
responsible fo r ce rta in  cardiovascular, endocrine and nervous disorders in man.
The a c tiv ity  of the hypotha lam us-pitu itary-adrenal axis and/or levels o f 
c ircu la ting  opioid peptides appears c r it ic a l in determ ining the responsiveness o f the 
animal to exogenous opioid peptides. The use o f hypophysectomised rats would 
enable the role of the p itu ita ry  and im portance o f levels o f c ircu la ting  3-endorphin 
to be fu lly  assessed. The marked changes in the cardiovascular responses to 
proenkephalin products fo llow ing manipulations o f the hypotha lam us-p itu ita ry- 
adrenal axis re a ffirm s  the suggestion tha t the endogenous opioid system may play a 
more s ign ifican t ro le in cardiovascular function under pathophysiological
conditions, such as stress and shock, ra ther than in the norm al physiological 
s ituation.
In conclusion, proenkephalin products do not appear to exert d ire c t e ffects  on 
the heart or vasculature of the ra t. In the urethane-anaesthetised ra t, the 
adm in istra tion o f pharm acological doses of proenkephalin products results in a 
decrease in mean a rte ria l pressure and heart ra te  which is mediated via peripheral 
opioid receptors, probably o f the p subtype. This response is transm itted  to the 
centra l nervous system by the vagus nerve, where a decrease in mean a rte ria l 
pressure and an atropine sensitive bradycardia is produced.
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